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SUMMARY
The epidermal growth factor receptor (EGFR) is overexpressed in a wide range of 
tumour types. Molecules which target and sterilise EGFR-overexpressing cells, or 
increase their sensitivity to conventional therapies may have a beneficial effect in the 
clinical management of these tumours. This study describes two approaches adopted 
to target EGFR-overexpressing cells.
Firstly, we examined the effect of exogenous epidermal growth factor (EGF), a 
polypeptide growth factor which binds to and activates EGFR, on the radiation 
sensitivity of a panel of cell lines with a wide range of EGFR expression. This effect 
was assessed by colony forming assay and the results obtained were analysed using 
the linear quadratic model of cell survival. Our results indicated that the presence of 
EGF did not alter the radiosensitivity of any of the cell lines examined. This suggests 
that the use of EGF as a radiosensitising agent is unlikely to be of benefit in a clinical 
setting.
The second approach adopted was to investigate the possibility of using EGF as a 
means of delivering therapeutic ultra-short range radionuclides to EGFR- 
overexpressing cells. The short range of the particles emitted from these 
radionuclides (Auger electrons) requires that decay occurs in close proximity to 
cellular DNA for a radiobiological effect to be observed. For EGF to act as an 
effective delivery vehicle for these radionuclides, it must be capable of delivering the 
radionuclide to the nucleus of the target cell.
Studies were carried out to assess the sub-cellular distribution of EGF after receptor 
binding and internalisation. Using both light and elctron microscopic techniques 
along with cell fractionation, we established that exogenous EGF does accumulate in 
the nucleus of some EGFR-overexpressing cell lines under the appropriate 
conditions. These results suggested that EGF may be suitable as a delivery vehicle for 
Auger-emitting radionuclides. Finally, we examined the effect of EGF conjugated to 
the Auger-emitting radionuclide 1231 on the clonogenic survival of a cell line panel 
with a wide range of EGFR expression. We observed that 123I-EGF was able to 
sterilise some EGFR-overexpressing cell lines, and that cell lines with a higher 
EGFR expression were more senitive tol23I-EGF than those with a lower EGFR 
expression. It was also observed that incubation conditions which abolished the 
nuclear uptake of EGF also abolished 1231-EGF-mediated cytotoxicity, suggesting 
that 123I-EGF sensitivity is dependent upon the nuclear uptake of the radioconjugate.
The function of nuclear EGF remains to be established, as does the nuclear 
translocation mechanism. However, the possibility of EGFR-targeted therapies based 
upon this phenomenon, as outlined in this report, implies that further studies into the 
nuclear accumulation of EGF and other polypeptide growth factors are warranted.
CHAPTER 1 
IONISING RADIATION AND CELL DEATH
1
1.1 Overview
Ionising radiation is presently one of the most widely used and efficacious cancer 
therapies. Generally, the range of intrinsic cellular radiosensitivity varies much less 
than sensitivity to cytotoxic drugs, and the emergence of clonal radioresistance 
occurs less frequently than does resistance to chemotherapeutic agents. The 
effectiveness of external beam radiotherapy, however, is limited by the amount of 
radiation damage sustained by non-malignant cells, primarily those of the 
hematopoetic system. Agents which are able to selectively sensitise tumour cells, or 
protect normal cells from radiation damage have the potential to improve the 
clinical outcome of patients undergoing standard radiotherapeutic regimes.
This thesis is concerned with the exploitation of the overexpression of the 
epidermal growth factor receptor (EGFR) by some tumour cell types in a 
radiotherapeutic context. One approach taken was to examine the effect on the 
radiosensitivity of tumour cells by ligand-induced activation of EGFR. Previous 
reports have suggested that EGFR activation results in an increase 
in cellular radiosensitivity in some tumour cell lines (Kwok and Sutherland, 1989, 
1991b). Chapter 7 describes experiments which were performed to establish the 
effect of exogenous EGF on the radiosensitivity of EGFR-expressing tumour cell 
lines.
This thesis also describes preliminary experiments to determine the effectiveness 
of epidermal growth factor (EGF) as a vehicle for targeted radionuclide therapy. The 
specific targeting of EGFR-overexpressing tumours by EGF-radionuclide conjugates 
has the potential to allow tumour cell irradiation without the degree of normal tissue 
damage sustained by conventional external beam irradiation.
There are many radionuclides with diverse physical properties which may be 
suitable for targeted radiotherapy. However, one of the primary determinants of the 
effectiveness of any radionuclide therapy is the ability of the targeting moiety 
(delivery vehicle) to deliver radionuclide to the tumour site. If the radionuclide used 
has a very short range (less than one cell diameter), the sub-cellular localisation of 
the targeting vehicle becomes important. Chapter 8 describes experiments to
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establish the sub-cellular localisation of exogenously added EGF, and thus its 
suitability as a vehicle for ultra-short range radionuclides. Chapter 9 describes 
experiments which demonstrate the ability of EGF-ultra-short range radionuclide 
conjugates to sterilise EGFR-expressing tumour cell lines.
1.2 Ionising radiation-induced cell death
The link between ionising radiation-induced genomic DNA damage and cell 
sterility is now well established. The selective irradiation of cell nucleus and 
membrane (by the use of 125I-IUDR and 1251-concanavalin A respectively) 
demonstrated that the radiation dose to the nucleus is of primary importance in 
determining cell survival (Warters et al, 1977). Of the various types of DNA 
damage sustained after irradiation, double strand breaks (dsb), and the efficiency of 
dsb repair have been shown to be the most important factors in radiation-induced 
cell death (Kemp et al, 1984; Schwartz et al, 1991). There is evidence to suggest 
that a single unrepaired dsb results in cell sterility, and can be regarded as a lethal 
lesion (Frakenberg-Schwager and Frakenberg, 1990).
1.3 Mechanisms of radiation-induced cell death
There are two morphologically distinct mechanisms of cell death: necrosis 
(mitotic cell death) and apoptosis (programmed cell death). Apoptosis is 
characterised by several features which are absent in necrotic cell death. These 
include shrunken cell size, shrunken nuclei and a characteristic DNA fragmentation 
‘ladder’ demonstrable by electrophoresis (reviewed by Wyllie, 1993). Generally, 
necrosis occurs during mitosis, while apoptosis occurs during interphase. Apoptosis 
usually occurs rapidly after irradiation, and is thought to be a cell-regulated process 
(Sellins and Cohen, 1987). Necrotic cell death does not necessarily occur during the 
first cell division after irradiation. Introduction of dsb by either radiation or DNA- 
cleaving restriction enzymes results in the progressive accumulation of gross 
chromosome abnormalities (Bradford, 1991; Zhang and Dong, 1987). Lethally-
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irradiated cells may undergo several divisions before metabolic and structural 
integrity is lost due to these chromosome abnormalities (Hurwitz and Tolmach, 
1969).
Whilst necrotic cell death is prevalent in most cell types, radiation-induced 
apoptosis has been observed in an increasing range of cell types. These include 
lymphoid and hematopoetic cells, and undifferentiated progenitors of testicular, 
renal and neuronal cell lineages (reviewed by Allan, 1992).
1.4 Factors involved in radiation-induced apoptosis
Classical apoptosis is defined as a type of cell death that requires gene expression 
(Wyllie et al, 1980), and may be suppressed by inhibitors of protein or RNA 
synthesis. The molecular events which initiate apoptosis are not well defined. 
Apoptosis has been observed in some cell types after ligand-induced activation of 
Fas (APO-1/CD95) and tumour necrosis factor receptor (TNF-R1). However, 
apoptosis initiated by these mechanisms is not inhibited by protein synthesis 
inhibitors, suggesting that the intracellular mediators of apoptosis may already by 
expressed in some cells (Nagata, 1996).
Recent reports have highlighted the role of sphingomyelin metabolites in the 
cellular response to radiation. Sphingomyelin is an integral membrane sphingolipid 
which yields intracellular ceramide upon hydrolysis. Ceramide has been 
demonstrated to be involved in the regulation of several intracellular signal 
transduction pathway intermediates (including intermediates in the stress-activated 
kinase pathway), the phosphorylation status of the retinoblastoma gene product, and 
the interleukin-ip converting enzyme (ICE)- like protease family (Hannun, 1996). 
The result of increased intracellular ceramide concentration varies amongst cell 
types, but reported effects include apoptosis, cell cycle arrest, differentiation and 
cell senescence (Venable et al, 1995, Jayadev et al, 1995, Obeid et al, 1993)
Ionising radiation has been demonstrated to trigger the hydrolysis of 
sphingomyelin to produce intracellular ceramide (Haimovitz-Friedman et al, 1994 
a). This effect was also observed in enucleated cells, implying that radiation has a
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direct effect on radiation-sensitive intracellular targets other than genomic DNA. 
Subsequent investigations established that ceramide-induced apoptosis in 
endothelial cells could be blocked by direct activation of protein kinase C (PKC), 
and by indirect activation of PKC via the receptor for basic fibroblast growth factor 
(bFGF) (Haimovitz-Friedman et al, 1994(b); Fuks et al, 1995). Molecular events 
downstream of PKC in ceramide-induced apoptosis have yet to be established.
Further studies have highlighted the role of the cell membrane in the apoptotic 
pathway. Trolox, a vitamin E analogue which inhibits oxidative membrane damage, 
has been shown to protect irradiated thymocytes from radiation-induced apoptosis 
(Ramakrishnan et al, 1993). Also, chemical agents which cause cell membrane lipid 
damage are able to induce apoptosis (Langley et al, 1993).
The precise mechanism by which radiation induces sphingomyelin hydrolysis 
remains obscure, as does the nature of the non-DNA radiation-sensitive target.
1.5 The linear quadratic model of cell survival
The linear quadratic model of cell survival in response to ionising radiation was 
first outlined by Kellerer and Rossi (1972). This model was developed further by 
Chadwick and Leenhouts (1973), who arrived at the same empirical equation as 
Kellerer and Rossi using several different assumptions.
The equation which relates cell survival and dose is now widely used to describe 
the sensitivity of cells to ionising radiation, and usually takes the form:
( ad + Bd2)
Survival (S) = exp -
a  and p are constants, relating to different parts of a survival curve which has no 
shoulder nor linear portion, but is continuously bending.
The Kellerer and Rossi model makes the assumption that each cell has two 
‘targets’, and that both must be hit to cause cell sterility. This could be achieved by a 
single track of radiation hitting both targets, or by two distinct ionisation events,
5
each hitting a distinct target. The a  component is related to the probability of a 
single track causing lethal damage, while the |3 component is related to the 
probability of lethal damage being caused by two tracks.
The Chadwick and Leenhouts model assumes that only an unrepaired double 
strand break in DNA causes cell sterility, and that a single track of ionising radiation 
may cause either a double or single strand break. It is also assumed that if a single 
track causes a single strand lesion, then a second track is required to cause a further 
lesion in the complementary DNA strand, close enough to the primary lesion to 
generate what appears to be a double stranded lesion.
In relation to the survival curve produced using this model, the a  component 
describes the initial slope of the curve, while the |3 component describes curvature 
of the line.
These models are unlikely to closely represent the actual effects of ionising 
radiation tracks on cellular DNA, but the linear quadratic equation does appear to fit 
the data obtained from cultured cell response to radiation, within the dose range 
normally used to examine monolayer and spheroid cultures.
1.6 Tumour radiobiology
Clinical management of malignant disease often utilises fractionated radiotherapy. 
The rationale for dose fractionation is based mainly upon the fact that tumour cells 
generally repair DNA damage less efficiently than normal cells. The inter-fraction 
time results in preferential repair and repopulation of damaged normal tissue 
However, several processes may affect the outcome of fractionated radiotherapy. 
Re-oxygenation, redistribution, and intrinsic radiosensitivity, as well as repair of 
DNA damage and repopulation of normal tissue, are collectively known as the five 
‘Rs’ of radiotherapy. Re-oxygenation refers to the tumour regions which have a poor 
blood supply, and are thus hypoxic. Hypoxic cells are much more resistant to y- 
irradiation than the same cells under oxic conditions. Under fractionated 
radiotherapy, hypoxic regions may undergo re-oxygenation, and thus ensure that no 
cell remains permanently hypoxic, and thus resistant to y-irradiation. Redistribution
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refers to cell cycle status of tumour cells, and allows cells which are initially in a 
relatively radiation-insensitive cell cycle phase to re-assort into more sensitive 
phases. Intrinsic radiosensitivity is discussed below.
1.6.1 Intrinsic radiosensitivity.
Cells from different tumour types produce different shapes of radiation survival 
curve. An examination of the radiation response of many cell lines and the tumours 
from which they were derived revealed that cell lines derived from generally 
radioresponsive tumours (e.g lymphomas) were more radiosensitive than cell lines 
derived from radioresistant tumours (e.g gliomas) (Malaise et al, 1987). The 
difference in radiosensitivity was only observed in the low-dose region of the 
survival curve (described by the a  parameter from the linear quadratic model of cell 
survival).
Another parameter which allows discrimination between radiation sensitive and 
resistant cell lines is the surviving fraction at 2 Gy (SF2) (Steel, 1988). 2 Gy is the 
most common fractionated dose administered during radiotherapy. Cell lines 
examined by Steel (1988) showed a range of SF2 values between 0.19 and 0.52. A 
precise explaination of the differences in intrinsic radiosensitivity observed between 
different cell types remains elusive.
It is important to note that the curability of a tumour in situ is not wholly dependent 
upon intrinsic radiosensitivity. The additional influence of the remaining four ‘Rs’ 
combine to determine clinical outcome. However, induced alteration in the intrinsic 
radiosensitivity of a tumour cell could have important ramifications in a clinical 
setting.
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CHAPTER 2 
TARGETED RADIONUCLIDE THERAPY
8
2.1 Introduction
The major problem encountered in conventional radiotherapy is the unavoidable 
damage sustained by normal tissue. The sensitivity of normal tissue to radiation 
limits the total dose per fraction administered, and thus the effectiveness of the 
therapeutic strategy. Ideally, cancer radiotherapy involves the selective irradiation of 
tumour deposits without irradiation of the surrounding normal tissue.
Targeted radiotherapy involves the conjugation of radionuclides to carrier 
molecules which are preferentially accumulated in tumours. Systemic administration 
of such conjugates results in tumour cell accumulation of cytotoxic radionuclide, 
whilst non-tumour tissue, which does not accumulate the conjugate, is not irradiated.
The efficacy of targeted radiotherapy is dependent upon the nature of both the 
radionuclide and the tumour-seeking delivery vehicle.
2.2 Radionuclides in targeted therapy
There are many radionuclides available for conjugation to targeting vehicles, with a 
wide range of physical and chemical properties. Some of those of current interest are 
listed in table 2.1.
There are several criteria by which an appropriate radionuclide may be selected. 
The half-life should match as closely as possible the biological half-life of the 
delivery vehicle. This ensures that the majority of decay energy is deposited whilst 
the targeting vehicle is available for tumour association. Another important factor is 
the chemistry of the isotope in question. The stability of the conjugate is of primary 
importance, and a simple and rapid conjugation method is preferable. The most 
important criterion for selection of a radionuclide is the form in which the decay 
energy is deposited, and the range of these emissions.
2.2.1 Nature and range o f emitted particles
The decay of many radionuclides includes a gamma component. These emissions, 
whilst of negligible therapeutic benefit, are useful in scintigraphy, allowing imaging 
of tumour deposits, and providing information on the distribution and tumour uptake 
of the conjugate. The particulate emissions of the radionuclide are responsible for 
radiobiological effect. The mean range of emitted particles describes the distance 
from the site of decay in which energy is deposited. Irradiation of the cell nucleus,
9
and thus DNA damage, is the primary objective of radionuclide therapy. As outlined 
in table 2.1, the mean range of emitted particles varies considerably. Long range p 
particles have a range of several cell diameters (e.g 1311), whilst Auger electrons 
have a mean range of less than one cell diameter (e.g 1251). The selection of an 
appropriate radionuclide therefore depends upon the subcellular distribution of the 
targeting vehicle. A vehicle which remains bound to a cell surface antigen, or is 
internalised into the cell cytoplasm (e.g an antibody) would require a particle 
emission with a range of at least one cell diameter to ensure irradiation of the cell 
nucleus. A targeting vehicle which localises in the cell nucleus allows the possibility 
of using short range Auger electron-emitting radionuclides (e.g 1251- 
iododeoxyuridine). Auger electron-emitting radionuclides have a greatly decreased 
radiobiological effect when localised in the cytoplasm or cell membrane (Warters et 
al, 1977). The sub-cellular localisation of a long range p-emitting radionuclide (e.g 
1311) is less important, because the particle range is longer than a single cell 
diameter, and the nucleus of targeted cells will receive a radiation dose regardless of 
sub-cellular localisation.
2.2.2 Linear energy transfer
Linear energy transfer (LET) describes the energy imparted (in kiloelectron volts) 
to a medium by a radioactive emission travelling 1pm along its path or track (Hall, 
1994). The terms low and high LET describe the relative ionising potential of 
different radioactive emissions. Radionuclides with low LET radiation (e.g 1311- 
emitted p-particles) are less effective in causing DNA damage, as energy exchanges 
with matter are more widely spaced, and thus less likely to interact directly with 
DNA. High LET radiation (e.g 1251-emitted Auger electrons) is preferable for 
radiobiological effect, as energy exchanges with matter occur frequently, and is more 
likely to result in DNA damage.
The LET nature of a radioactive emission also has implications for DNA damage 
repair. Ionising radiation inflicts several types of damage on DNA, including base 
modification and protein-DNA cross-linking as well as single and double strand 
breaks. The densely ionising nature of high LET radiation results in multiple lesions 
in a localised region of the DNA strand. The correct repair of multiple lesions
10
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occurs with a much lower frequency than single lesions, where the undamaged strand 
may be used as a template.
The complexity and number of DNA lesions caused by high LET radiation makes 
radionuclides which emit such particles especially suitable for targeted radiotherapy.
2.3 Targeting Vehicles
As outlined earlier, the efficacy of any targeted radionuclide therapy is dependent 
upon the ability to deliver radionuclide to the target cell. One of the earliest, and 
possibly most effective targeted radionuclide strategies is the administration of ionic 
1311 for the treatment of thyroid tumours. This treatment is effective due to the 
unique sequestration of iodine by thyroid cells. Ionic strontium-89 (89Sr) has also 
been used for palliative therapy of bone metastases, as it is preferentially 
accumulated in metabolically active bone. However, there are very few tumour types 
in which administration of radionuclide in ionic form would result in preferential 
tumour uptake. Conjugation of radionuclide to a tumour-seeking carrier molecule is 
usually required. Tumour cells have several biological and metabolic features which 
distinguish them from the surrounding normal tissue, and a variety of agents have 
been used to exploit these differences.
2.3.1 Antibodies
Although treatment of patients with radiolabelled antibodies raised against tumour 
markers was first described in 1953 (Pressman and Komgold), modem 
radioimmunotherapy began with the development of hybridoma technology, i.e the 
ability to produce large quantities of monoclonal antibody with pre-defined 
specificity. Monoclonal antibodies were originally envisaged as ‘magic bullets’, 
which would specifically seek out tumour-specific markers, and elicit an anti-tumour 
effect. However, clinical trials involving the use of naked (unconjugated) antibodies 
have yielded disappointing results (reviewed by Grossbard et al, 1992, Riethmuller et 
al, 1993), mainly due to the lack of an host antibody-dependent cytotoxic response.
Attempts to improve on these results have led to the conjugation of a wide variety 
of cytotoxins and radionuclides to monoclonal antibodies. However, investigators 
have encountered many problems with such strategies. Heterogeneity of antigen 
expression within the tumour mass, poor tumour vasculature, poor diffusion of 
antibody within the tumour mass and low levels of absolute antibody uptake in
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tumours have been identified as problems affecting the efficacy of antibody- 
conjugate therapy (reviewed by Stold et al, 1997, Wheldon, 1994). In addition, the 
systemic administration of mouse monoclonal antibodies may result in a host 
immune response, reducing the efficacy of subsequent treatments. Attempts are 
currently underway to circumvent many of these problems by the use of smaller 
antibody fragments and ‘humanised’ antibodies (reviewed by von Mehren and 
Weiner, 1996).
In relation to immunoconjugates, radioisotopes have some advantages over 
cytotoxic drugs and biological toxins. Conjugation of a radionuclide with a long 
range (3-emission results in both the target cell, and those in close proximity, being 
irradiated and thus sterilised. The process by which untargeted cells are killed by 
emissions from a neighbouring targeted cell is known as crossfire. Cytotoxic drugs or 
biological toxins are only capable of killing cells to which they are directly targeted, 
i.e. there is no crossfire effect. Heterogeneity of antigen expression within the tumour 
mass will have less effect on the efficacy of radioimmunoconjugates than on 
cytotoxic drug/toxin immunoconjugates due to the effects of crossfire. Other 
disadvantages of cytotoxic drug immunoconjugates are the potential denaturation of 
the drug after internalisation, and the sparing of tumour cells with multi-drug 
resistance. Biological toxins may also precipitate a host immune response. These 
problems are not encountered by radioimmunoconjugate strategies.
The most successful clinical application of radiolabelled antibodies is in the 
treatment of haematological malignancy. In particular, the treatment of B-cell 
lymphoma with 1311-labelled antibody has resulted in significant patient response 
and prolonged remission (Press et al, 1993, Kaminski et al, 1993). Haematological 
malignancies are good candidates for radioimmunotherapy, as the penetration 
problems encountered in solid tumours are greatly reduced. In addition, 
haematopoetic cells are generally radiosensitive, and the target antigens are not 
widely expressed on other tissue types.
2.3.2 Nucleotide analogues
Analogues of DNA precursor molecules (nucleotides) are incorporated into cellular 
DNA during the S-phase of the cell cycle, and are preferentially accumulated by 
proliferating cells. Deoxyuridine, an analogue of thymidine, and deoxycytidine have 
both been used as radioisotope delivery vehicles in cultured cell models (Makrigioros 
et al, 1989, Howell et al, 1991). Auger electron-emitting radionuclides are
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particularly suitable for nucleotide analogue-conjugation, as the conjugate is 
incorporated into DNA.
Because this type of delivery vehicle exploits tumour/normal tissue proliferative 
differential, rather than any tumour-specific marker, systemic administration could 
lead to significant normal tissue toxicity. Work is currently underway to examine 
different types of drug administration, in an attempt to confine the biodistribution to 
the local tumour region, and maximise tumour uptake (Kassis et al, 1990). Tumours 
such as glioma are good candidates for radiolabelled nucleotide analogue therapy, as 
the proliferating tumour cells are surrounded by non-proliferating tissue.
2 3 3  Agents which target metabolic differences o f tumour cells
Some tumour types display metabolic differences from the surrounding normal 
tissue. An example of this is malignant melanoma, in which the pigmented cells 
overproduce melanin. Compounds, such as methylene blue, which posses a high 
binding affinity for melanin are preferentially accumulated in melanoma cells, in 
proportion to the cellular melanin content. Radiolabelled methylene blue has been 
demonstrated to posses in vivo anti-tumour activity in animal models (Link and 
Carpenter, 1990, Link et al, 1996).
One of the most successful targeted radiotherapy strategies is the use of 1311-meta- 
iodobenzylguanidine (MIBG) in the treatment neuroblastoma and 
phaeochromocytoma. MIBG, similar in structure to noradrenalin, exploits the 
noradrenalin active uptake mechanism of these tumours. MIBG is currently in 
clinical use, both as a diagnostic tool and as a therapeutic agent.
2.3.4 Growth factors and steroid hormones
Many tumour cells overexpress, or have enhanced sensitivity to peptide growth 
factors. The small size and high receptor binding affinity of these peptides makes 
them good candidates as radionuclide delivery vehicles. Radiolabelled analogues of 
somatostatin have proven effective in human breast and small cell lung cancer 
xenograft models (Zamora et al, 1996). Ligands which bind the epidermal growth 
factor receptor (EGFR) have also been examined as potential delivery vehicles 
(Andersson et al, 1992). The use of EGFR ligands as delivery vehicles is discussed in 
chapter 5.
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Steroid hormones are also candidates as delivery vehicles for radionuclides. Steriod 
hormones enter the cell by passive diffusion, and interact with specific intracellular 
receptors which associate with DNA in the ligand-bound state. Several tumour types, 
including breast and ovarian tumours, express high levels of oestrogen receptor. The 
DNA-association characteristic of the ligand-bound receptor allows the use of 
radionuclides with short-range emissions. 1231 and 1251-oestrodiol derivatives have 
been demonstrated to selectively sterilise oestrogen receptor-positive cells (De 
Sombre et al, 1992, Beckman et al, 1993).
2.4 The therapeutic potential of Auger electron-emitting radionuclides
2.4.1. Auger electron emitting radionuclides and their radioactive decay.
Several radionuclides decay by electron capture and/or internal conversion. These 
terms describe the manner in which a nucleus absorbs an inner shell orbital electron 
(electron capture). The vacancy created in the inner shell is filled by another orbital 
electron from a higher energy level, generating another vacancy. The energy 
produced from this electronic transition may be transferred to one or more orbital 
electrons, causing further ionisation of the atom. This causes a cascade of electronic 
transitions, and a release of a large number of electrons, resulting in a highly charged 
atom. The atom is then charge neutralised by acquisition of electrons from the 
surroundings.
Emitted electrons resulting from transition from a higher to lower electron shell are 
termed Auger electrons, while those emitted as a result of a transition from a higher 
to lower energy sub-shell are termed Coster-Kronig electrons (Sastry, 1992).
The electron absorbed into the nucleus from the inner orbital shell combines with a 
proton to form a neutron. This process results in the emission of a y-ray photon from 
the nucleus. This energy may be transferred to an orbital electron, causing further 
ionisation, and thus another cascade of electronic transitions as described above. This 
results in emission of Auger electrons. This process (internal conversion) is rarely 
100 % efficient, and thus some of the energy of the photon will be released from the 
atom as y-rays. The emitted y-rays are characteristic of the radionuclide. In this 
report, for simplicity, all electrons emitted as a result of electron capture and/or 
internal conversion are termed Auger electrons.
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Auger electrons generally have low energies (< 500 eV), and thus have very short 
ranges in biological material (< ljxm). However, the number of electrons emitted per 
radioactive decay can result in extremely high energy deposits within this range.
To date, the major clinical application of radionuclides which decay in either of 
these ways has been in radio-imaging. The technique of radio-imaging utilises the 
emitted y-ray component of these radionuclides, while the Auger electrons cannot be 
detected due to the extremely short range of emission. Commonly encountered 
radionuclides in radio-imaging include 1231, l l l ln ,  210TI and 99mTc.
2.4.2. Auger electron cytotoxicity
The decay of a radionuclide by electron capture and/or internal conversion 
produces Auger electrons with an extremely short range. To achieve a radiobiological 
effect from such electron emissions, it is necessary that the radioactive decay occurs 
close enough to DNA to be within the range of these electrons.
1251, incorporated into DNA in the form of the thymidine analogue 1251 -5 iodo- 
2’-deoxyuridine (1251-IUdR) results in double-strand DNA breaks, and a decrease in 
cell survival and clonogenic capacity (Kirsch, 1972). The biological effects of 1251 
incorporation into DNA are consistent with those produced by high LET radiation, 
i.e. large clusters of ionisations within the range of the emitted Auger electron 
(Charlton, 1986). A high LET radiation track interacting with DNA will cause much 
greater damage than a low LET track, for example X-ray photon tracks. The relative 
biological effectiveness (RBE) of DNA-incorporated 1251 when compared to 
estimated equivalent dose 250 KeV X-rays is over seven times greater (Kassis et al,
1989). However, 1251 localised in the cytoplasm, cell membrane or in the 
extracellular medium produces a cell survival curve comparable with that achieved 
with low LET radiation, with an RBE similar to that observed with externally applied 
X-rays of estimated equivalent dose (Kassis et al, 1989), suggesting that the 
radionuclide must be localised within, or close to DNA for the high LET effect to be 
observed.
The damage caused to DNA by disintegration of incorporated 1251 is very great, 
with each disintegration on average producing at least one double strand break 
(Humm and Charlton, 1989). Studies using synthetic oligonucleotides demonstrated 
that the majority of strand breaks occurred within 1-2 nm (approximately 5 bases) of 
the incorporation site, with some strand breaks occurring up to 7 nm (approximately 
20 bases) from the site of incorporation (Martin and Haseltine, 1981). This study also
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suggested that the decay of incorporated 1251 causes multiple double strand lesions 
within a 10-20 base range. Typical radiation survival curves observed after treatment 
with high LET radiation characteristically show little curvature, and a steep ‘linear’ 
component.
The therapeutic potential of Auger electron-emitting radionuclides depends entirely 
upon selective nuclear delivery, as cytoplasmic localisation of these radionuclides has 
very little effect in either tumour or normal tissue (Kassis et al, 1989). Due to the 
short range of these particles, the high LET characteristic will only be observed after 
localisation within the targeted cell nucleus. Damage to surrounding cells should be 
greatly reduced compared to that induced by external beam radiotherapy, provided 
that an effective means of exclusive delivery to tumour cell nuclei can be developed. 
The photon emissions from the decay of Auger-emitting (and beta-emitting) 
radionuclides (either gamma or x-rays) rarely have any therapeutic benefit. However, 
in a clinical setting, the high concentration of radionuclide administered can result in 
the patient receiving a significant whole body dose from these emissions. This may 
be particularly important in multi-modal theapeutic strategies where the 
haematopoetic system is already under considerable stress.
2.4.3. Delivery vehicles for Auger emitters
The ultra-short range of Auger electrons requires a delivery vehicle which either 
binds, or is incorporated into DNA. Several studies have examined the potential of 
the use of nucleotide analogues as delivery vehicles. Deoxyuridine, a thymidine 
analogue, has been used to deliver 1231 and 1251 (in the form of iododeoxyuridine, or 
IdUR) and 77Br (in the form of bromodeoxyuridine, or BdUR) to DNA in cultured 
cell models (Chan et al, 1976, Kassis et al, 1982, Makrigiorgos et al, 1989). 
Similarly, deoxycytidine has been used to deliver 1251 in the form of 
iododeoxycytidine (IdC) (Howell et al, 1991, Narra et al, 1992). All of these labelled 
nucleotide analogues produce high LET-type survival curves.
Molecules which bind DNA in a non-covalent manner have also been assessed as 
delivery vehicles for Auger emitters. Cisplatin analogues and the vitamin A analogue 
acetamidoiodo-proflavin, when labelled with Auger emitting radionuclide, have been 
shown to be highly cytotoxic (Kassis et al, 1989, Howell et al, 1994).
As outlined above (section 2.3.4), preliminary studies have also been carried out 
into the potential for the use of steroid hormones as delivery vehicles. These 
hormones enter the cell by passive diffusion, and recognise an intracellular receptor
17
which associates with DNA in the ligand-bound state (reviewed by Carson-Jurica et 
al, 1990). 1231- and 1251-labelled oestrogens have been demonstrated to be cytotoxic 
to oestrogen receptor-positive cells, displaying high LET-type effects (Beckman et al, 
1993, DeSombre et al, 1992).
18
CHAPTER 3
THE EPIDERMAL GROWTH FACTOR RECEPTOR AND 
PHYSIOLOGICAL LIGANDS
19
3.1 Discovery and characterisation of EGFR and cognate ligands
3.1.1. Epidermal Growth Factor
The epidermal growth factor (EGF) was first described in 1962, when it was 
observed that an extract of mouse submaxillary gland was able to induce precocious 
tooth eruption in neonatal mice (Cohen, 1962). These effects were demonstrated to 
be a result of increased epidermal proliferation, hence the name epidermal growth 
factor. Following purification, analysis of the factor indicated that it was of low 
molecular weight (6 kD), and consisted of 53 amino acid residues, with three 
intermolecular di-sulphide bonds (Savage et al, 1972). The human equivalent of 
EGF, subsequently isolated from urine, was found to be identical to a peptide known 
as urogastrone, which acted as an inhibitor of gastric acid secretion (Gregory, 1975).
Since its discovery, EGF has been found to be the prototypic member of an 
extended family of peptides. These peptides all contain three di-sulphide bonds in the 
general sequence indicated (Carpenter and Cohen, 1990):
XnCX7 CX2/3 GXCX10/13 CXCX3 YXGXRCX9LXn
Individual members of the family are encoded by separate genes, and include 
transforming growth factor alpha (TGF-a), amphiregulin (AR), heparin-binding 
EGF-like growth factor (HB-EGF), cripto and betacellulin (BTC) (Carpenter and 
Cohen, 1990, Todaro et al, 1976, Shoyab et al, 1988, Higashiyama et al, 1991, 
Sasada et al, 1993). A viral gene frequently encoded by members of the pox virus 
family also produces a peptide with homology to EGF (Todaro et al, 1990). EGF-like 
motifs can also be found in a wide range of both secreted and cell-bound proteins. 
While these proteins have no EGF-like effect, they appear to have functions in 
development, cell adhesion and protein-protein interactions (Carpenter and Cohen
1990). It has been speculated that the growth factor/receptor system utilised by 
members of the EGF-like family may have evolved from an ancestral form of cell­
cell communication (Prigent and Lemoine, 1992).
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3.1.2. The epidermal growth factor receptor
The cellular receptor for EGF was isolated and purified to homogeneity by affinity 
chromatography in 1980 (Cohen et al, 1980). Both the purification and early study of 
the epidermal growth factor receptor (EGFR) was facilitated by the establishment of 
the A431 cell line derived from a human carcinoma of the vulva (Giard et al, 1973). 
A431 has an abnormally high EGFR content on the cell membrane, established by 
125I-EGF binding as approximately 2x106 per cell (Haigler et al, 1978).
The full cDNA and amino acid sequence of the receptor was reported in 1984, 
which greatly enhanced the study of EGFR expression (Ullrich et al, 1984). EGFR is 
expressed normally in a wide range of tissues, with the notable exception of 
haemopoetic cells (Carpenter, 1987).
The observation that EGFR expression may be increased in human malignancies 
was first reported in 1984, where it was observed that both epidermal tumour biopsy 
material, and cell lines derived from this material, invariably has an enhanced EGFR 
expression (Hendler and Ozanne, 1984). More recent studies have demonstrated that 
EGFR overexpression is a characteristic of tumours of many diverse sites of origin. 
This overexpression may be involved in both the initial transformation process and in 
the clinical progression of the disease (Di Fiore et al, 1987, Sainsbury et al, 1987).
Subsequent investigation has established that the EGFR belongs to a family of 
structurally related proteins with regions of conserved sequence homology. The Type 
1 (EGFR-like) growth factor receptor family includes HER 1 (also known as EGFR, 
erb-Bl, pl70 erb-Bl ), HER 2 (erb B2, pl85 erb B2, pl85 neu ), HER 3 (erb B3, 
pl60 erb B3 ) and HER 4 (erb B4, pl80 erb B4 ) (Prigent and Lemoine, 1992, Kraus 
et al, 1989, Plowman et al, 1993). Whilst ligand molecules for HER 3 and 4 have 
been described, none has been demonstrated to be able to directly bind and activate 
EGFR (Carraway et al, 1994, Plowman et al, 1993). EGFR remains the best 
characterised member of this family.
3.1.3. EGFR signalling
Initial observations of the effect of ligand binding to the EGFR indicated that 
protein kinase activity was involved in the transduction of the EGF signal. The 
addition of EGF to partially purified extracts of A431 cell membranes resulted in a 
rapid increase in protein phosphorylation (Carpenter et al, 1979). Subsequent studies 
indicated that the EGFR itself, as well as other substrate proteins, were
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phosphorylated in response to EGF stimulation (King et al, 1980). The finding that 
both substrate proteins and the EGFR itself were phosphorylated specifically on 
tyrosine residues gave rise to the hypothesis that EGF exerted its effect on receptor- 
expressing cells via an increase in receptor associated tyrosine kinase activity (Ushiro 
and Cohen, 1980). Failed attempts to dissociate the ligand binding activity from the 
tyrosine kinase and substrate portions of the receptor indicated that all 3 regions were 
contained within a single molecule (Buhrow et al, 1982).
The EGFR was the first described membrane-bound growth factor receptor with 
intrinsic tyrosine kinase function. Subsequent investigations have revealed many 
other receptor tyrosine kinases, including the receptors for insulin, insulin-like 
growth factor (IGF), colony stimulating factor (CSF), platelet-derived growth factor 
(PDGF) and the fibroblast growth factor family (reviewed by Ullrich and 
Schlessinger, 1990).
3.2 Control of normal and aberrant EGFR expression
3.2.1. Regulation o f EGFR expression
The regulation of EGFR expression is a complex process, with many cellular 
compounds exerting regulatory influence at several stages of the 
transcription/translation pathway.
The EGFR gene promoter was first characterised in 1985, with the observation that 
the GC-rich promoter which contained an SP1 binding motif did not contain CAAT 
or TATA boxes (Ishii et al, 1985). Subsequent investigations have revealed a number 
of transcription factors which positively regulate EGFR gene transcription, including 
SP1, ETF1 and 2 (EGFR-specific transcription factor) (Merlino, 1990, Kageyama et 
al, 1988). p53 has also been demonstrated to bind and activate the EGFR promoter 
region (Deb et al, 1994). Additional co-operative factors, which bind to different 
sequences in the promoter region and enhance transcriptional activity, have been 
described (Maikawa et al, 1989). Transcription repressing DNA-binding proteins 
have also been reported, including ETR (EGFR transcriptional repressor) and GCF 
(GC factor) (Kageyama and Pastan, 1989, Hou et al, 1994).
The cellular expression of EGFR has been demonstrated to be regulated at the 
transcriptional level by a variety of physiological systems. Both progestin and 
glucocorticoid treatment of a human breast cancer cell line (T-47D) have been shown 
to result in increases in EGFR mRNA and cell surface receptor expression (Murphy
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et al, 1986,1988, Ewing et al, 1989). Growth hormone has also been demonstrated to 
increase EGFR expression and mRNA levels in rodent hepatic cells (Jansson et al, 
1988, Ekberg et al, 1989). An interesting regulator of EGFR expression is EGF itself, 
which has been shown to increase EGFR mRNA transcription in two different cell 
lines (Clark et al, 1985, Kudlow et al, 1986). This effect is achieved as a result of an 
increase in the intracellular half-life of the mRNA species (Jinno et al, 1988). There 
is no report of any other EGFR regulation system causing this effect. Other known 
regulators of EGFR transcription include interferon-gamma (IFN-y), and the negative 
regulators, thyroid hormone (T3) and retinoic acid (Hamburger and Pinnamaneni, 
1991, Hudson et al, 1990, Grandis et al, 1996).
EGFR transcription is also upregulated by elevated intracellular concentrations of 
cAMP, and the protein kinase C activator, PMA (4p-phorbol 12-myristate 13- 
acetate) (Hudson et al, 1989), suggesting that other cellular signalling systems may 
affect EGFR expression.
In summary, the transcription and expression of EGFR is under precise control by a 
range of intracellular signalling intermediates and hormonal influences at the 
transcriptional and post-transcriptional level. Complex regulation of EGFR 
expression is essential due to the consequences of abnormal expression. These 
consequences are discussed in section 3.3.
3.2.2. EGFR gene amplification
The overexpression of EGFR is most commonly a consequence of increased 
mRNA production and/or stability. However, amplification of the EGFR gene may 
also be involved in receptor overexpression. EGFR gene amplification has been 
observed, both as double minute chromosomes and homogeneous staining regions, in 
tumours of several sites. Amplification is most commonly observed in gliomas, 
particularly glioblastoma multiforme, to a lesser degree in lung squamous cell 
carcinomas and head and neck squamous cell tumours (Schwechheimer et al, 1995, 
Gorgoulis, 1993, Saranath et al, 1993). Due to the higher incidence of gene 
amplification in gliomas, many of the studies addressing the characteristics of EGFR 
gene amplification have been carried out using material and cell lines derived from 
tumours of this type.
EGFR gene amplification invariably results in EGFR protein overexpression, but 
there appears to be no direct correlation between gene copy number and the level of 
protein expression (Chaffanet et al, 1992). This suggests that control of expression at
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the transcriptional level remains the most important determinant of EGFR protein 
overexpression.
In early stage gliomas, investigators have observed other genetic alterations which 
usually precede EGFR gene amplification. These most commonly include loss of 
heterozygosity (allele loss) in regions of chromosomes 10 and 17p (Fujimoto et al, 
1989, James et al, 1989). The incidence of these genetic mutations is high (LOH 10 = 
60-75%, LOH 17p = 30-35%), but the influence on subsequent EGFR gene 
amplification is unclear (Venter et al, 1991). One study has observed that EGFR gene 
amplification occurs with higher frequency in patients without LOH 17p, and only 
occurs in patients with LOH 10 (Von Deimling et al, 1993). However, another study 
has indicated that EGFR gene amplification can be observed without LOH 10 
(Diedrich et al, 1995). Both of these studies found that EGFR gene amplification 
incidence increases with age of patient.
Whilst an explaination of how chromosome 10 and 17p allele losses directly affect 
EGFR gene amplification remains elusive, the prognostic significance of 
amplification and the resultant EGFR overexpression is clear. Individuals with a 
glioma carrying an EGFR gene amplification have a significantly poorer prognosis 
(Diedrich et al, 1995).
3.2.3. EGFR gene rearrangement
As well as amplification of the EGFR gene in gliomas, there is also a high 
incidence of structural rearrangement of the gene, resulting in an in-frame deletion 
mutant EGFR protein (Sugawa et al, 1990). The most commonly observed mutant 
receptor is characterised by the loss of nucleotides 275-1075 in the receptor gene, 
encoding amino acid residues 16-273 (Wong et al, 1992). This corresponds to the 
deletion of exons 2 to 7, and the direct fusion of exons 1 and 8. The resultant protein, 
termed EGFR VIII, has almost no extracellular domain and is unable to bind EGFR 
ligand. This protein bears great similarity to the w-erb gene product, and behaves in a 
similar manner i.e as a constituitively active membrane-anchored tyrosine kinase 
(Ekstrand et al, 1994). The expression of EGFR VIII was first reported in 17% of 
primary glioblastoma tumours (Wong et al, 1992, Yamazaki et al, 1988). Subsequent 
studies have revealed that EGFR VIII expression can be observed in 16% of non­
small cell lung carcinomas (Garcia de Palazzo et al, 1993), 78% of (infiltrating 
ductal) breast carcinomas, 75% of ovarian carcinomas, and several brain tumours, 
including astrocytoma (56%) and medulloblastoma (86%) (Moscatello et al, 1995).
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Other EGFR deletion mutants have been reported, but occur at a much lower 
frequency (Garcia de Palazzo et al, 1993). These studies have also failed to detect any 
EGFR deletion mutant in corresponding normal tissue, suggesting that EGFR VIII 
expression may be exploited as a tumour-specific marker.
3.3. The EGFR system in human tumours
3.3.1. The role o f EGFR in tumour initiation and progression
One of the earliest indications that EGFR may play a role in the development of the 
malignant process was the observation that the product of the v-erb B oncogene has 
many similarities to the intracellular tyrosine kinase-containing region of the human 
EGFR (Downward et al, 1984a). The v-erb B (avian erythroblastosis virus) 
oncogene, which induces malignancies in chickens, is derived from the avian EGFR 
gene and thus indicated the proto-oncogenic potential of the EGFR.
The observation that the v-erb B gene product contained a constituitively active 
tyrosine kinase domain, which appeared to be responsible for the transforming 
potential of the virus, gave rise to the hypothesis that the observed increase in EGFR 
expression in some tumour types may be responsible, or at least involved in either the 
malignant transformation process, or in the progression of the disease (Gilmore et al,
1985).
The role of EGFR overexpression in the transformation process has since been 
studied, revealing a number of interesting findings. Two independent studies 
determined that overexpression of normal human EGFR in NIH 3T3 fibroblasts 
resulted in transformation (defined by soft agar colony formation) only when the cells 
were exposed to an EGFR ligand (Di Fiore et al, 1987, Riedel et al, 1988). 
Overexpression of normal human EGFR in the absence of an activating ligand was 
not sufficient to confer the transformed phenotype. However, transfection of a similar 
cell line with an N-terminal deleted EGFR, containing no extracellular (ligand 
binding) domain was sufficient for transformation (Haley et al, 1989). The N- 
terminal mutants were shown to have a constituitively active kinase domain, similar 
to that observed with the v-erb B gene product. This study indicated that EGFR- 
related transformation was dependent upon the activity of the intracellular kinase 
domain of the receptor. It should be noted though, that overexpression of EGFR in 
vivo in a number of different cell types failed to produce neoplasia in transgenic 
animals (Merlino, 1990), suggesting that EGFR overexpression may lie downstream
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of another important transformational event. Similar work using TGF-a transgenic 
mice demonstrated that overproduction of EGFR ligand is implicated in the 
development of epidermal tumours of several sites without initial EGFR 
overexpression (Jhappan et al, 1990, Sandgren et al, 1990, Vassar et al, 1992).
Whilst the exact role of ligand and receptor overexpression in the transformation 
process remains obscure, the finding that EGFR ligand is frequently detected in 
tumours overexpressing EGFR suggests that the formation of self-stimulating 
(autocrine) loops plays an important role in the pathology of these tumours (Iihara et 
al, 1993, Fang et al, 1996).
3.3.2 EGFR overexpression in human tumours
The EGFR is overexpressed in a wide range of sarcomas and carcinomas. 
Overexpression is most commonly seen in squamous cell carcinomas, and is also 
observed less frequently in some brain tumours, in particular malignant glioma. 
Common sites of EGFR overexpression are tumours of the head and neck, breast, 
bladder, lung (non-small cell, and lung adenocarcinomas), as well as tumours of the 
digestive tract and several gynaecological tumours, especially those of cervical and 
ovarian epithelium (reviewed by Gullick, 1991, Modjtahedi and Dean, 1994a).
The reliability of EGFR expression as a prognostic indicator remains to be fully 
established. Routine screening of biopsy material may help to confirm the prognostic 
significance of EGFR overexpression, but questions still remain over the clinical 
relevance of such screening. The degree of overexpression in many malignancies 
appears to correlate with tumour stage/grade, and thus may not have 
much value as a tumour independent marker (Gusterson, 1992). Also, standardisation 
of the screening technique is required. Many anti-EGFR antibodies do not perform 
reliably in paraffin-embedded sections, and data obtained using immunocytochemical 
techniques may be open to misinterpretation (Gusterson, 1992). Studies carried out 
on biopsy material using radioligand binding or radioimmunoassay can only be semi- 
quantitative, as the results obtained are dependent on the amount of normal tissue in 
the sample. The observation that production of EGFR mRNA generally correlates 
with expression of EGFR protein on the cell surface suggests that more accurate and 
informative screening of tumour samples may be possible using RT-PCR techniques 
(Xu et al, 1984).
Whilst the prognostic implications of EGFR overexpression remain controversial, 
there are several reports which appear to correlate high EGFR expression with poor
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prognosis. This is most apparent in superficial bladder tumours, where 
overexpression of EGFR is associated with tumour multiplicity, short relapse time, 
high recurrence rate and early death (Neal et al, 1990), while EGFR overexpression 
in breast tumours also correlates with poor tamoxifen response, early recurrence and 
death in lymph node-positive patients (Horak et al, 1991, Nicholson et al, 1990). 
Similarly, EGFR overexpression may predict poor survival in patients with squamous 
lung tumours (Hendler et al, 1989).
3.4. Structure of the EGFR
The EGFR is a 170 kD membrane-anchored protein, consisting of 1186 amino 
acids (figure 3.1). This protein is encoded by the c-erb B1 proto-oncogene, located on 
chromosome 7 in humans. The receptor is a single chain protein which crosses the 
cell membrane once, the transmembrane domain consisting of 24, mainly 
hydrophobic, residues.
The amino terminus of the EGFR (amino acid residues 1-621) contains the 
extracellular ligand binding domain, which, in vivo, contains a large amount of N- 
linked polysaccharide (Carpenter and Cohen, 1990). Also, it contains two cysteine- 
rich regions which can be aligned, and give the external part of the EGFR a rigid, bi- 
lobal structure (Hunter, 1984). Evidence suggests that the non-cysteine rich regions 
of the extracellular domain are involved in ligand binding (Lax et al, 1988). The 
cytoplasmic, carboxy 1-terminus of the peptide chain (amino acid residues 645 -1186) 
can be divided into 3 domains based on function:
3.4.1. Juxtamembrane domain
The juxtamembrane domain (648-668) contains several phosphorylation sites 
which appear to be involved in the modulation of receptor function. Thr 654, Thr 669 
and Ser 671 have been implicated as substrates for Ser/Thr kinases, with Thr 654 
being the major protein kinase C (PKC) substrate. PKC interaction with EGFR 
results in attenuation of receptor tyrosine kinase activity (Davis et al, 1985, Livneh et 
al, 1988) and downregulation of high affinity EGF binding (Lund et al, 1990, 
Countaway et al, 1990). These effects are abrogated by point mutation of the EGFR 
at Thr 654. Phosphorylation of Thr 669 and Ser 671 results in altered receptor 
internalisation kinetics (Heiserman et al, 1990). Thr 669 has been implicated as a 
ceramide-activated protein kinase substrate (Dressier et al, 1992, Joseph et al, 1993),
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Figure 3.1 Schematic representation of the epidermal growth 
factor receptor. Domains and amino acid residue numbers are 
indicated on the left, while individual amino acids of functional 
significance are indicated on the right.
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and has also been found to be a phosphorylation site for MAP kinase (Takishima et 
al, 1991). However, more recent studies have suggested that these sites are not under 
direct control by PKC and MAP kinase, and that an intermediate protein may be 
involved in mediating the effects of these kinases on EGFR function (Griswold- 
Prenner et al, 1993, Morrison et al, 1996). The upregulation of PKC and MAP kinase 
activity by EGFR suggests the presence of auto-inhibitory loops involved in 
regulating EGFR tyrosine kinase activity.
The juxtamembrane domain also interacts with several proteins with signalling 
functions, including phosphatidylinositol-4P kinase (PIP-4 kinase), adenylyl cyclase 
and the cytosolic kinase, eps 8 (Cochet et al, 1991, Castagnino et al, 1995, Sun et al,
1995).
3.4.2 Kinase domain
The kinase domain is the most highly conserved region between members of the 
type 1 family of receptors. Of central importance in this domain is the ATP binding 
site, Lys 721. Point mutation of this site abrogates ATP binding and receptor tyrosine 
kinase activity (Honneger et al, 1987). This domain also contains two short 
sequences which are highly conserved in nucleotide binding proteins, both of which 
are involved in the correct orientation and binding of ATP (Wierenga and Hoi, 1983, 
Carpenter, 1987). Within these sequences, residues Gly 695 and Asp 831 appear to 
be the main sites of interaction with ATP.
3.4.3. Carboxyl terminal domain
The carboxyl terminal tail domain contains two regions of functional importance. 
Amino acids 973 to 1022 contain a number of negatively charged residues which 
appear to play a role in ligand-induced EGFR internalisation. Truncation of the 
receptor to residue 972 results in a receptor which is unable to undergo ligand- 
induced downregulation (Chen et al, 1989). This region is also implicated in EGFR- 
mediated alterations in Ca2+ ion flux.
The carboxyl tail (residues 1022-1186) contains the main autophosphorylation sites 
on the receptor. Tyrosine resides 992 1068, 1086, 1148 and 1173 have all been 
reported as being phosphorylated in response to EGF stimulation of the receptor 
(Downward et al, 1984, Margolis et al, 1989, Walton et al, 1992). Phosphorylation of 
these sites allows the carboxyl terminus of the receptor to form binding sites for
29
several SH2 (src homology 2) domain proteins (Margolis et al, 1990). These proteins 
include the ras GTPase activating protein (GAP), phosphatidylinositol-3 kinase (PI-3 
kinase), phospholipase C-gamma (PLC-y), the src homology and collagen protein 
(She), GRB2, and the SH2 domain protein-tyrosine phosphatase (SHP-l)(Batzer et 
al, 1994, Tomic et al, 1995, Soler et al, 1994). Interaction with these proteins serves 
to link the EGFR to a variety of intracellular signalling pathways. However, point 
mutation of all known autophosphorylation sites, or their removal by truncation of 
the carboxyl tail does not prevent the phosphorylation of these proteins or the 
activation of downstream signalling proteins associated with EGFR stimulation 
(Chen et al, 1989, Li et al, 1994). The mechanisms involved in the activation of SH2 
proteins by these mutant receptors have not been fully elucidated.
3.5. Signal transduction and signal abrogation
3.5.1.Signal transduction from activated EGFR
EGF exerts all of its cellular effects by binding the extracellular domain of the 
EGFR. No other mechanism of EGF-mediated alteration in cell function has been 
suggested. The transduction of this signal from the cell surface to nucleus has been 
the subject of extensive investigation, with the result that the EGFR intracellular 
signalling mechanism is now the best characterised of any growth factor receptor. 
There are several physical and biological events associated with EGFR activation and 
attenuation of the signal.
3.5.1.1. Ligand induced dimerisation
First described for EGFR, and now accepted as a property of all known growth 
factor receptors, is the phenomenon of ligand-induced receptor dimerisation 
(Schlessinger and Ullrich, 1992). Receptor dimerisation is a crucial early event in the 
EGF response, as co-expression of extracellular-truncated and wild type EGFR 
results in the formation of an inactive heterodimer (Honneger et al, 1990, Kashles et 
al, 1991). This work was expanded upon with the demonstration that the dimeric 
form of the receptor was not only more catalytically active than the monomer, but 
that the dimer represented the high affinity component of the EGFR dual affinity 
ligand binding characteristic (Sorokin et al, 1994).
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3.5.1.2. Recruitment and activation o f signalling intermediates
The first reported substrate for EGFR was EGFR itself (King et al, 1980). As 
outlined earlier, receptor autophosphorylation increases the interaction of SH2 
domain proteins (Honneger et al, 1988, 1989). These proteins assemble at the 
receptor, resulting in the activation of downstream signalling pathways. Many of 
these pathways converge at MEK kinase (MAP kinase/extracellular signal related 
kinase kinase), with a subsequent activation of the p42/p44 MAP kinases, a family of 
ser/thr kinases (Pelech and Sanghera, 1992). MAP kinases are rapidly translocated to 
the nucleus after activation, where they play an important role in the regulation of 
several transcription factors and other nuclear proteins (reviewed by L’Allemain, 
1994).
3.5.1.3. Attenuation o f signalling
The primary mechanism by which EGFR signalling is arrested is receptor 
endocytosis and lysosomal degradation (Chen et al, 1989). Expression of mutant 
receptors which do not internalise results in cell transformation in vitro, and 
enhanced tumorigenicity in vivo (Nishikawa et al, 1994). Receptor dimers rapidly 
form clusters in membrane invaginations, which are coated in clathrin, a glycoprotein 
which forms part of the cytoskeleton. These invaginations are then fully internalised 
as clathrin-coated vesicles, with the ligand-binding portion of the receptor to the 
inside of the vesicle (Bequinot, 1984). The vesicles are then uncoated and acidified, 
the fall in intravascular pH serving as a ligand-receptor uncoupling mechanism 
(Dunn et al, 1984, Maxfield, 1982).
Before the uncoupled ligand and receptor enter the endosome stage, a degree of 
receptor recycling may occur, where a proportion of the internalised receptors are 
returned, apparently undegraded, to the cell surface. The remaining receptor and 
ligand are then delivered to lysosomes where complete degradation occurs (Dunn et 
al, 1986).
Internalised EGFR has been demonstrated to retain signalling capacity (Vieira et al,
1996). This could allow EGFR to interact with cytoplasmic proteins which are not 
found at the cell membrane, resulting in EGFR regulation of other cellular systems.
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CHAPTER 4
THE NUCLEAR UPTAKE OF POLYPEPTIDE GROWTH
FACTORS
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4.1. Transport of macromolecules into the cell nucleus
4.1.1. Nucleocytoplasmic transport
The nuclear and cytosolic compartments of a eukaryotic cell are separated by a 
double-membrane structure termed the nuclear envelope (Dingwall and Laskey,
1992). Since gene transcription and translation occur in different cellular 
compartments, macromolecules must cross the nuclear envelope in both directions to 
allow the cell to function normally. Transport across the nuclear envelope occurs 
through the nuclear pore complex (NPC), an envelope-bound multi-subunit protein 
complex of 108 daltons (Reichelt et al, 1990). The NPC is arranged into two ring 
structures, with a central pore which connects nuclear matrix (nucleoplasm) and 
cytoplasm (Hanover, 1992). The pore itself has a radius of 4.5 - 6.0 nM, and allows 
the passive diffusion of proteins up to 50 kDa, with the diffusion rate inversely 
proportional to protein size (reviewed by Gorlich and Mattaj, 1996). However, even 
small proteins have been demonstrated to enter the nucleus actively, rather than by 
diffusion (Breeuwer and Goldfarb, 1990).
4.1.2 Nuclear localisation sequences
Nuclear localisation sequences (NLS) are defined as “those sequences both 
necessary and sufficient for nuclear localisation” (Jans, 1995). Such sequences are 
short stretches of consecutive basic amino acids, usually 10 residues or less. A 
bipartite NLS comprises two such basic sequences, separated by a length of any 10 
amino acids (Silver, 1991). Conjugation of these sequences to proteins which 
normally localise in the cytoplasm confers the ability to translocate to the nucleus. 
Conversely, mutation of a single residue in the NLS can severely impair nuclear 
localisation capacity (Kalderon et al, 1984, Lanford and Butel, 1984).
4.1.3 Mechanisms involved in nucleocytoplasmic transport
Early experiments indicated that protein translocation across the nuclear envelope 
is an active process. In vitro studies determined that translocation is NLS and ATP- 
dependent, and was inhibited at 4oC (Newmeyer et al, 1986). Subsequent studies 
indicated that binding of the protein to the nuclear envelope was NLS-dependent, but
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was not affected by low temperature or ATP withdrawal (Newmeyer and Forbes,
1988). The translocation process could then be described in two stages; an energy- 
independent NPC-docking stage, and an energy-dependent translocation stage 
(Newmeyer and Forbes, 1988). More recently, a cytosolic NLS binding protein 
complex, importin a|3, has been described (Gorlich et al, 1994). The a-subunit is 
responsible for binding the NLS-containing protein, while the |3-subunit is 
responsible for docking the NLS-protein-importin complex to the nuclear pore 
(Imamoto et al, 1995).
The active transport of the importin-NLS-protein complex through the NPC is 
facilitated by the hydrolysis of GTP by the Ran GTPase (TC4). (Moore and Blobel,
1993).
4.2. Growth factors in the cell nucleus
4.2.1 Introduction
The classical model for the action of a growth factor on its target cell consists of 
three individual components. The growth factor must first bind to its cognate 
membrane-bound receptor. The ligand-receptor complex then facilitates the 
activation of intracellular secondary messengers, which ultimately results in the 
appropriate biological response. Finally, the attenuation of this signal is achieved by 
internalisation and lysosomal degradation of the ligand-receptor complex. This model 
assumes that all of the observed cellular responses to growth factor stimulation are a 
result of events initiated at the cell surface. There is little doubt that this model 
encompasses many important features of growth factor signalling. However, the 
persistent and consistent reports of growth factor localisation in the target cell 
nucleus suggest that the model may be far from complete.
The number of growth factors which reportedly associate with the cell nucleus is 
growing steadily (Table 4.1). However, many of these observations remain 
controversial, and definitive data is awaited in several instances. The nuclear 
localisation of the fibroblast growth factor (FGF) family of peptides is by far the 
most widely investigated to date.
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4.2.2. Nuclear accumulation o f the FGF peptide family
The fibroblast growth factor (FGF) family currently consists of nine distinct 
members (reviewed by Baird and Klagsburn, 1991).The most detailed studies of the 
signalling mechanisms employed by the FGFs have concentrated on the two 
prototype members of the family, acidic FGF (FGF-1, aFGF) and basic FGF (FGF-2, 
bFGF). These growth factors bind with high affinity to distinct transmembrane 
receptors with intrinsic cytoplasmic tyrosine kinase activity. They also bind with low 
affinity to cell surface heparan-sulphate proteoglycans (HSPG), ensuring the correct 
orientation of the growth factor for presentation to the high affinity receptor (Basilico 
and Moscatelli, 1992, Yayon et al, 1991).
Both FGF-1 and FGF-2 have a wide range of biological activities in a variety of cell 
types. The mitogenic activities of FGF-1 and 2 are partly transduced via the intrinsic 
tyrosine kinase function of the FGF receptor (Friesel et al, 1989). However, another 
widely accepted pathway of FGF signalling is the internalisation and nuclear 
localisation of the growth factor.
The nuclear uptake of of FGF-2 was first observed in endothelial cells, and was 
demonstrated to be specific to the G1 phase of the cell cycle (Bouche et al, 1987, 
Baldin et al, 1990). Subsequent studies have demonstrated this to be a general effect, 
which can be observed in many cell types (Tessler and Neufeld, 1990, Speir et al, 
1991, Hawker and Granger, 1994).
Studies into FGF-2 expression have revealed that multiple isoforms exist, due to the 
presence of several translation initiation codons, and that the isoforms which contain 
a nuclear localisation signal sequence (NLS) in the amino terminus localise in the 
nucleus, while those lacking a large amino terminal tail are mainly cytoplasmic 
(Renko et al, 1989, Quarto et al, 1991, Bugler et al, 1991).
Unlike many other growth factors, the cellular function of nuclear FGF-2 has also 
been investigated. Early studies indicated that the peptide may have a role in the 
transcriptional regulation of ribosomal RNA (Bouche et al, 1987), these findings 
supported by the observation that nuclear FGF-2 has opposite effects on the 
transcription of phosphoglycerate kinase 1 and 2 (Nakanishi et al, 1992). Similar 
observations have also been reported in a study on rat myoblasts (Hawker and 
Granger, 1994). In addition to transcriptional regulation, nuclear FGF-2 has also been 
implicated in the regulation of the activity of two nuclear proteins - CKII kinase and 
histone HI. Thus nuclear FGF-2 can indirectly affect gene expression (Amalric et al,
1994).
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Investigations into the nuclear uptake of FGF-1 have also provided information on 
the functional significance of the NLS. Initial studies into the putative NLS in the 
amino terminus showed that mutation of this region reduced the mitogenic potency of 
FGF-1 (Imamura et al, 1990). N-terminal deletion does not affect receptor binding or 
receptor tyrosine kinase activation (Weidlocha et al, 1994).
The role of heparan-sulphate proteoglycans (HSPG) in the nuclear localisation 
mechanism of the FGF family remains controversial. The binding of FGF-2 to cell 
surface HSPG is essential for FGF-2 binding to high affinity receptors, and thus 
ligand-induced receptor mediated internalisation (Yayon et al, 1991). Nuclear 
populations of cell surface proteoglycans have been described by several groups 
(Hiscock et al, 1994, Jackson et al, 1991), although a translocation mechanism has 
yet to be established. Amalric and colleagues have suggested that FGF-2 and HSPG 
are co-transported into the cell nucleus (Amalric et al, 1994). There have also been 
suggestions that HSPG protects the growth factor from intracellular degradation, 
thereby increasing intracellular half-life and subsequent nuclear delivery (Sommer 
and Rifkin, 1989). The finding that FGF-dependent DNA synthesis is blocked by 
heparin treatment, which acts to stabilise the FGF molecular conformation, suggests 
that the tertiary structure of FGF may be important to nuclear localisation, and that 
HSPG may influence or regulate the folding of FGF (Weidlocha et al, 1992).
In summary, both FGF-1 and FGF-2 appear to exert their biological effect by a 
combination of two mechanisms: activation of membrane-localised, FGFR tyrosine 
kinase activity, and by nuclear translocation of the ligand. Nuclear uptake of 
exogenous FGF may occur by internalisation and nuclear translocation of 
FGF/FGFR complexes and/or FGF/HSPG complexes. The degree of interdependency 
of these postulated translocation mechanisms has yet to be established, as has a 
detailed translocation mechanism in each case. Nuclear FGF may act directly to 
regulate transcription, or indirectly via nuclear FGFR kinase, or other FGF-sensitive 
nuclear kinases. Both FGF-1 and 2 contain putative nuclear localisation sequences in 
the amino terminal of the peptide, which appear to be involved in the regulation of 
nuclear uptake.
4.2.3. Nuclear uptake ofEGFR ligands
The EGFR binds and mediates the cellular effects of several polypeptide mitogens. 
There is little published work describing the nuclear accumulation of these ligands. 
However, investigators have noted the nuclear accumulation of one EGFR-binding
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peptide, amphiregulin (AR), and its rat homologue, Schwannoma-derived growth 
factor (SDGF).
Immunohistochemical studies have established the nuclear localisation of AR in a 
range of normal and malignant tissues and cell lines (Johnson et al, 1992, Yokoyama 
et al, 1995, Lysiak et al, 1995). AR differs from EGF in two important respects. AR 
contains a nuclear localisation sequence (NLS) in the amino terminus of the peptide 
which is absent from EGF (Plowman et al, 1990). Secondly, AR, unlike EGF, is able 
to bind cell surface HSPGs (Piepkorn et al, 1994). The heparin-binding 
characteristics of AR appear to be essential to its mitogenic activity, as the addition 
of soluble heparin, heparan sulphate or hexadimethrine (a heparin antagonist) inhibit 
AR-induced mitogenesis (Johnson and Wong, 1994, Cook et al, 1995). None of these 
treatments affects EGF-induced mitogenesis.
SDGF, like amphiregulin, contains an NLS in its amino terminus and is able to 
bind heparin. It is readily detectable in the nucleus of cells transfected with SDGF 
cDNA. Deletion of the NLS results in a peptide which is able to bind and activate 
EGFR, but has no mitogenic capacity (Kimura, 1993). This mutation also abolishes 
nuclear localisation of the peptide. These observations indicate that the nuclear 
localisation of SDGF is essential to its mitogenic capacity. It was also observed that 
SDGF is able to bind DNA in a sequence-specific manner, which also suggests a 
nuclear role for this peptide. Similar evaluations have yet to be made of AR.
4.2.4. Nuclear uptake o f EGF and EGFR
The accumulation of EGF in the cell nucleus was first reported in 1980, using 
cultured rat pituitary cells (Johnson et al, 1980). Since then, work has centred mainly 
on the physiological nature of this accumulation, and the identification of the nuclear 
EGF binding site. As yet there is very little work published on the function of nuclear 
EGF and its receptor, or the part that this may play in the response of the cell to EGF 
stimulation.
Immunoflourescent staining of the A431 squamous carcinoma cell line using 
polyclonal antibodies raised to purified EGFR demonstrated that internalised EGFR 
localised mainly in the perinuclear region. This accumulation appeared to be EGF- 
dependent, and was enhanced in the presence of the lysosomal protease inhibitor, 
chloroquine (Murthy et al, 1986).
Another study examining 125I-EGF distribution in fractionated nuclei 
demonstrated that EGF was not associated with the perinuclear membrane but was
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tightly bound to chromatin. The accumulation of chromatin-bound EGF was maximal 
after 48 hrs exposure to EGF. This study also demonstrated that an antibody raised to 
the EGFR ligand binding domain was able to prevent EGF binding to chromatin, and 
thus that the chromatin binding site was “EGFR-like” (Rakowicz-Szulczynska et al,
1986).
A subsequent study into the EGF binding characteristics of a hepatic nuclear 
fraction showed that the nuclear EGF binding site displayed dual affinity binding, 
with binding constants similar to the membrane bound EGFR (Ichii et al, 1988). It 
was also shown that EGF stimulation of this fraction was unable to enhance ligand- 
induced autophosphorylation, suggesting that the putative nuclear EGFR was already 
maximally autophosphorylated.
Most of the experiments up until this point had been performed in the presence of 
chloroquine, a lysosomal protease inhibitor, which prevents metabolism of EGF 
resulting in enhanced nuclear delivery. A study in 1989 investigated nuclear delivery 
under physiological conditions without the use of chloroquine (Rakowicz- 
Szulczynska, 1989). It was shown that EGF binding to chromatin was highly specific 
and that an anti-EGFR antibody raised to the EGF binding site bound to the same 
chromatin ‘receptor’ as EGF. EGF remained bound to chromatin in the presence of 
2M NaCl, which discounted the possibility of non-specific association. The same 
study also demonstrated that EGF bound to specific regions in the chromatin 
structure. EcoRl digestion of 1251-EGF-labelled chromatin produced a distinct band 
upon electrophoresis, rather than a smearing pattern which would be seen if EGF 
association was at random sites.
The role of the cell surface receptor in nuclear EGF delivery was examined using 
the technique of physical reconstitution of EGFR from donor hepatic membranes to 
receptor-deficient fibroblasts (Jiang and Schindler, 1990). This technique ensured 
that there was no endogenous nuclear EGFR, and that any EGFR found subsequently 
in the nucleus was translocated, cell surface receptor. This study demonstrated that 
nuclear accumulation of EGF occurred at a rate similar to those previously reported, 
and that translocated EGFR could be detected in the cell nucleus. These experiments 
were carried out at 4oC, at which internalisation of EGFR is inhibited (Carpenter and 
Cohen, 1976). At this temperature, no nuclear delivery of EGF was observed, further 
implicating the role of normal membrane receptor function in the delivery of growth 
factor to the nucleus.
A revealing study into the physiology of nuclear delivery of EGF noted that hepatic 
nuclei from partially hepatectomised rats appeared to bind less EGF than control
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nuclei (Marti et al, 1991). It was also established by ELISA that hepatectomised rats 
have higher circulating EGF levels than control rats. The authors hypothesised that 
the decrease in EGF binding sites in the nucleus was due to prior occupation of these 
sites by endogenous EGF.
Further studies have produced interesting observations in proliferating tissue. An 
investigation into anti-EGFR antibody binding in normal skin cells showed that in 
20% of keratinocyte samples, there was strong immunolabelling of the cell nucleus 
with a stronger superimposed labelling of what was assumed to be chromatin 
(Pierard-Franchimont et al, 1991). In the population of cells showing nuclear 
immunoreactivity, there was a marked decrease in membrane and cytoplasmic EGFR. 
A similar pattern been observed in hepatocytes of bile duct-ligated rats (Oguey et al, 
1992). Three days after ligation, rat livers displayed decreased cytoplasmic and 
increased nuclear EGFR. Both of these studies suggest that increased nuclear EGFR 
may be linked to DNA synthesis.
More recent studies into nuclear EGFR have attempted to establish whether the 
receptor has a signalling function within the nucleus. Using anti-phosphotyrosine 
antibodies together with anti-EGFR antibodies, it was shown that after incubation of 
HN5 (squamous cell carcinoma) cells with EGF, there was a 4-fold increase in 
nuclear EGFR, along with a doubling in the amount of EGFR-dependent 
phosphotyrosine, suggesting that the nuclear receptor may retain its tyrosine kinase 
activity (Holt et al, 1994). This study also reported that nuclear EGFR associated 
with chromatin. In a subsequent report the same group demonstrated using 
immunoelectron microscopy, that the ligand-mediated nuclear translocation of EGFR 
and the concomitant EGFR-dependent increase in nuclear phosphotyrosine was 
serum dependent (Holt et al, 1995). Previous studies had demonstrated that EGF and 
EGFR are delivered to the nucleus in an undegraded form, (Rakowicz-Sulczynska, 
1989, Jiang et al, 1990) but these were the first reports describing functional, nuclear 
EGFR. The nature of the tyrosine kinase substrates and the consequences of their 
phosphorylation are yet to be established.
Another revealing study has suggested a direct consequence of EGF in the cell 
nucleus. Examination of nuclei isolated from a human choriocarcinoma cell line and 
from normal human placenta revealed the presence of functional EGFR (Cao et al,
1995). This group also found that addition of EGF to the same isolated nuclei caused 
a reduction in the transcription rate of the chorionic gonadotropin receptor gene 
(CGR).
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In addition to the cell lines and tissues outlined above, nuclear accumulation of 
EGF or nuclear EGFR populations have also been observed in tumour sections of 
bladder and cervical epithelium, as well as malignant and non-malignant 
mesothelioma, hepatocytes, fallopian tube, placental trophoblast, bovine corneal 
endothelium, rat epithelium and murine chondrocytes (Lipponen and Eskelinen, 
1994, Groppinger et al, 1989, Tervahauta et al, 1993, Ramael et al, 1991, Raper et al, 
1987, Lei and Rao, 1992, Arnholdt et al, 1991, Savion et al, 1981, Green et al, 1987, 
Tajima et al, 1993). However, many of these studies have employed positive nuclear 
immunoreactivity as the determinant of nuclear EGFR, which falls short of 
conclusive proof of nuclear EGFR populations. This technique only indicates the 
presence of "EGFR-like" epitopes in the cell nucleus.
In summary, it has been demonstrated that both EGF and EGFR can be detected in 
the cell nucleus in a variety of tissue types and cultured cell lines. EGF, EGFR 
protein and tyrosine kinase activity have been detected in the nuclei of cells with and 
without exogenous EGF treatment. Much of the evidence suggests that translocation 
of ligand-bound receptor from the cell surface is involved in the nuclear 
accumulation mechanism. The nature of the apparent chromatin association has yet to 
be fully elucidated, as has the detail of the receptor translocation mechanism. The 
correlation between increased nuclear delivery of EGF and DNA 
synthesis/transcription also requires further examination before any definitive 
conclusions can be drawn regarding the respective roles of EGF/EGFR chromatin 
binding and nuclear tyrosine kinase activity in the cellular response to EGF.
4.2.5. Methods used in the detection o f nuclear EGF and EGFR
Methods used to assay the nuclear uptake of EGF and EGFR fall into two broad 
categories - those which involve the microscopic detection of EGF/EGFR in intact 
cells, and studies involving intact nuclei isolated from cells treated with labelled EGF 
(usually 125I-EGF). However, there are inherent problems with both techniques 
which must be taken into account before definitive conclusions about EGF/EGFR 
nuclear localisation can be drawn.
Microscopic examination of intact cells can provide qualitative data about the 
intracellular localisation of labelled EGF. Semi-quantitative analysis may also be 
possible, but is dependent upon the sensitivity of the microscopic technique 
employed. The amount of EGF which localises in the nuclei of cells treated in the 
absence of endosomal protease inhibitors (e.g. chloroquine) is usually very low (<
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1% of cell-associated EGF) (Johnson et al, 1980, Savion et al, 1981), and the use of 
classical EM immunogold techniques results in a low number of grains per nucleus 
(Holt et al, 1994, 1995). It would be preferable to use a technique which allows 
similar unequivocal nuclear localisation, but which has a higher sensitivity.
The isolation of intact nuclei is most commonly performed by washing cells in a 
detergent-containing buffer. Washing with detergent disrupts the lipid cell membrane 
and membranous cytosolic vesicles such as endosomes, without disruption of the 
protienatious inner nuclear membrane. However, it is not possible to simply equate 
isolated nuclei with a detergent-insoluble fraction. It is important to control for the 
uptake of labelled EGF by nuclei during the isolation procedure, to confirm that EGF 
released from cytosolic vesicles is not taken up non-specifically. Assessment of the 
contamination of the isolated nuclear pellet by cell membrane and cytosolic 
organelles must also be performed. Membrane contamination can be assessed by 
membrane-specific enzyme activity. The most common is 5’-nucleotidase, although 
other membrane-specific marker enzymes have been used (Burwen and Jones, 1987). 
EGF-containing lysosomes are another potential source of contamination. Some 
investigators have used the activity of the lysosome-specific acid phosphatase 
enzyme to assess lysosomal contamination (Savion et al, 1981, Holt et al, 1994). 
However, this does not control for contamination by other EGF-associated cytosolic 
organelles, such as detergent-insoluble actin filaments, which have been shown to 
bind EGFR (Rijken et al, 1995, den Hartigh et al, 1997).
It is also important to note that neither technique is able to exclude the possibility 
that the positive nuclear signal is derived from a degradation product of EGF, which 
is rapidly metabolised after internalisation. This possibility and its implications are 
discussed in chapter 8.
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CHAPTER 5
EGFR-TARGETED THERAPEUTIC STRATEGIES
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5.1. Introduction
The rationale for EGFR-directed, anti-cancer therapy is now well established. The 
role of EGFR overexpression in tumour initiation and disease progression, along with 
the observation of autocrine and paracrine stimulation via increased ligand 
production has led many investigators to attempt to interrupt EGFR signalling 
function by the use of monoclonal antibodies (mAb) raised against either the 
receptor or ligand. In addition, many compounds have now been developed which 
inhibit the intrinsic tyrosine kinase activity of the receptor, and thus prevent EGFR 
signalling.
The overexpression of EGFR in many tumour types, compared to surrounding 
normal tissue, confers a degree of tumour-specificity which may be exploited 
therapeutically. Many of these strategies involve the conjugation of a toxin, anti­
proliferative drug or radionuclide to an EGFR-seeking molecule, usually a 
monoclonal antibody or receptor ligand, to achieve a tumour/normal tissue dose 
differential.
5.2. Monoclonal antibody-based strategies
5.2.1 Anti-EGFR monoclonal antibody therapy
There are several anti-EGFR mAbs with anti-proliferative activity both in vitro 
and in vivo . Some of these have been evaluated clinically.
Initial studies in cell lines with a mouse anti-human EGFR IgGl (mAb 225) and 
IgG2a (mAb 528) found that these antibodies were effective in blocking EGF/TGF-a 
binding, EGFR kinase activity, and EGF-dependent proliferation in cell lines and 
xenograft models (Mendelssohn, 1990). Neither of these antibodies attached directly 
to the ligand binding portion of the receptor, but to a region close enough to interfere 
with ligand/receptor binding. Neither was able to activate the EGFR kinase function, 
but the rate of receptor internalisation after mAb binding was identical to that of 
ligand-bound receptor (Sunada et al, 1986).
A phase 1 clinical trial suggested that patients were able to tolerate the presence of 
saturating doses of mAb (300 mg total dose) for over 3 days without toxic effect, and 
that tumour uptake of mAb was significant (Mendelssohn, 1990). However, the 
effectiveness of anti-EGFR mAb as a single-mode therapy is affected by two major
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limitations. Firstly, xenograft models indicate that while these antibodies inhibit 
tumour growth, the growth inhibitory effect is reversible, and no cytotoxicity is 
observed. Secondly, administration of these antibodies elicits a host immune 
response which can affect the efficacy of subsequent antibody administrations (Divgi 
et al, 1991).
Another antibody to reach clinical trial is mAb 425 (also known as EMD 55 900) 
(Murthy et al, 1987). Again, this mAb is a mouse anti-human EGFR IgG2a, with 
similar receptor binding properties to mAb 225 and 528. In common with these 
antibodies, mAb 425 was effective in inhibiting the growth of tumours in xenograft 
models, and exhibited low toxicity at phase I trial. However, this mAb had limited 
therapeutic benefit in preliminary phase II trial (Schnurch et al, 1994; Stragliotto et 
al, 1996).
Studies have also been carried out with an anti-EGFR IgG2b (ICR62) (Modjtahedi 
et al, 1993). Treatment of squamous cell tumour xenografts with this antibody 
resulted in the appearance of markers of terminal differentiation (Modjtahedi et al,
1994). The authors concluded that differentiation of tumour cells may play an 
important role in the therapeutic effect of this treatment. A phase I trial indicated that 
administration of this mAb was well tolerated, but as yet there is no data indicating 
therapeutic benefit (Modjtahedi et al, 1996).
5.2.2 Anti-EGFR mAb/cytotoxic combination therapy
Combined administration of mAbs 225 or 528 with conventional chemotherapeutic 
drugs has been evaluated in xenograft models. Combination treatment of mAb and 
doxorubicin, or mAb and a cisplatin analogue have both resulted in tumour 
eradication in a proportion of tumour-bearing athymic mice (Baselga et al, 1993, Fan 
et al, 1993). The anti-tumour effect of these combined therapies appears to be at least 
additive. Clinical trials based on these observations are currently underway.
5.2.3 Anti-EGFR mAb-toxin conjugates
Many EGFR-targeting conjugates have employed either EGF or TGF-a as the 
targeting vehicle. However, some studies with anti-EGFR mAb conjugates have been 
undertaken. One experimental therapy involved conjugation of ricin, a plant-derived 
toxin which acts by inactivation of ribosomal subunits, to mAb 225 (Masui et al,
1989). A similar study involved an anti-EGFR mAb-gelonin conjugate. Gelonin also
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acts as a protein synthesis inhibitor by inactivation of ribosomal subunits (Hirota et 
al, 1989). While these immunoconjugates were cytotoxic to EGFR-bearing cell lines 
and xenograft models, the extreme toxicity of the plant-derived toxins requires that 
the degree of tumour-specific targeting, and the stability of the immunoconjugate are 
accurately established. The widespread distribution of normal EGFR-bearing cells 
may preclude such immunotherapies, and few are currently being studied.
Anti-EGFR antibodies have also been used to target conventional cytotoxic drugs 
to EGFR-bearing tumours. Doxorubicin, conjugated via a dextran bridge to another 
anti-EGFR IgG2a (mAb 108) showed increased efficacy when compared to 
equivalent free doxorubicin doses in cell line and xenograft models (Aboud-Pirak et 
al, 1989). However, the immunoconjugate had reduced antigen binding capacity, and 
thus reduced tumour/normal tissue dose differential. A similar study involving a 
doxorubicin-mAb 425 immunoconjugate demonstrated that mAb-doxorubicin 
conjugate was more cytotoxic than doxorubicin alone in a metastatic melanoma 
model (Sivam et al, 1995).
Another interesting approach to antibody therapy led to the generation of an anti- 
EGFR (mAb 225)/interleukin 2(112) chimera (Naramura et al, 1993a). 112 acts via its 
receptor on T-cells to amplify the host immune response, and thus the chimera may 
enhance the host anti-tumour immune response. In xenograft models, the chimera 
was able to stimulate cellular cytotoxicity mediated through activated mononuclear 
effector cells at the equivalent free IL2 dose, and displayed the same antigen-binding 
capacity as intact mAb 225 (Naramura et al,1993b).
5.2.4 Radio-immunoconjugates
Anti-EGFR mAbs have also been conjugated to radioisotopes. Whilst initial studies 
have focused on the tumour imaging potential of these radioimmunoconjugates, some 
studies have indicated a possible therapeutic response. Epenetos and colleagues have 
reported a beneficial response in glioma patients using an 1311-labelled anti-EGFR 
mAb which binds to the receptor at a region distinct from the growth factor binding 
site (Epenetos et al, 1985, Kalofonos et al, 1989). This mAb does not induce receptor 
internalisation upon antigen recognition.
Two other groups have investigated the potential of mAb 425 conjugated to 1251 
and 1311. 1251-mAb 425 has been demonstrated to significantly increase the survival 
of patients with malignant glioma (Brady et al, 1990a and b). Further studies in 
xenograft models suggested that 1251-mAb 425 has a greater anti-glioma effect than
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either 1311-mAb 425 or unlabelled antibody (Bender et al, 1992). These findings 
imply that elements of the decay of 1251 have an important cytotoxic effect when 
conjugated to anti-EGFR antibody.
1251-mAb 425 has successfully undergone phase II clinical trial, and is currently the 
most clinically promising anti-EGFR mAb conjugate (Brady et al, 1992, Snelling et 
al, 1995). Studies have indicated that mAb 425 localises in the nuclei of cells derived 
from high-grade glioma. The intranuclear concentration of antibody was enhanced by 
chloroquine, in a similar manner to chloroquine-enhanced nuclear EGF uptake 
(Emrich et al, 1994). However, chloroquine did not enhance tumour uptake of 1251- 
mAb 425 in xenograft models using the same cell lines (Emrich et al, 1996).
5.3 Ligand based targeting strategies
All of the ligand-based EGFR targeting strategies currently under investigation 
employ either EGF or TGF-a. It is not yet clear whether the other EGFR ligands are 
suitable targeting vehicles in the context of these strategies, or whether their 
individual characteristics may enhance the potency of a particular conjugate.
5.3.1 Ligand-cytotoxin fusion proteins!conjugates
The rationale behind the use of ligand-exotoxin conjugates is identical to that of 
antibody-exotoxin conjugates, i.e receptor- mediated, tumour cell-specific delivery of 
cytotoxin. A major difference lies in the methods employed in their synthesis. Fusion 
of cDNA encoding both ligand and exotoxin, and expression in a suitable expression 
system (e.g. E. coli.) allows intact ligand-exotoxin fusion protein to be purified from 
whole cell lysates or inclusion bodies. The fusion peptide approach ensures that the 
ligand and toxin are fused at the correct amino acid residues, so that the fusion 
peptide retains maximal EGFR binding capability and minimal non-specific (i.e. 
toxin receptor-mediated) toxicity. This approach results in a significant improvement 
in product yield over even the most efficient chemical conjugation methods.
The most extensively studied fusion toxin was first described by Pastan and 
colleagues in 1987. TP40 was generated by the fusion of TGF-a and the 
Pseudomonas exotoxin PE40 (Chaudhary et al, 1987). This fusion peptide has 
affinity for EGFR comparable to native TGF-a, and is toxic to cells in an EGFR- 
dependent manner (Pastan and Fitzgerald, 1991). Modifications to the toxin region 
have resulted in several fusion peptides (TGF-a-PE38, PE35/TGF-a-KDEL) with
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several hundred-fold increases in in vitro cytotoxicy over TP40 (Phillips et al, 1994, 
Theuer et al, 1994). TP40 cytotoxicity correlates directly with EGFR expression in a 
variety of cell lines and xenograft models, without bone marrow cell damage 
(Baldwin et al, 1996, Kirk et al, 1994, Siegall et al, 1990, Berger et al, 1995).
A similar approach has led to the generation of DAB389EGF. This molecule, a 
fusion of portions of diphtheria toxin with EGF, also inhibits cellular protein 
synthesis in an EGFR expression-dependent manner (Shaw et al, 1991). More recent 
studies confirmed that DAB389EGF-mediated cytotoxicity correlated with EGFR 
expression in a panel of breast cancer cell lines (Osbourne, 1996). One advantage of 
DAB389EGF over TP40 is that it irreversibly binds EGFR (Shaw et al, 1991). This 
suggests that the serum concentration required for efficacy may have to be 
maintained for a shorter period for therapy using than TP40. Clinical trials are 
currently underway.
53.2 Ligand-Based EGFR targeted radiotherapy
The potential of EGF-radionuclide conjugates for use as tumour-imaging agents 
has already been established, using 123I-, 99mTc-, l l l ln -  and 76Br- EGF (Schatten 
et al, 1991, Capala et al, 1997, Remy et al, 1995, Scott-Robson et al, 1991). The 
potential of therapeutic ligand-radioconjugates has been examined by Carlsson and 
colleagues. Initial studies in glioma cell line models demonstrated that 131I-EGF 
preferentially killed EGFR-overexpressing cells (Capala and Carlsson, 1991). 
Subsequent work has addressed the problem of intracellular EGF degradation which 
could result in loss of intracellular radionuclide. Conjugation of large (20kD), 
biologically inert, dextran chains to 131I-EGF significantly increased the intracellular 
radionuclide retention time, and was demonstrated to have a greater radiobiological 
effect than 131I-EGF (Andersson et al, 1992, Carlsson et al, 1994). These 
observations have provided the basis for a novel approach to boron neutron capture 
therapy. 10B is a non-radioactive, non-toxic boron isotope which, upon exposure to a 
thermal neutron field, decays into highly ionising 4He2+ (alpha) and 7Li3+ ions, 
both with a mm range (Barth et al, 1990). 10B-EGF conjugates may facilitate tumour 
uptake of 10B. Subsequent exposure of the tumour region to a neutron field should 
result in tumour-associated 10B activation and cell sterilisation without irradiation of 
regions of non-tumour 10B uptake (Carlsson et al, 1994). The conjugation of boron 
to EGF is more complicated than halogenation methods and the requirement of a 
large number of 10B atoms to sterilise cells (109 per cell) are potential problems with
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this therapeutic mode. However, a recent report described an EGF-boron conjugate 
incorporating a large number of boron atoms which retained EGFR binding and 
internalisation capability (Capala et al, 1996). Such developments hold promise for 
clinical implementation of boron neutron capture therapy.
5.4 Aims of this study
The purpose of this study was to investigate novel radiotherapeutic strategies based 
upon the overexpression and subcellular distribution of EGFR by tumour cells.
5.4.1 Characterisation o f a panel o f EGFR-expressing cell lines
Experiments described in this thesis were performed using a panel of eleven cell 
lines (table 6.1). Chapter 6 describes the determination of the growth parameters, 
EGFR expression and EGFR signalling capacity of these cell lines.
5.4.2 EGF-mediated enhancement o f cellular radiosensitivity
Chapter 7 describes experiments performed to establish the effect of EGF on the 
radiosensitivity of a panel of cell lines with widely varying EGFR expression.
5.4.3 Nuclear accumulation o f EGF
Chapter 8 describes experiments performed to assess the suitability of EGF as a 
delivery vehicle for Auger-emitting radionuclides. Nuclear uptake of EGF by EGFR 
expressing cell lines is examined using both previously characterised and novel EGF 
detection methods.
5.4.4 Effect on clonogenicity o f 123I-EGF
Chapter 9 describes preliminary experiments to determine the effect of 123I-EGF 
treatment on a panel of cell lines with widely varying EGFR expression.
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CHAPTER 6
CHARACTERISATION OF A PANEL OF EGFR-EXPRESSING
CELL LINES
50
6.1 Introduction
6.1.1 Derivation o f cell lines
A panel of cell lines was selected for use in the experiments described in this 
report (table 6.1). Seven of these cell lines are derived from human squamous cell 
carcinomas of various sites including head and neck (B2A4, HN5, SCC 12), vulva 
(A431), cervix (CaSki, SiHa) and bladder (EJ). Two cell lines derived from breast 
adenocarcinomas were also included (MCF-7 and MDA-MB 231). In addition, two 
murine fibroblast cell lines were examined (HER 14 and K721A) (Honegger et al, 
1987). These cell lines are stable transfections of NIH 3T3 fibroblasts devoid of 
endogenous EGFR. HER 14 is transfected with cDNA encoding wild type human 
EGFR, whilst K721A is transfected with cDNA encoding a mutant human EGFR. 
The mutation introduced results in the substitution of the lysine residue at position 
721 of the receptor for an alanine residue. Lys721 in the wild type EGFR has been 
identified as the intracellular ATP binding site of the receptor. Substitution of this 
residue renders the receptor incapable of binding ATP, and thus ligand-induced 
autophosphorylation.
The breast adenocarcinoma-derived cell line MDA-MB 231, whilst expressing 
functional EGFR, is not responsive to stimulation by EGF (Davidson et al, 1987). 
The particular downstream signalling event responsible for the lack of response to 
ligand-induced EGFR activation have not been fully elucidated.
6.1.2 Aims of this study
Experiments described in this chapter were designed to characterise a panel of 
tumour cell lines with respect to doubling time, EGFR expression and EGFR 
signalling capacity. The purpose of this investigation was to establish a panel of cell 
lines with a wide range of EGFR expression, suitable for the the study of EGFR- 
mediated cellular events.
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-Tahle 6.1 P a n e l  o f  C e l l  L i n e s ______
C e l l  L i n e ______________ T i s s u e  o r i g i n _________________ C e l l  h a n k  N u m b e r .  R e f e r e n c e
A431 H u m a n  s q u a m o u s  e p i d e r m a l  ATCc  - CRL 1555 G i a r d  e t  a l ,
c a r c i n o m a  ( V u l v a )  1 9 7 3
B 2 A 4  H u m a n  s q u a m o u s  e p i d e r m a l
c a r c i n o m a  ( H e a d  a n d  N e c k )
N / A C o w l e y  e t  a l ,  
1 9 8 4
H N 5  H u m a n  s q u a m o u s  e p i d e r m a l
c a r c i n o m a  ( H e a d  a n d  N e c k )
N / A E a s t y  e t  a l ,  
1 9 8 1
C a S k i  H u m a n  s q u a m o u s  e p i d e r m a l  A T C C  C R L  1 5 5 0  P a t i l l o  e t  a l  
c a r c i n o m a  ( C e r v i x )  1 9 7 7
H E R  1 4  M u r i n e  f i b r o b l a s t  ( N I H  3 T 3 )
t r a n s f e c t e d  w i t h  w i l d - t y p e  E G F R  N / A  H o n n e g e r  e t  a l ,
c D N A  1 9 8 7
K 7 2 1 A  M u r i n e  f i b r o b l a s t  ( N I H  3 T 3 )  H o n n e g e r  e t  a l ,
t r a n s f e c t e d  w i t h  A 7 2 1  E G F R  c D N A  1 9 8 7
M C F  - 7  H u m a n  a d e n o c a r c i n o m a  A T C C -  H T B  2 2  S o u l e  e t  a l ,
( B r e a s t )  1 9 7 3
S i H a  H u m a n  s q u a m o u s  e p i d e r m a l  A T C C _ H T B 3 5  F r i e d l e t a l
c a r c i n o m a  ( C e r v i x )  A 1 1 9 7 0
S C C 1 2  H u m a n  s q u a m o u s  e p i d e r m a l  N / A  R h e i n w a l d  a n d
c a r c i n o m a  ( H e a d  a n d  N e c k )  7 B e c k e t t ,  1 9 8 1
M D A - M B  2 3 1  H u m a n  a d e n o c a r c i n o m a  A T C C - H T B  2 6  C a i l l e a u  e t  a l ,
( r s r e a s t j  1 9 7 4
H u m a n  s q u a m o u s  e p i d e r m a l  E C A C C  -  8 5 0 6 1 1 0 8  H a l l  e t  a l ,
c a r c i n o m a  ( B l a d d e r )  1 9 8 3
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6.2 Materials and Methods
6.2.1 Cell Culture
A panel of eleven cell lines was selected for this study (table 6.1). Cell lines were 
maintained in the cell culture medium and serum concentration described in table 
6.2, supplemented with L-glutamine (2mM), penicillin(100 I.U./ml), streptomycin 
(lOOpg/ml), amphotericin-B (2.5pg/ml) and sodium bicarbonate to a pH of 7.4. All 
cell lines were grown in a 2% C02 atmosphere, at 37oC. The cells were screened 
every 8 weeks for mycoplasma infection, and shown to be consistently free from 
infection.
6.2.2 Growth characteristics and doubling times
Cells were cultured in 24 well plates (Nunclon, Roskilde, Denmark) at 1x104 
cells/well, and left for 24 h in an incubator at 37oC in a 2% C02 atmosphere. Cells 
were then washed in PBS, followed by the addition of fresh medium.
Cells were removed from the appropriate wells by trypsinisation, and counted in a 
Coulter counter (Coulter Electronics, Luton, U.K.).
Cell number per well was determined every 24 h. Medium was replaced every 48 h 
to ensure consistent conditions throughout the course of the experiment. Each data 
point was determined in triplicate.
6.2.3 EGFR ligand binding analysis
Cells (between 5x104 and 5x105, depending upon cell line) were grown overnight 
in 24-well plates. The original medium was then removed, and cells were washed 
twice with 1 ml binding buffer (PBS containing 70 pg/L bacitracin, 0.1% (w/v) 
bovine serum albumin, pH 7.4). Cells were then incubated with human 125I-EGF 
(Amersham International, Buckinghamshire, U.K., specific activity 1440 Ci/mmol) at 
a concentration range 0.05 to 5.5 nM, total volume 140 pi, for 1 h at 20oC.
The radioactive solution was then aspirated, and the cells washed three times with 
ice-cold binding buffer. The cells were then lysed in 1 ml of 1M NaOH containing 
0.1% SDS (w/v), the lysate transferred to Eppendorf tubes, and radioactivity 
measured in a gamma counter (Canberra Packard, Berkshire, UK.).
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Table 6.2 . Cell culture conditions 
Cell line Cell culture medium Serum content
A431 Ham’s F-10/D-MEM (50:50 v/v) 10% Foetal Calf Serum
(FCS)
B2A4 Ham’s F-10/D-MEM (50:50 v/v) 2% FCS
HN5 Ham’s F-10/D-MEM (50:50 v/v) 10% FCS
CaSki Ham’s F-10/D-MEM (50:50 v/v) 1Q% FCS
HER 14 Ham’s F-10/D-MEM (50:50 v/v) 10% Donor Calf Serum
(DCS)
K721A Ham’s F-10/D-MEM (50:50 v/v) io% DCS
MCF -7 RPMI1640 10% FCS
SiHa Ham’s F-10/D-MEM (50:50 v/v) 10% FCS
SCC 12 Ham’s F-10/D-MEM (50:50 v/v) 10% FCS
MDA-MB 231 RPMI 1640 10% FCS
EJ Ham’s F-10/D-MEM (50:50 v/v) 10% FCS
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Non-specific binding was assessed in the presence of a 100-fold excess of 
unlabelled human EGF.
Receptor affinity and abundance were determined by Scatchard analysis (Scatchard, 
1949), using the binding data analysis program LIGAND (Munson and Rodbard, 
1979). Each data point was determined in triplicate.
6.2.4 Preparation o f whole cell lysate
When the cell cultures attained 70% confluence, medium was removed, and 
replaced with medium containing the desired concentration of EGF was added, and 
the cells were placed in an incubator at 37oC for 15 min. The medium containing 
EGF was then aspirated and the cells washed twice with PBS. The cells were then 
lysed in sample buffer (0.0625 M Tris-HCl, 10% (w/v) sucrose, 5% (v/v) p- 
mercaptoethanol, 2% (w/v) SDS, 5mM sodium fluoride, ImM sodium
orthovanadate, pH 6.8) on ice for 1 hour.
The lysate was then centrifuged at 20 000 x g for 5 min. The supernatant was 
removed and stored at -70oC until required. A small aliquot was removed for protein 
estimation (Bio-Rad, Beaconsfield, U.K.).
6.2.5 Preparation o f membrane-rich cell fraction
Cells were grown to 70% confluence, the medium aspirated, and the cells washed 
twice in ice-cold PBS. The cells were then harvested, resuspended in 10 ml ice-cold 
PBS containing 0.007% (w/v) bacitracin (PBS-B), and homogenised in a tight-fitting 
glass-glass homogeniser. The cell homogenate was then centrifuged at 20 000 x g at 
4oC for 10 min, and the supernatant was removed and kept on ice.
The pellet was resuspended in 1ml PBS-B and sonicated (MSE, Essex, U.K) for 3 x 
10 seconds at the highest setting. Again, the homogenate was centrifuged at 20 000 x 
g and the supernatant kept on ice.
The supernatant was then centrifuged in a Beckman Optima TLX ultracentrifuge 
(Beckman, Fullerton, U.S.A.) at 100 000 x g for 30 mins. The pellet was then 
resuspended in PBS-B, and stored at -70oC.
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6.2.6 SDS/polyacrylamide gel electrophoresis (SDS/PAGE)
The methodology is essentially the same as the Tris/glycine buffered 
electrophoresis system described by Laemmli (1970).
Protein samples, prepared as described in sections 6.2.4 and 6.2.5 were diluted in 
an equal volume of sample buffer (section 6.2.4), and incubated at lOOoC for 4 mins. 
20 pi loading buffer (33% (v/v) glycerol, 20% (w/v) SDS, 0.05% (w/v) bromophenol 
blue) was then added to each sample.
Samples were applied to a polyacrylamide gel, which was cast using the Protean II 
vertical gel casting apparatus (Bio-Rad).
Electrophoresis was carried out at a constant current of 50 mA (4-6 hours), or 
10mA (18-24 hours), until the bromophenol blue dye marker was 0.5 cm from the 
bottom of the plate.
6.2.7 EGFR detection by western blotting
Proteins separated by SDS/PAGE were transferred to Immobilon P blotting 
membrane (Millipore, Bedford, U.S.A.) by means of an Immobilon semi-dry 
electroblotter. Transfer was made at constant current of 0.8mA/cm2 for 60 mins. 
When protein transfer was complete, the blockade of non-specific binding to the 
membrane was achieved by immersion of the membrane in blocking solution (5% 
(w/v) milk powder prepared in Tris-buffered saline with 0.05% (v/v) Tween 20) 
overnight at 4oC.
Mouse monoclonal antibody, (mAb F4 - lpg/ml in blocking solution), specific for 
an epitope on the EGFR, was then applied to the membrane and allowed to bind for 
2 h at room temperature. The membrane was then washed in TBS-T (Tris-buffered 
saline with 0.05% (v/v) Tween 20) for 15 mins.
Anti-mouse IgG-horseradish peroxidase (Amersham) at a dilution of 1:5000 was 
then added, and allowed to bind for 15 min. The membrane was then washed for 2 
hours at room temperature in TBS-T, dried, and coated in a hydrogen peroxide- 
luminol mixture (ECL solution)(Amersham).
The membrane was dried, exposed to Kodak X-OMAT film for 2 min and then 
developed.
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6.2.8 32P-labelling o f the EGFR
An aliquot of cell membrane preparation (section 6.2.5) was added to an equal 
volume of NP-40 solution (50 mM NaCl, 10 mM Tris-HCl, 0.5% (v/v) NP-40). EGF 
was added to the desired final concentration and allowed to stand on ice for 30 min. 
y-32P dATP (Amersham, specific activity 3000Ci/mmol) was added to a final 
concentration of 2 pM, vortexed gently, and allowed to stand on ice for 1 h.
6.2.9 Immunoprecipitation
3ml of 10% (w/v) immobilised Staphylococcus aureus (immuno- 
precipitin) was washed twice by centrifugation with NP-40 solution (section 6.2.8). 
Centrifugations were carried out at
10 000 x g for 5 min at 4oC. After the final wash, the pellet was resuspended in 3 ml 
NP-40 solution containing 100 pi of 10% (w/v) BSA.
4 pg mAb F4 was pre-absorbed to 900 pi washed immuno-precipitin, for 1 hour at 
room temperature. 100 pi aliquots of this mixture were then added to protein samples 
prepared as described in section 6.2.5, and placed on ice for 1 hour. To establish that 
mAb F4 binding to EGFR was specific, a competitor peptide (peptide 2E) which 
contains the same amino acid sequence as the epitopic recognition site on EGFR, was 
added to control samples.
After centrifugation at 20 000 x g for 5 min at 4oC, the supernatants were 
discarded. The pellets were washed 3 times in NP-40 solution and resuspended in 
100 pi sample buffer (section 6.2.4).
20 pi loading buffer (section 6.2.6) was then added to each sample before 
incubation at lOOoC for 4 min. The samples were then centrifuged at 20 000 x g for 5 
min at 4oC, the pellet discarded, and the supernatant was electrophoresed on an 8% 
polyacrylamide gel.
Finally, the gel was dried, covered in Saran wrap, and exposed to Kodak X-OMAT 
film for 4 to 6 hours at -70oC.
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6.3 Results
6.3.1 Growth characteristics and doubling times
The growth characteristics of the cell line panel are depicted in figure 6.1 (a-f). The 
population doubling times, calculated from the linear portion of the growth curve, 
were as follows :
A431 -33 hours, B2A4 -20 hours, CaSki -28 hours, HN5 -35 hours, K721A - 24 
hours, HER 14 -20 hours, SCC12 -36 hours, MDA-MB 231 - 35 hours, SiHa -38 
hours, EJ - 28 hours, MCF-7 -26 hours.
6.3.2 EGFR ligand binding analysis
Scatchard plots were prepared from the data obtained by ligand binding analysis 
(figure 6.2. (a-f)). Receptor concentrations and dissociation constants (kDs) are 
tabulated (table 6.3.). Cell lines were ranked according to EGFR expression, and 
tabulated (table 6.4)
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Fig 6.1 Growth characteristics of cell lines
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Fig 6.2 Scatchard plots of EGFR ligand binding data obtained 
from a panel of cell lines
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6.3.3 Immunodetection ofEGFR
Figure 6.3 (a) Immuno-detection of EGFR by western blotting. The relative density 
of each band is expressed as a percentage of the most dense band (lane 4). Cell lines 
were ranked according to the relative density, and tabulated (table 6.4). The highest 
ranked cell line was HN5, whilst the lowest ranked cell line was MCF-7. Of the two 
fibroblast cell lines, HER 14 was ranked higher than K721A.
(b) Detection of EGFR by 32P-labelling followed by immunoprecipitation. 32P-labelled 
EGFR appears as a band at 170 kDa. The membrane-rich-fraction prepared from HN5 
cells provided the strongest signal (lane 4). 32P-labelled EGFR could not be detected in 
membrane preparations extracted from K721A cells (lane 8).
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6.3.4 Effect ofEGFpre-stimulation on immunodetection ofEGFR in 
A431 cells
Figure 6.4.(a) demonstrates the effect of EGF pre-stimulation of A431 cells prior to 
western blotting. Each lane was loaded with 50 pg protein of a whole cell lysate of A431 
cells which were pre-stimulated with a range of concentrations of EGF, as described in 
section 6.2.4
Lane 1. 50 pg A431 whole cell lysate, prestimulated with 
25ng/ml hEGF 
Lane 2. 50 pg A431 whole cell lysate, prestimulated with 
10 ng/ml hEGF 
Lane 3. 50 pg A431 whole cell lysate, pre-stimulated with 
5 ng/ml hEGF
Lane 4. 50 pg A431 whole cell lysate, pre-stimulated with 
1 ng/ml hEGF 
Lane 5. 50 pg A431 whole cell lysate
Figure 6.4.(b) demonstrates the effect of EGF and peptide 2E on the detection of EGFR 
by 32P-labelling and immunoprecipitation.
Lane 1. 25 pg A431 membrane, with lpg/ml hEGF 
Lane 2. 25 pg A431 membrane, with 5 pg/ml hEGF 
Lane 3. 25 pg A431 membrane, with 10 pg/ml hEGF 
Lane 4. 25 pg A431 membrane, with 10 pg/ml hEGF, 
precipitated with normal rabbit serum 
Lane 5. 25 pg A431 membrane, with 10 pg/ml hEGF, and 
20 pg/ml peptide 2E 
Lane 6. 25 pg A431 membrane, with 10 pg/ml hEGF, and 
10 pg/ml peptide 2E 
Lane 7. 25 pg A431 membrane, with 10 pg/ml hEGF, and 
1 pg/ml peptide 2E
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Figure 6.4 (a) demonstrates that the antibody mAb clone F4 showed greater affinity for 
EGFR which had been exposed to EGF prior to separation by SDS-PAGE (lanes 1-4), 
than to EGFR which had not been pre-stimulated (lane 5).
Figure 6.4 (b) demonstrates the effect of EGF on EGFR 32P-incorporation. Lanes 1-3 
contain 25 pg protein of A431 membrane-rich fraction stimulated with increasing 
concentrations of EGF. The increasing density of the band at 170 kDa indicated that 
32P-incorporation was EGF-dependent.
Lanes 4-7 indicate that the immunoprecipitation technique was antibody dependent. 
Lane 4 contains 25 pg protein labelled with 32P, which has been precipitated with whole 
rabbit serum, rather than anti-EGFR antibody. The absence of a band at 170 kDa 
demonstrated the dependence of this detection upon the presence of mAb clone F4. 
Lanes 5-7 demonstrate that peptide 2E, which contains the same amino acid sequence as 
the epitopic recognition site on EGFR, was able to compete with EGFR for the binding 
of mAb clone F4.
Table 6.4 indicates the rank order of EGFR expression, determined by ligand binding 
analysis and western blotting, of the cell line panel. Most cell lines were ranked similarly 
by both methods. The EGFR expression of the K721A cell line was ranked lower by 
western blotting than by ligand binding analysis. Statistical analysis was performed using 
the Wilcoxton signed rank test. The p value obtained (0.433) was greater that 0.05, 
indicating that there was no significant difference in the rank order of EGFR expression 
determined by these two methods.
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Table 6.4 . Comparison of the rank order of EGFR expression
determined bv ligand binding analysis and western blotting 
in a panel of cell lines.
Cell line
HN5
A431
B2A4
CaSki
MDA-MB 231
K721A
HER 14
SCC12
SiHa
EJ
MCF-7
Ligand binding analysis 
Rank order (1= highest)
1
3
4
5
6 
7
9
10 
11
Western blotting 
Rank order (1= highest)
3
4 
6
9
5
7
8 
11
10
Table 6.4 Values represent the EGFR expression rank order of 
the cell line in the panel (l=highest). Rank orders were 
determined from ligand binding data (table 6.3.) and the relative 
density of the 170 kDa band observed by western blotting 
(figure 6.4 a). Wilcoxton signed rank significance > 0.05.
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6».4 Discussion
The purpose of the experiments described in this section was to characterise a panel of 
cell lines with respect to EGFR expression and signalling capacity, to enable the 
investigation of EGFR-mediated cellular events.
EGFR expression was determined by western blotting using a monoclonal antibody 
which recognises a sequence on the intracellular portion of the receptor (residues 985- 
996). This antibody was chosen in preference to those which recognise the extracellular 
portion of the receptor, because the latter antibodies tend to bind more strongly to the 
receptor used in the primary inoculation. For example, EGFR1 binds with stronger 
affinity to receptors expressed on A431 cells than other cell lines (Ozanne, personal 
communication). This is possibly due to differences in the glycosylation of the 
extracellular region between cell lines.
Figure 6.3 (a) demonstrates EGFR detection in all of the cell lines examined by 
western blotting. Densitometric assessment of the intensities of the 170 kDa band 
indicated a wide range of receptor expression, and hence suitability of the panel of cell 
lines for the study of EGFR-mediated cellular events.
The number of EGFR was determined by ligand binding analysis. This technique 
assays the binding of a labelled EGFR ligand (125I-EGF) to a known number of cells (or 
a known protein content of homogenised tissue) at different ligand concentrations. From 
this data, receptor concentration and affinity can be estimated.
Figure 6.2 (a-f) and table 6.3. show the results obtained using ligand binding analysis. In 
nine cell lines, a bi-phasic binding curve was obtained. Two cell lines (MCF-7 and EJ) 
showed linear binding characteristics. Dissociation constants (Kd) ranged from 0.08 - 
0.33 nM (high affinity), and 1.97 - 12.12 nM (low affinity). Previous studies have 
demonstrated that, in intact cells, the extracellular region of the EGFR is insensitive to 
trypsin, and that tyrpsinisation of intact cells does not result in a decrease of in 125I-EGF 
binding capacity (Carpenter, 1987).
EGFR signalling capacity was assessed by in vitro kinase 32P-labelling, followed by 
immunoprecipitation using the same monoclonal antibody used for western blotting. The 
phosphorylation of EGFR after stimulation with EGF is now well documented (King et 
al, 1980). Using y-32P-ATP as substrate, the degree of 32P incorporation is a function of 
both the receptor tyrosine kinase activity and receptor concentration. Figure 1.7.3 (b)
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indicates that all of the cell lines examined, with the exception of K721A, expressed 
EGFR which was capable of autophosphorylation after stimulation with EGF.
It was observed (figure 6.4.(a)) that the antibody used for the detection of EGFR (mAb 
clone F4) bound with greater affinity to ligand-bound, or active receptors than to inactive 
receptors. There are two possible explanations for this phenomenon. EGFR ligand 
binding to the receptor may cause a change in the three-dimensional conformation of the 
receptor, which is more easily recognised by the antibody. Another possibility is that Tyr 
992, a residue within the epitopic site recognised by mAb F4, is a receptor 
autophosphorylation site (Walton et al, 1990). It is possible that the antibody has a 
greater affinity for the epitope when this site is phosphorylated.
Figure 6.4 (b) shows the effect of EGF concentration on the amount of 32P-labelled 
EGFR detected by immunoprecipitation and autoradiography. Increasing EGF 
concentration resulted in an increase in the density of the 170 kDa band. The dependence 
of the immunoprecipitation technique on the specific binding of the antibody to the 
receptor is also demonstrated. The addition of increasing concentrations of a peptide 
which competes with EGFR for antibody binding (peptide 2E) resulted in a decrease in 
the amount of 32P-labelled receptor precipitated.
Table 6.4 shows a comparison of the concentration of EGFR detected by both western 
blotting and ligand binding analysis. An strong correlation was observed between the 
results obtained using these methods. One exception was the K721A cell line, in which 
proportionately less EGFR was detected by western blotting.
The quantification of EGFR concentration using western blotting is problematic, as 
several factors may influence the degree of specific antibody binding. Figure 6.4 (a) 
demonstrates that mAb clone F4 bound to active (ligand-bound) receptor with greater 
affinity than inactive receptor. Alterations in external EGFR-ligand concentration will 
therefore affect the result obtained. Whilst no additional EGF was included in the cell 
lysate incubation mixtures prior to western blotting (figure 6.3 (a)), the external EGFR 
ligand concentration may vary for two reasons. Firstly, the extracellular concentration of 
EGFR-ligands in culture fluid depends on the concentration and type of serum used. 
Serum concentration and type were not constant (table 6.2.) Another source of EGFR 
ligand is the cells themselves. Many EGFR-expressing cell lines secrete EGFR-ligands, 
mainly TGF-a, into the extracellular medium, resulting in autocrine and paracrine
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stimulation (e.g. Hirsch et al, 1996). Thus the results obtained using western blotting 
with mAb clone F4 are a function of both receptor number and external EGFR-ligand 
concentration.
A further complicating factor is the unique expression of kinase-deficient EGFR by 
K721A cells. This receptor is incapable of activation by EGF, unlike the wild-type 
EGFR expressed by the other members of the cell line panel (figure 6.3 (b)). Therefore 
the increase in affinity of mAb clone F4 for active EGFR may be dependent upon 
activation of the intrinsic receptor kinase, and may not be due solely to the receptor 
binding to an appropriate ligand. This may explain why EGFR detection by this method 
does not exactly mirror the results obtained by ligand binding analysis (table 6.3). For 
these reasons, western blotting should be regarded as a semi-quantitiative method of 
EGFR detection.
The analysis of ligand binding data by Scatchard plot is a common method of 
estimation of EGFR number and affinity in cell lines or tissue samples (Scatchard, 
1949). Parameters are obtained by plotting bound ligand against the bound/free ligand 
ratio and extrapolating the best fit line to the x axis. The dissociation constant (Kd) is 
the negative reciprocal of the slope of the best fit line. This system is susceptible to many 
possible inaccuracies, which may explain the divergence in reported results between 
groups of investigators.
The experimentally derived data makes the assumption that both of the ligand species 
(EGF and 1251 EGF) are identical with respect to receptor binding, and that they are able 
to compete equally for EGFR. The Chloramine T method of iodination (Hunter and 
Greenwood, 1962), produces a small proportion of 125I-EGF product which is able to 
form covalent cross-links with the EGFR. This is also true of 1251 EGF synthesised by 
the Iodo-Gen method (Fraker and Speck, 1978). Binding by this cross-linking species 
cannot be overcome by excess unlabelled EGF and this affects the derived Kd (Comens 
et al, 1982).
It is also assumed that 1251 EGF is a single iodinated molecular species, in which all 
iodinated molecules behave identically. Since it is known that one compound is 
produced in the labelling reaction which affects the derived Kd, it is possible that 
additional sub-species are present which may also cause an alteration in the apparent Kd. 
Another source of inter-laboratory variation in data derived by Scatchard analysis may be 
the type of unlabelled EGF used. Little account is usually taken of the different binding
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characteristics displayed between recombinant and purified EGF, or in the differences 
between human and murine EGF. While the differences are probably small, the additive 
effects of errors such as these can give rise to large variations in derived parameters, 
especially when these parameters are obtained by extrapolation of a best-fit line and not 
directly from the data itself.
The technique of Scatchard analysis is also open to misinterpretation in a number of 
respects. Firstly, mathematical models have demonstrated that at low receptor 
concentrations, the Kd becomes a linear function of the receptor concentration 
(Carpenter, 1987). This may explain the dual affinity binding characteristics displayed by 
EGFR. Recently, a stable active dimeric form of the EGFR has been synthesised which 
displays binding characteristics similar to the high affinity component of the bi-phasic 
Scatchard curve. (Sorokin et al, 1994). This confirms that observed dual binding affinity 
is not simply an artifact of the detection method. Also, binding studies carried out at 
room temperature are prone to error due to internalisation of ligand. It has been 
demonstrated that EGFR internalisation is reduced, but not abolished at 20oC, compared 
with 37oC (Carpenter and Cohen, 1976). Unlabelled ligand can not compete for 
internalised EGFR-125I-EGF complexes, and will lead to an increase in the estimation 
of receptor number.
Despite these qualifications, the data presented in table 6.3 characterising the cell lines 
used in this investigation provides Kd values and receptor numbers per cell which are 
similar to previously published values for these cell lines (Reiss et al, 1991, Kwok and 
Sutherland, 1991, Cowley et al, 1984, Honegger et al, 1987). It can be concluded from 
this data that the cell lines used in this study are as previously reported with regard to 
receptor number and binding affinity.
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CHAPTER 7
THE EFFECT OF EPIDERMAL GROWTH FACTOR ON 
CELLULAR RADIOSENSITIVITY
7.1 Introduction
There is a growing interest in the use of cytokines and growth factors to modify the 
cellular response to ionising radiation. The identification of chemical agents which 
may increase the sensitivity of tumours, or decrease the sensitivity of non-malignant 
tissue to radiation are potentially of considerable significance, given the widespread 
use of radiotherapy in cancer treatment. In particular, several studies have focused on 
the radioprotective effect of cytokines in heamatopoietic tissue. Erythropoetin, GM- 
CSF, interleukin-1 (IL-1), interleukin-11 (IL-11) and basic fibroblast growth factor 
(bFGF) have all been demonstrated to increase radioresistance both in vitro and in 
animal and human studies (Santucci et al, 1994, Neta et al, 1989, Uckun et al, 1989, 
Gallicchio et al, 1991, Goff et al, 1997). In addition, bFGF has also been shown to 
protect endothelial cells against radiation-induced apoptosis (Fuks et al, 1994). There 
are several possible mechanisms underlying these observations. IL-1 has been 
demonstrated to induce mitochondrial superoxide dismutase, resulting in a 
radioprotective effect in bone marrow stem cells (White and Tsan, 1994, Eastgate et 
al, 1993), while bFGF-induced radioresistance appears to be mediated through an 
FGF receptor/protein kinase C-dependent pathway (Haimovitz-Friedman et al, 1994). 
Subsequent studies have indicated that activated PKC may act to inhibit apoptotic 
signals generated by the radiation-induced hydrolysis of membrane sphingomyelin 
(Fuks et al, 1995). Interleukin-11 has been shown to reduce cellular production of 
tumour necrosis factor (TNF), whose effects are partly mediated through the 
sphingomyelin pathway (Redlich et al, 1996).
The ability of EGF to modify the cellular radiosensitivity of epithelial cells was 
first examined by Kwok and Sutherland (1989). They demonstrated that EGF added 
to cell culture medium enhanced the sensitivity of a human carcinoma cell line to 
ionising radiation. Further investigation showed that this radiosensitisation could be 
observed in a panel of human squamous cell lines which expressed different levels of 
EGFR. This effect appeared to be dependent upon the expression of high affinity 
EGF binding sites, and was maximal in all cell lines at 10 ng/ml EGF. (Kwok and 
Sutherland, 1991(a)). Examination of damage repair kinetics showed that EGF- 
dependent sensitisation was not related to alterations in potentially lethal damage 
repair, or sub-lethal damage repair (Kwok and Sutherland, 1991(b)). A further report 
from this group suggested that cell cycle distribution may be an important factor in 
the sensitisation effect (Kwok and Sutherland, 1992). An examination of the
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combined effects of radiation and EGF showed that EGF increased the length of G2- 
M arrest caused by y-irradiation (Laderoute et al, 1994). From these observations, the 
authors formed the hypothesis that the increase in G2-M arrest may be cytotoxic to a 
sub-population of cells, which undergoes apoptosis. This hypothesis, however, 
remains to be proven.
Other investigators have also studied the effect of EGF on the radiosensitivity of a 
variety of cell lines. The addition of EGF to hormone-deprived MCF-7 cells 
increased radioresistance when compared to hormone-deprived controls (Wollman et 
al, 1994). Another study reported that pre-incubation of two different squamous cell 
carcinoma cell lines with exogenous EGF reduced the radioresistance without 
alteration of cell cycle distribution (Bonner et al, 1994). There has, as yet, been no 
report of EGF-induced alteration of radiosensitivity in vivo.
7.1.1 Aim o f this study
The aim of this study was to characterise the effect of exogenous EGF on the 
radiosensitivity of the panel of EGFR-expressing cell lines described earlier (table 
6.1). Experiments were also designed to establish the effect of EGF on the 
proliferation and cloning efficiency of the cell line panel.
7.2 Materials and methods
7.2.1 Analysis o f growth response to EGF
1x104 cells per well were grown in 24 well plates under the conditions described in 
table 6.2. After 24 hours, the FCS content of the medium was changed from 10% to 
0.5% (v/v), and the cells were incubated for a further 24 hours. This medium was 
then replaced with medium containing 0.5% (v/v) FCS plus a range of concentrations 
of murine EGF.
Cells were then counted every 24 hours using a Coulter counter (Coulter 
Electronics). In an attempt to maintain a constant EGF concentration, EGF- 
containing medium was renewed every 48 hours. All determinations were performed 
in triplicate. Statistical analysis of the results was carried out using the paired 
Student’s t-test.
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7 .2.2 Radiation survival assay
A feeder layer of cells was prepared by irradiating a single cell suspension using a 
6OC0 source at a dose rate of approximately 1.75 Gy/min, until a dose of 60 Gy had 
been given. Feeder cells were either used immediately or stored for a maximum of 48 
hours at 4oC.
Viable cells were prepared by harvesting at 70% confluence by trypsinisation. The 
cells were then transferred to 25 cm2 tissue culture flasks (between 500 and 20 000 
cells per flask), containing the stated medium and serum conditions (table 6 .2 .). 
Feeder cells were then added, so that each flask contained a total of 5 xl04 cells. 
Three flasks containing 5x104 viable cells were also prepared to allow the 
measurement of multiplicity. The flasks were then placed in a 2% C02 atmosphere 
for 24 hours.
The multiplicity factor (n) for each assay was established by scoring the number of 
single, double and treble divisions which occurred in the flasks containing only 
viable cells after 24 hours, and determining the mean number of divisions per cell.
Cells to be irradiated were then placed under a 60Co source and given a dose from 
2 to 8 Gy, at a dose rate of approximately 1.75 Gy/min.
Immediately after irradiation, the original culture medium was removed and 
replaced with medium containing normal serum plus the appropriate concentration of 
human EGF. Flasks were then incubated at 37oC for 10 to 14 days to allow colony 
formation.
Colonies were stained with Carbol-fuschin. Those colonies which contained 50 or 
more cells were scored as viable.
The actual surviving fraction (f) was calculated from the observed surviving 
fraction (F) using the equation :
f= 1 - (l-F)l/n 
as previously described (Elkind and Whitmore, 1967).
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7.3 Results
7.3.1 Effect o f EGF on cellular proliferation
The effect of EGF on the proliferation of a panel of 11 cell lines was examined. 
The proliferative effect of EGF at two concentrations (10 and 25 ng/ml) was 
established at 24 hour intervals over a five day period.
EGF displayed a bi-functonal growth modulatory effect on this cell line panel. 
The proliferation of HN5, B2A4, CaSki, (p < 0.01) EJ and A431 (p < 0.05) was 
inhibited significantly at both 10 and 25 ng/ml EGF (figures 7.1 a-k and figure 7.2). 
A positive proliferative effect was observed in HER14 (p < 0.01), MCF 7 and SiHa 
(p < 0.05) at the same concentrations of EGF. EGF treatment failed to modify the 
proliferative capacity of K721A, MDA-MB 231 and SCC 12.
7.3.2 Effect o f EGF on cloning efficiency
The effect of EGF on cloning efficiency was established. Cloning efficiency is 
calculated from the number of colonies (of 50 or more cells) which are eventually 
formed following the seeding of a known number of single cells, expressed as a 
percentage.
The presence of EGF in the tissue culture medium during the colony-forming 
period reduced the cloning efficiency of A431, B2A4, CaSki and HN5 cell lines 
(table 7.1). Of these four cell lines, only A431 was able to form colonies in the 
presence of 10 ng/ml EGF. The maximal EGF concentration which permitted colony 
formation with B2A4 and CaSki cell lines was 3 ng/ml. Colony formation with HN5 
cells was only possible in an EGF concentration of 1 ng/ml. No significant alteration 
in the cloning efficiency of the remaining cell lines (HER14, K721A, MCF-7, SiHa, 
MDA-MB 231, SCC12 and EJ) was observed at 10 ng/ml EGF (table 7.1.).
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F ig  7 .2  Effect of  EGF on cell number  after 120 hours incubation. 
Columns represent the effect of  10 or 25 ng/ml EGF on cell number  
when compared to untreated controls (100%). Data was analysed using 
the paired S tuden t’s t-test 
* represents both columns p < 0.05 
i  represents both columns p < 0.01
cloning efficiency (%)
Cell line_________no EGF_______ with EGF EGF Concentration(ng/ml)
A431 34 +/- 9 14 +/- 3 10
B2A4 29 +/- 4 14 +/- 2 3
HN5 31 +/- 7 21 +/- 4 1
CaSki 23 +/- 4 14 +/- 4 3
HER 14 25+/-6 21 +/-7 10
K721A 26+/-7  21 +/-3 10
MCF7 47 +/- 13 45 +/-8 10
EJ 26 +1-3 29+/-6 10
SiHa 23+/-2  18+/-4 10
MDA-MB 231 37 +/“ 6 41 +/'  3 10
SCC12 16 +/- 6 17 +/- 5 10
Table 7.1. Effect of EGF on the cloning efficiency of eleven 
cell lines. Results from at least three experiments performed 
in triplicate. Figures are means +/- S.E.M.
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7.3.3 Effect o f EGF on radiation sensitivity
The effect of post-irradiation EGF administration on radiation sensitivity was 
established by colony forming assay. The data from the colony forming assay was 
fitted to the linear quadratic model of cell survival, described in secton 6 .1 . 
Radiobiological parameters obtained from the model were tabulated (table 7.2).
The data from the radiation survival assay was fitted to the linear quadratic model 
of cell survival (figure 7.3). The parameters a  and P, as well as the surviving 
fractions at 2 and 10 Gy (SF2 and SF10 respectively) were obtained using this model 
(table 7.2). Statistical analysis was carried out using the paired Student’s t-test. The p 
value was used to indicate statistical significance of differences in radiosensitivity 
and was derived by comparison of the SF2 and SF10 values of the EGF treated cells 
with the untreated controls.
Of the cell lines examined, none showed a statistically significant alteration in the 
SF2 value at any EGF concentration (table 7.2). Likewise, the SF10 values showed 
no significant EGF-modulation, with the exception of CaSki cell line, which showed 
an increased radioresistance when treated with EGF at 1 and 3 ng/ml.
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Fig 7.3 Effect of EGF on the radiation dose/response plots 
of a panel of cell lines
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cell lines. Curves were fitted to the data using the linear 
quadratic model of cell survival. Results are from three separate 
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Cell line
EGF conc. 
(no/mll a (Gy-1) 8 (Gy
2
SF2 SF10 (x 10‘3)
A431 0 0.238 +/- 0.037 0.0221 +/- 0.0044 0.569 +/- 0.144 10.15 +/- 2.81
1 0 0.279 +/- 0.078 0.0231 +/- 0.0092 0.522 +/- 0.108 6.10 +/- 2.79
50 0.333 +/- 0.041 0.0091 +/- 0.0048 0.495 +/- 0.079 14.41 +/- 3.62
HN5 0 0.307 +/- 0.046 0.0169 +/- 0.0054 0.506 +/- 0.186 8.57 +/- 2.24
1 0.163 +/- 0.095 0.0380 +/- 0.0113 0.620 +/- 0.118 4.38 +/- 2.95
B2A4 0 0.226 +/- 0.061 0.0297 +/- 0.0072 0.565 +/- 0.234 5.35 + / - 1.34
1 0.327 +/- 0.114 0.0272 +/- 0.0136 0.466 +/- 0.102 2.50 +/- 1.77
3 0.425 +/- 0.081 0.0127 +/- 0.0096 0.406 +/- 0.098 4.01 +/- 1.17
CaSki 0 0.130 +/- 0.044 0.0411 +/- 0.0053 0.654 +/- 0.073 4.47 +/- 0.93
1 0.245 +/- 0.056 0.0193 +/- 0.0067 0.567 +/- 0.149 1 12.52 +/- 4.84
3 0.296 +/- 0.085 0.0174 +/- 0.0101 0.516 +/- 0.088  ^ 9.09 +/- 2.28
HER 14 0 0.394 +/- 0.058 0.0208 +/- 0.0069 0.418 +/- 0.094 2.43 +/- 1.06
1 0 0.345 +/- 0.031 0.0209 +/- 0.0036 0.461 +/- 0.133 3.92 +/- 0.49
50 0.294 +/- 0.071 0.0432 +/- 0.0084 0.516 +/- 0.105 1.16 +/- 1.72
K721A 0 0.262 +/- 0.118 0.0381 + / - 0.0140 0.508 +/- 0.100 1.61 +/- 1.47
10 0.364 +/- 0.054 0.0216 +/- 0.0064 0.443 +/- 0.048 3.03 +/- 0.85
50 0.337 +/- 0.081 0.0346 +/- 0.0095 0.444 +/- 0.071 1.08 +/- 0.61
MCF 7 0 0.177 +/- 0.019 0.0272 + / - 0.0023 0.629 +/- 0.128 11.22 + / - 5.19
1 0 0.241 + / - 0.130 0.0258 + / - 0.0155 0.557 + / -  0.061 6.81 + / - 3.87
50 0.310 +/- 0.061 0.0108 + / - 0.0073 0.515
05COd1"+ 15.30 +/- 6.22
MDA 231 0 0.239 +/- 0.052 0.0172 +/- 0.0062 0.579 +/- 0.063 16.41 +/- 6.81
1 0 0.172 +/- 0.052 0.0316 +/- 0.0061 0.625 +/- 0.054 7.60 +/- 3.44
50 0.353 +/- 0.048 0.0048 +/- 0.0057 0.484 +/- 0.123 18.13 +/- 7.06
SCC 12 0 0.321 +/- 0.081 0.0215 +/- 0.0096 0.483 +/- 0.086 4.70 +/- 1.21
10 0.406 +/- 0.077 0.0198 +/- 0.0091 0.410 +/- 0.111 2.38 +/- 2.07
50 0.331 +/- 0.147 0.0318 +/- 0.0173 0.454 +/- 0.058 1.52 +/- 1.97
SiHa 0 0.192 +/- 0.057 0.0237 +/- 0.0068 0.619 +/- 0.144 18.32 +/- 7.93
1 0 0.316 +/- 0.028 0.0142 +/- 0.0033 0.502 +/- 0.158 10.25 +/- 4.28
50 0.287 +/- 0.062 0.0210 +/- 0.0074 0.518 +/- 0.101 6.94 +/- 3.73
EJ 0 0.173 +/- 0.070 0.0370 +/- 0.0082 0.611 +/- 0.067 4.43 +/- 1.55
1 0 0.253 +/- 0.088 0.0319 +/- 0.0103 0.531 +/- 0.122 3.28 +/- 0.89
50 0.201 +/- 0.068 0.0265 +/- 0.0081 0.602 +/- 0.089 9.47 +/- 4.70
Table 7.2 R adiobiological param eters obtained from  clonogenic assay of 
cell lines, a  and p values are means of three experim ents, +/- S.D. SF2 and 
SF10 values w ere obtained from  the m odel, and represent three separate 
determinations +/- S.E. U denotes p < 0.05
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7..4 Discussion
The experiments described were designed to establish the effect of exogenous EGF 
om the sensitivity of a panel of cell lines to ionising radiation. The effect of EGF on 
the growth and cloning efficiency of each cell line was established using standard 
techniques (Freshney, 1987). The effect of EGF on the radiation sensitivity of each 
cell line was then established by colony forming assay.
The colony forming assay was performed by seeding the viable cells in flasks prior 
to irradiation. The cells were then allowed to attach overnight, and an estimate of the 
average number of doublings made immediately prior to irradiation. Immediately 
after irradiation, EGF was added to the culture medium, and the cells were incubated 
until colonies formed. This method was used in preference to seeding the cells after 
irradiation, as it resulted in a higher cloning efficiency. The effect of the overnight 
incubation on the viable cell number was taken into account in the final calculation 
of the surviving fraction. This method did not result in errors greater than those 
observed when cells were seeded post-irradiation.The multiplicity value obtained 
using this method was typically small ( 2-5% +/- SEM) The SEM of triplicate 
determinations was typically 10% (Between 2-5 cells per 1000). The effect of this 
error on the final SF2 value was negligible, and was therefore not included in the 
results presented in table 7.2.
The data obtained from the colony forming assay was fitted using the linear 
quadratic model of cell survival. This model differs from the multi-targel model in 
that all of the parameters derived from this model are obtained directly from the 
equation of the curve, rather than by extrapolation. The n value in the multi-target 
model is obtained by extrapolation of the linear component of the line to the y-axis. 
As with any extrapolated value, small differences in observed data may be amplified 
erroneously by the extrapolation, leading to a misinterpretation of the data. The a  and 
P coefficients, SF2 and SF10 values derived from the linear quadratic model are 
much more stable, and thus less prone to misinterpretation.
The effect of EGF on the growth of the different cell lines was established (figures 
7.1(a-k) and 7.2). The growth of three cell lines (HER14, MCF-7 and SiHa) was 
stimulated by EGF at 10 and 25 ng/ml. Five cell lines (A431, B2A4, HN5, CaSki and 
EJ) were inhibited by EGF at the same concentrations, while the growth of three cell 
lines (K721A, MDA-MB 231 and SCC12) was unaffected by EGF.
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The effect of EGF on the cloning efficiency of the cell lines in the panel was also 
established. Seven cell lines (HER14, K721A, MCF-7, EJ, SiHa, MDA-MB 231 and 
SCC12) did not show a significant alteration in cloning efficiency in the presence of 
10 ng/ml EGF (table 7.1.). Four cell lines (A431, B2A4, HN5 and CaSki) showed a 
reduction in cloning efficiency in the presence of EGF. Colony formation in three cell 
lines (B2A4, HN5 and CaSki) was completely abolished in the presence of EGF at 10 
ng/ml. Colony formation by these cell lines was observed at 3, 1 and 3 ng/ml EGF 
respectively (table 7.1.). In each case, a significant reduction in cloning efficiency 
was observed when compared to untreated controls. A431 cells showed a significant 
decrease in cloning efficiency at 10 ng/ml EGF.
The effect of EGF on the radiosensitivity of the cell line panel was then 
determined. In the cell lines examined, there was no statistically significant 
radiosensitisation effect at any concentration of EGF (figure 7.3 and table 7.2.). We 
observed a significant increase in the SF10 value for the CaSki cell line at both 1 and 
3 ng/ml EGF (p < 0.05). However, an increase was not apparent in the SF2 value, and 
the lack of alteration of either the a  or p coefficients suggests that the radiation 
response of CaSki is not significantly altered by EGF.
The data shown in figure 7.1 indicate the growth rates of the panel of cell lines 
examined in the presence of different concentrations of EGF. Our observation of a 
growth inhibitory effect of EGF on some tumour-derived squamous cell lines has 
also been documented by others (Gill and Lazar, 1981, Kamata et al, 1986, Hirari, 
1988). The mechanisms underlying this inhibition are unclear. However, it has been 
suggested that an EGFR-mediated increase in the cyclin-dependent kinase inhibitor 
p21 may be responsible (Fan et al, 1995).
Our observation of the effect of EGF upon cell growth on the CaSki cell line 
(figure 7.1 (c)) is at variance with a previously published report (Kwok and 
Sutherland, 1991a), who reported that EGF has little or no inhibitory effect on this 
cell line. Interestingly, our observation of the growth of HN5 cells in the presence of 
EGF (figure 7.1.(a)) is similar to the results reported in the above publication. That 
is, after five days in medium containing 25 ng/ml EGF, the cell population underwent 
between one and two doublings. However, as shown in figure 7.1 (a), after an initial 
increase in cell number between 0 and 48 hours, the population size of HN5 cells 
remained constant, suggesting almost complete inhibition of growth. The possibility 
of this type of growth curve having been produced by the rate of increase in number 
of a putative cellular sub-population resistant to the effects of EGF being paralleled
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by the rate of death of the normal cell population is discounted by the apparent failure 
of colony formation over a 14 day assay period. The data published by Kwok and 
Sutherland (1991a), however, does not allow this possibility to be discounted.
The present data indicates that EGF had no significant effect on the radiation 
sensitivity of the cell lines examined. There are several previously published reports 
of studies of EGF-mediated alteration in radiation sensitivity. One study involving 
human colon cancer cells reported radiosensitisation by TGF-a (Leith and 
Michelson, 1991). The cell line examined (HCT-8) had an EGFR expression level of 
104 per cell, with maximal radiosensitisation observed at concentrations of TGF-a in 
excess of 200 ng/ml. This concentration is well in excess of physiological levels. 
Therefore, the effect observed is probably independent of the cell surface EGFR 
expression. Other investigators observed EGF-mediated radiosensitisation in two cell 
lines derived from squamous cell tumours of the head and neck (Bonner et al, 1994). 
This effect was only apparent when the cells were pre-incubated in EGF at 10 ng/ml 
for 24 hours prior to irradiation. Kwok and Sutherland (1991a) reported an EGF- 
mediated radiosensitisation effect, which was maximal at 10 ng/ml EGF, in all of the 
cell lines which they studied, but found that EGF administration either before or 
during irradiation had no effect upon the radiosensitivity of the cell. Only the post­
irradiation administration of EGF resulted in alteration in radiosensitivity. The 
divergence of these reports is significant because they suggest that the 
radiosensitisation observed is effected by different mechanisms.
EGF has also been reported to have a radioprotective effect in some cell lines. 
Wollman and colleagues (1994) have reported that EGF reduces radiosensitivity in 
MCF-7 cells. Unfortunately, it is not possible to directly compare this observation 
with the data presented in this report, as the experiments were performed using low 
serum concentrations, and EGF was added prior to irradiation. Another study using 
prostate epithelial cells observed that growth factor deprivation after irradiation 
resulted in increased radiosensitivity (Howard et al, 1995). Replacement of growth 
factors, including EGF, abrogated this effect.
The present data is at variance with the results previously published by Kwok and 
Sutherland (1991a), who reported EGF-mediated radiosensitisation in three of the 
cell lines used in our study (A431, HN5 and CaSki). We were unable to observe 
similar responses in these cell lines, or any other from the panel of cell lines used in 
this study. There are several possible explanations for these differences:
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(a) The cloning efficiencies of the cell lines examined in this study (table 7.1.) are 
significantly lower than those previously reported (Kwok and Sutherland, 1991a). 
This may be due to differences in age and passage number resulting in the evolution 
of altered growth characteristics. However, ligand binding analysis of the cell lines 
used in the present study (table 6.3.) indicated that the EGFR expression and binding 
affinities were similar to those of Kwok and Sutherland.
(b) A further methodological difference between this investigation and that of Kwok 
and Sutherland (1991a) is the absence of an irradiated feeder layer in the latter report. 
The authors stated, however, that cell seeding density had no effect on the 
radiosensitisation effect.
(c) There may be variations in the EGF concentration in the culture medium during 
the colony forming period. Cells were incubated in medium containing FCS or DCS 
(table 6.2) for the duration of the colony forming period. The concentration of serum- 
derived EGF, or any other members of the EGF family, is unknown and varies 
between serum batches. Also, no account was taken of the cellular uptake and 
degradation of the exogenous EGF, or the cellular production of EGF or TGF-a. 
Consequently, the EGFR ligand concentration is not constant throughout the colony 
forming period.
A more recent report has suggested a mechanism by which an observed EGF- 
mediated radiosensitisation of A431 cells may occur (Laderoute et al, 1994). This 
study indicated that EGF increased the length of radiation-induced cell cycle arrest in 
the G2-M phase. The authors hypothesised that the observed radiosensitisation effect 
was a result of an increase in apoptotic cell death as a consequence of arrest in the 
G2-M phase. The initiation of apoptosis in the G2-M phase, however, has only been 
observed in the presence of toxic concentrations of cytotoxic drugs, particularly 
cisplatin (Sorensen et al, 1990), and there is no evidence to suggest that the onset of 
apoptosis in this phase of the cell cycle is directly linked to the DNA damaging 
action of this drug. Indeed, there is experimental evidence which indirectly 
contradicts the above hypothesis. One study observed an inverse relationship between 
the length of radiation-induced G2-M delay and apoptosis in HeLa cells (Bernhard et 
al, 1996). Other investigators have demonstrated that an FGF-4-mediated 
enhancement of the radiation-induced G2 arrest in adrenal carcinoma cells resulted in 
increased cell survival (Jung et al, 1994). Both of these observations imply that an 
increase in the G2-M population does not correlate with an increase in apoptosis.
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The published literature examining EGF-mediated alteration in cellular 
radiosensitivity contains many inconsistencies. The various effects of incubation of 
cells with EGF pre-and post-irradiation require clarification, and standardisation of 
the methodologies used would be of benefit. Another obstacle to resolving this issue 
is establishing cultures in media whose EGFR-ligand content is accurately quantified. 
This would greatly simplify comparison of results from different studies. The results 
presented in this report indicate that EGF-mediated increase in radiation sensitivity of 
squamous carcinoma cells is unlikely to be of benefit in a clinical context.
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CHAPTER 8
ACCUMULATION OF EGF IN THE NUCLEI OF EGFR- 
EXPRESSING CELL LINES
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8.1 Introduction
As outlined in section 2.2.1, one of the criteria used in the selection of an 
appropriate radionuclide for conjugation to a delivery vehicle is the sub-cellular 
distribution of the vehicle in the target cell. The experiments described in this and the 
subsequent chapters were designed to evaluate the suitability of EGF as a vehicle for 
the delivery of Auger-emitting radionuclides to EGFR-expresing cells. Due to the 
short range of Auger electrons, high LET-type DNA damage is only observed after 
radionuclide decay occurs in close proximity to cellular DNA. Therefore, the 
suitabililty of EGF as a delivery vehicle for Auger-emitting radionuclides is 
dependent upon the nuclear uptake of EGF by EGFR-expressing cells. This chapter is 
concerned with the detection and characterisation of the nuclear accumulation of 
EGF by EGFR-expressing cell lines.
8.1.1 A ims o f this study
The experiments described in this chaper were designed to determine whether 
exogenous EGF accumulated in the nuclei of the EGFR-expressing cell line A431. 
Two microscopic techniques, not previously used for nuclear EGF detection, were 
employed. In addition, experiments were designed to establish the kinetics of nuclear 
accumulation in the same cell line. Experiments were also performed to evaluate 
nuclear EGF uptake in cell lines with various levels of EGFR expression.
8.2 Materials and methods
8.2.1 Detection o f nuclear EGF by laser scanning confocal 
microscopy
Glass microscope coverslips (13mm diameter) were immersed in PBS containing
13.3 pg/ml poly-L-lysine for 30 mins at 37oC. Coverslips were then washed 3 times 
by immersion in PBS, and placed individually in the wells of 24 well tissue culture 
plates. 5x104 A431 cells were then added to the wells in a volume of 0.5 ml, and 
incubated overnight at 37oC. Medium was then removed and replaced with medium 
containing 50 ng/ml of an EGF-biotin conjugate (Boehringer Mannheim) and 
incubated at the required temperature for 24 hours. Coverslips with attached cells
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were then removed from the wells, and washed 3 times by immersion in staining 
solution (DMEM containing 20mM HEPES, 20mM HEPES (Na+ salt), 0.05% (w/v) 
NaN3, pH 7.4). Cells were then fixed by immersion in paraformaldehyde solution 
(PBS containing 4%(w/v) paraformaldehyde, ImM CaCl2, 0.5 mM MgCl2, pH 7.4) 
for 15 minutes at 20oC.
Fixed cells were washed three times by immersion in staining solution, and 
permeablised by immersion in PBS containing 0.1% (v/v) Tween 20 for 10 seconds, 
followed immediately by three washes in staining solution.
To detect the presence of EGF-biotin in the cell, 50 pi avidin-FITC conjugate 
(25 ng/ml in staining solution) was applied to the coverslips, and incubated for 30 
min in a sealed container at 20oC, followed by three washes in staining solution.
Coverslips were then placed, with cells down, in a drop of Vectashield mounting 
medium containing 0.3 pg/ml propidium iodide and sealed with clear nail varnish.
Slides were viewed on a Nikon Diaphot - TMD microscope attached to a Bio-Rad 
MRC 600 confocal laser scanner. The krypton/argon laser excited at 488 and 568 nm, 
with red and green fluorescent emissions collected at 588 and 552 nm respectively.
Non-specific binding of avidin-FITC was assessed by viewing cells treated with 
avidin-FITC only. Fluorescence observed using these control cells was subtracted 
from that observed in the treated cells.
8.2.2 Detection of nuclear EGF using Electron Spectroscopic 
Imaging (ESI)
(This work was carried out in collaboration with Dr Max Huxham, electron 
microscopy unit, University of Glasgow)
A431 cells were incubated with 50 ng/ml EGF-biotin in medium with or without 
serum for 24 hours at 37oC. Cells were washed with PBS and removed from the 
culture surface by trypsinisation. Cells were harvested in serum-free medium and 
pelleted by centrifugation. The cell pellets were chemically fixed in 4% (w/v) 
paraformaldehyde, 0.5% (v/v) glutaraldehyde in 0.1M cacodylate buffer (pH 7.4) for 
1 hour at 4oC. The pellets were then washed in buffer and dehydrated in an ethanol 
series using a progressive lowering of temperature technique (from 4oC to -35oC) 
and then finally embedded in Lowicryl HM20 methacrylate resin. The resin was 
polymerised at -35oC using UV light for 48 hours. Sections were cut to a thickness of 
70-80 nm, and picked up on to 400 mesh gold grids and then immediately incubated
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on droplets in a moist chamber with streptavidin-lOnm gold diluted 1/80 (v/v) with 
PBS containing 0.1% (w/v) fatty-acid-free BSA for 36 hours at 4oC. The sections 
were then washed three times in PBS/BSA followed by a single wash in water prior 
to examination without further staining. To maintain control of the staining protocol, 
sections from the plus-serum and minus-serum cell pellets were incubated 
simultaneously.
Sections were examined at 20000 x magnification at 80 kV using a Zeiss TEM 902 
energy filtering transmission electron microscope in order to enhance visualisation of 
both the gold probe and cellular material without the use of conventional heavy metal 
stains. This allowed both unequivocal identification of gold particles by ESI and the 
determination of local macromolecular mass by measurement of the relative 
elemental nitrogen content of defined nuclear and cytoplasmic areas included in the 
analysis using serial electron energy loss spectroscopy (SEELS) (Huxham et al, 
1992). This approach allowed the assessment of the relationship between the number 
of gold particles and the relative density of the intracellular domain with which they 
were associated, rather than simply the cross-sectional area.
For ESI, cell sections were visualised at E=265 eV using a 15eV spectrometer exit 
slit and a focused beam. The number of gold particles per square micron of nuclear 
and cytoplasmic domains for each cell pellet was counted. To control for the non­
specific association of streptavidin-gold, streptavidin-gold-only treated cells were 
also assessed for nuclear and cytoplasmic gold particles. The values obtained were 
then subtracted from the values obtained from the EGF-biotin-treated cells.
For SEELS analysis, an intermediate aperture was used to define pairs of nuclear 
and cytoplasmic domains of 1.5 pm2 (n=15 for each domain). Relative intensity 
ratios for nitrogen were calculated using in-house software.
8.2.3 Radio-iodination of EGF
Radio-iodination of murine epidermal growth factor (mEGF) was carried out using 
Iodo-beads (Pierce, Rockford, U.S.A.) at room temperature. Carrier-free Nal25l 
(Amersham), diluted in lOOmM phosphate buffer, pH 6.5, was allowed to react with 
one washed Iodo-bead for 5 minutes. mEGF, also diluted in lOOmM phosphate 
buffer, was then added (approximately l|ig  mEGF per 10 MBq of Nal25l) and the 
reaction allowed to proceed for 12 minutes. The optimal reaction time was 
established by instant thin layer chromatography (ITLC). After completion of the 
reaction, 125I-EGF was separated from unincorporated 1251 using a 5 ml pre-packed
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disposable desalting column, equilibrated with PBS (Pierce). The specific activity of 
125I-EGF was 3.4 - 4.5 MBq/pg.
8.2.4 Isolation of intact cell nuclei
Isolation of intact nuclei was performed using a modification of the method of 
Murawaki et al (1990), which is a modification of the method described by 
Rakowicz-Szulczynska (1986).
Cells were harvested by trypsinisation, washed in PBS, and the pellet suspended in 
lml of nuclear isolation buffer (0.35M sucrose, 1% (v/v) Triton X-100, 12mM j3- 
mercaptoethanol, 1.5mM MgCl2, lOmM KC1, lOmM Tris-HCL, pH 7.6) and 
transferred to 1.5 ml Eppendorf tubes. The suspension was then centrifuged at 800 x 
g for 10 mins at 4oC.
The supernatant was discarded, and the pellet washed 5 times by centrifugation in 
nuclear isolation buffer. The nuclear pellet was then washed twice in PBS.
A sample was then analysed using phase-contrast light microscopy to confirm that 
the nuclear pellet was free from cell debris.
8.2.5 Determination o f membrane contamination o f nuclear 
pellet (i)
To determine the level of membrane contamination in an isolated nuclear pellet, 
1x106 A431 cells were plated out in a 60mm Petri dish, and allowed to attach. 
Medium was then removed, and replaced with 3 ml fresh medium containing 3pCi 
3H thymidine (S.A. 120 Ci/mmol, Amersham,), and cells incubated overnight at 
37oC. Medium was then removed, the cells washed twice in PBS, and incubated in 
fresh medium for 4 hours at 37oC, to ensure complete incorporation of all 
intracellular 3H-thymidine. Medium was then replaced with 2ml medium containing 
25 ng/ml 125I-EGF (section 8.2.3) and incubated at 4oC with gentle agitation for 4 
hours. Nuclei were extracted as described above (section 8.2.4), but the entire 
procedure was carried out at 4oC. Twenty pi of the suspension was removed after 
each wash, counted for 1251 content using a gamma counter (Canberra Packard) and 
3H content using an LS 5000 LE liquid scintillation counter (Beckman).
Whilst 3H cannot be detected by a gamma counter, 1251 can be detected by the 3H 
channel on the liquid scintillation counter. The relationship between 1251 cpm 
obtained by gamma detection, and cpm obtained by liquid scintillation was linear
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(figure 8.6). 3H counts were calculated by initial determination of 1251 cpm by 
gamma detection, followed by liquid scintillation counting. The cpm obtained by 
liquid scintillation contained two components - 3H and 1251-derived counts. 1251- 
derived counts were calculated from the standard curve (figure 8.5), and subtracted 
from the total.
Determination o f membrane contamination o f nuclear pellet (ii)
The level of membrane contamination in an isolated nuclear preparation was also 
determined by assay of the activity of the plasma membrane-marker enzyme 5’- 
nucleotidase. The method is similar to that previously described (Newby et al, 1975).
1x106 A431 cells were cultured in 60mm Petri dishes, and allowed to attach. Cells 
were harvested by trypsinisation, and washed twice in PBS. Nuclei were then isolated 
as described above (section 8.4.2). Each sample was washed up to six times by 
centrifugation in nuclear isolation buffer (figure 8.7). 5’-nucleotidase activity was 
determined by measuring the release of 3H-adenosine from 3H-AMP. The nuclear 
pellets were washed twice in PBS and sonicated (as described in section 6.2.5) and 
then added to 500pl of assay buffer (100 piM AMP, 2-3 xl05 c.p.m. of 3H-AMP 
(Amersham, S.A. 22 Ci/mmol), 50 mM Tris-HCl, pH 8.0.) A small aliquot of the 
homogenate was removed for protein determination.
Samples were then incubated at 37oC for 2 hr with agitation. The reaction was 
terminated by addition of lOOpl 0.15M ZnS04. AMP was then precipitated from the 
mixture by the addition of lOOpl Ba(OH)2. The supernatant, containing adenosine 
only, was then added to 5ml liquid scintillant, and radioactivity was measured in an 
LS 5000 LE scintillation counter (Beckman).
8.3.6 Determination o f nuclear uptake o f EGF
To determine the nuclear uptake of EGF, 1x106 cells were cultured in 60mm Petri 
dishes, and allowed to attach overnight. Medium was then removed, and replaced 
with fresh medium containing 3^iCi 3H-thymidine. The cells were then incubated 
overnight at 37oC. After incubation, the medium was removed, and the cells washed 
twice in PBS. Finally, cells were incubated in fresh medium for 4 hours to ensure 
complete incorporation of the remaining intracellular 3H-thymidine.
125I-EGF was then added at the required concentration and incubated for various 
lengths of time.
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The number of nuclei in each assay was determined by incubating control flasks, 
identical to those above, with unlabelled EGF instead of 125I-EGF. After the 
incubation period, cells were trypsinised, and counted using a Coulter counter. The 
remaining cells were then assayed for 3H by liquid scintillation.
Intact nuclei were then extracted as described (section 8.4.2), and the nuclear 
pellets assayed for 1251 and 3H. The 3H cpm were adjusted for 1251-specific counts 
as previously described (section 8.2.5).
8.3 RESULTS
8.3.1 Detection o f nuclear uptake o f EGF by laser scanning 
confocal microscopy
Figure 8.1 shows A431 cells which were incubated with 50 ng/ml EGF-biotin 
conjugate as described in section 8.2.1. The effects of serum deprivation and low 
incubation temperature on nuclear uptake of EGF-biotin were also examined (figures
8.2 and 8.3).
Figure 8.1 (a-c) show sequential optical sections of A431 cells. The optical sections 
(Z-steps) are 2 pm apart. The depth of field in each image was 1 pm. Green 
fluorescence indicates EGF-biotin-avidin-FITC, while red fluorescence indicated 
localisation of DNA-incorporated propidium iodide. Yellow fluorescence indicated 
co-localisation of both red and green fluorochromes. The optical sectioning technique 
allowed discrimination between cytoplasmic staining which overlies the nucleus, 
(equivalent to a false positive result), and genuine nuclear localisation. Genuine 
nuclear localisation was retained throughout the depth of the nucleus (indicated by 
blue arrows), whilst the cytoplasmic EGF-biotin distribution altered (arrowheads). 
Figure 8.1 demonstrates that exogenously added EGF could be detected in the 
nucleus of A431 cells after incubation under the conditions described. The majority 
of EGF-biotin localisation was intracellular, with little binding to the cell surface, 
indicating both receptor-ligand complex internalisation and cell surface receptor 
downregulation.
Figure 8.2 demonstrates the effect of incubation of A431 cells with 50 ng/ml EGF- 
biotin conjugate at 4oC for 24 hours. EGF binding to the cell surface was prominent, 
indicating an inhibition of receptor internalisation and downregulation. Less
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\F i g  8.1 ( a - c)  D e t e c t i o n  o f  E G F - b i o t i n  in t h e  n u c l e i  o f  A 4 3  1 c e l l s .  C e l l s  w e r e  t r e a t e d  w i t h  
E G F - b i o t i n  as  d e s c r i b e d  in s e c t i o n  8 . 2 . 1 . .  I m a g e s  a r e  s e q u e n t i a l  o p t i c a l  s e c t i o n s  w i t h  a d e p t h  
o f  f i e l d  o f  1 p m . E a c h  o p t i c a l  s e c t i o n  is 2 p m  a p a r t .  I m a g e s  o n  t h e  l e f t  s h o w  n u c l e u s  
( r e d  f l u o r e s c e n c e )  a n d  E G F - b i o t i n  ( g r e e n  f l u o r e s c e n c e ) . C o - l o c a l i s a t i o n  o f  b o t h  f l u o r o c h r o m e s  
a p p e a r s  a s  y e l l o w .  I m a g e s  o n  t h e  r i g h t  i n d i c a t e  t h e  d i s t r i b u t i o n  o f  E G F - b i o t i n  o n l y  ( g r e e n  
f l o u r e s c e n c e ) .  E G F - b i o t i n  is r e t a i n e d  t h r o u g h o u t  t h e  d e p t h  o f  t h e  n u c l e u s ,  as  i n d i c a t e d  b y  
b l u e  a r r o w s  . T h e  d i s t r i b u t i o n  o f  n o n - n u c l e a r  E G F - b i o t i n  a l t e r s  w i t h  e a c h  o p t i c a l  s e c t i o n  
( w h i t e  a r r o w h e a d s ) .  M a g n i f i c a t i o n  x 6 0 0 .
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Fig 8.2 E f f e c t  o f  l o w  t e m p e r a t u r e  o n  t h e  n u c l e a r  u p t a k e  o f  E G F - b i o t i n
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F i g  8 . 2  E f f e c t  o f  l o w  t e m p e r a t u r e  o n  t h e  n u c l e a r  u p t a k e  o f  E G F - b i o t i n . .  C e l l s  w e r e  
t r e a t e d  w i t h  E G F - b i o t i n  as  d e s c r i b e d  in s e c t i o n  8 . 2 . 1 .  I m a g e s  a r e  o p t i c a l  s e c t i o n s  w i t h  
a d e p t h  o f  f i e l d  o f  1 p m  . T h e  i m a g e  o n  t h e  l e f t  s h o w s  n u c l e u s  ( r e d  f l u o r e s c e n c e )  a n d  
E G F - b i o t i n  ( g r e e n  f l u o r e s c e n c e ) .  T h e  i m a g e  o n  t h e  r i g h t  i n d i c a t e s  t h e  d i s t r i b u t i o n  o f  
E G F - b i o t i n  o n l y  ( g r e e n  f l o u r e s c e n c e ) .  E G F - b i o t i n  is f o u n d  a s s o c i a t e d  w i t h  t h e  c e l l  s u r f a c e  
( b l u e  a r r o w s ) .  N o  n u c l e a r  u p t a k e  o f  E G F - b i o t i n  c a n  b e  o b s e r v e d  ( a r r o w  h e a d s ) .
M a g n i f i c a t i o n  x 4 0 0 .
1 1 1
Fig 8.3 E f f e c t  o f  s e r u m - d e p r i v a t i o n  o n  t he  n u c l e a r  u p t a k e  o f  E G F - b i o t i n
F i g  8 . 3  E f f e c t  o f  s e u m - d e p r i v a t i o n  o n  t h e  n u c l e a r  u p t a k e  o f  E G F - b i o t i n .  C e l l s  w e r e  t r e a t e d  
w i t h  E G F - b i o t i n  as  d e s c r i b e d  in s e c t i o n  8 . 2 . 1 .  I m a g e s  a r e  o p t i c a l  s e c t i o n s  w i t h  a d e p t h  o f  
f i e l d  o f  1 p m . I m a g e s  o n  t h e  l e f t  s h o w'  n u c l e u s  ( r e d  f l u o r e s c e n c e )  a n d  E G F - b i o t i n  ( g r e e n  
f l u o r e s c e n c e ) . .  T h e  i m a g e  o n  t h e  r i g h t  i n d i c a t e s  t he  d i s t r i b u t i o n  o f  E G F - b i o t i n  o n l y  ( g r e e n  
f l o u r e s c e n c e ) .  E G F - b i o t i n  is o b s e r v e d  in t h e  p e r i n u c l e a r  r e g i o n  ( b l u e  a r r o w s ) .  V e r y  l i t t l e  
E G F - b i o t i n  is a s s o c i a t e d  w i t h  t h e  c e l l  m e m b r a n e .  E G F - b i o t i n  d o e s  n o t  a s s o c i a t e  w i t h  t h e  
c e l l  n u c l e u s  ( w h i t e  a r r o w h e a d s )  M  a g n i f i c a t i o n  x 4 0 0 .
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intracellular EGF was observed, with an absence of localisation in the cell nucleus. 
The effect of serum starvation on nuclear accumulation is also demonstrated (figure
8.3). Serum-starved A431 cells were incubated in 50 ng/ml EGF-biotin for 24 hours 
at 37oC in serum-free medium. Cell surface staining was less intense than observed 
in cells incubated at 4oC, suggesting that receptor downregulation was not affected 
by serum-free conditions. Discreet regions of perinuclear staining (blue arrows) also 
indicated that the normal receptor internalisation mechanism was not impaired under 
conditions of serum-starvation. However, no localisation of EGF-biotin in the cell 
nucleus could be observed (arrowheads), indicating that the entry of EGF into the cell 
nucleus was serum-dependent.
8.3.2 Detection o f nuclear uptake o f EGF by electron 
spectroscopic imaging (ESI)
The relative distribution of EGF-biotin-streptavidin-gold complex between 
nucleus and cytoplasm was assessed using ESI in intact A431 cells incubated either 
with or without serum.
Figure 8.4 shows the average number of gold particles per square i^m (n=30) in 
both nucleus and cytoplasm. Cytoplasmic EGF predominantly associated with 
vesicles. Regions of vesicle-associated EGF in the cytoplasm were excluded from the 
analysis, and the data presented represents ‘free’ cytoplasmic EGF.
Nuclei of cells incubated with serum contained a mean of 62.5 gold particles per 
pm2, while nuclei of cells incubated without serum contained a mean of 13.5 gold 
particles per pm2. This corresponds to a 4.3 fold increase in nuclear-associated EGF 
in the serum-containing sample over the serum-free sample.
SEELS analysis indicated a nuclear/cytoplasmic nitrogen intensity ratio of 2.75 
(data not shown). This suggests that this concentration of EGF in the nucleus is not 
simply attributable to increased nuclear mass density.
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Nucleus C ytop lasm Nucleus C ytop lasm
Plus serum Minus serum
Fig 8.4 ESI determination of nuclear and cytoplasmic EGF- 
biotin-streptavidin-gold in A 4 3 1 cells. A431 cells were treated
with 50 ng/ml EGF-biotin as described in section 8.3.2. 1.5 m m -  
areas of  cytoplasm and nucleus were examined for the presence 
of EGF-biotin-streptavidin-gold. Columns represent means and 
standard  deviations  (n=30)
8.3.3 Determination of the level o f membrane contamination in
isolated nuclear preparations
Figure 8.5 shows the relationship between 1251-dependent counts detected on a 
gamma counter, and 1251-dependent counts detected on the 3H channel by liquid 
scintillation. This standard curve was used to calculate the number of 1251-dependent 
and 3H-dependent counts in dual-labelled (3H and 1251) isolated nuclei samples.
Figure 8.6 demonstrates the level of contamination of cell membrane in a nuclear 
pellet extracted as described in section 8.3.4. Performing the 125I-EGF labelling and 
nuclear extraction procedures at 4oC ensured that all 125I-EGF association with the 
cell was membrane-bound, as no internalisation of EGF occurs below lOoC 
(Carpenter and Cohen, 1976). 1251 counts in the nuclear pellet represented 
membrane contamination. 3H-thymidine counts were used as a measure of the 
number of nuclei in each sample assayed, as the mean concentration of 3H-thymidine 
incorporation per nucleus was constant. Results are expressed as the proportion of 
1251 counts to 3H counts, as a percentage of control (no wash) levels. The results 
shown in figure 8.7 demonstrate that 1251 contamination was 1.15% +/- 0.15% of the 
intact cell control after 5 washes in nuclear isolation buffer. This value represents the 
percentage of total cell membrane which remains associated with the nuclear pellet 
after 5 washes. Subsequent washes were unable to remove any further contamination.
Membrane contamination of isolated nuclear preparations was also determined by 
assay of the activity of the plasma membrane-marker enzyme 5’-nucleotidase (figure
8.7). Results represent the formation of 3H-adenosine from 3H-AMP, expressed as a 
percentage of the value obtained from the intact cell sample. These indicate that 5 ’- 
nucleotidase activity was reduced to 2.1% +/- 1.6% of the intact cell control control 
after 6 washes in nuclear isolation buffer. Subsequent washes were unable to remove 
any further contamination. It is important to note that both of these experiments were 
performed to assess the degree of contamination of the isolated nuclear pellet from 
cell membrane only. The results shown in figures 8.7 and 8.8 do not take account of 
the degree of contamination of the nuclear pellet from cytosolic, particulate 
components.
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Fig .  8.5 Standard curve indicating the relationship between
coun ts obtained by gamma detection and liquid 
scintil lation. Results shown are combined from two separate 
d e t e r m i n a t i o n s .
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Fig 8.6 Determination of  the contamination of extracted nuclei
by membrane-bound * -^I-EGF.  A431 cells incubated with
EGF at 4 °C  were washed successively in nuclear isolation buffer
(section 8.3.4). Columns represent the amount of  ^-^I-EGF,  as a
function of  incorporated ^H-thymidine,  detected after each wash
The results are expressed as a percentage of l ^ I - E G F  conta ined  
in unwashed (intact cell) preparations. Columns represent means 
and standard deviat ions of  triplicate determinations .
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N u m b e r  o f  w a s h e s
F ig  8 .7  Removal of  5 ’-nucleotidase activity from isolated nuclei. 
A 4 3 1 cells were washed successively in nuclear isolation buffer 
(section 8.3.4). Contamination of  nuclei by plasma membrane 
was assessed by assay of the membrane marker enzyme 5 ’- 
nucleotidase. Columns represent the relative 5 ’-nucleotidase 
activity detected after each wash. 25 pg  of  protein was assayed 
in each sample. Columns represent means and standard 
deviat ions  of  triplicate determinations .
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8.3.4 Assay o f nuclear EGF uptake using isolated intact nuclei
Having established that contamination of isolated nuclei by cell membrane was 
minimal, the nuclear uptake of 125I-EGF was assesed using nuclei isolated from 
1251-EGF-treated A431 cells. The results obtained are presented in figure 8.8. This 
demonstrates the accumulation of EGF in the nuclei of A431 cells after incubation 
with 50 ng/ml 125I-EGF for 24 hours at 37oC (column 1). The accumulation was 
significantly reduced by lowering the incubation temperature to 4oC (column 2), or 
by pre-incubation of the cells for 24 hours in serum-free medium (column 4), 
indicating that nuclear uptake of EGF was both temperature- and serum-dependent. 
Incubation of nuclei extracted from untreated A431 cells with 50 ng/ml 125I-EGF 
(column 3) did not result in uptake. This excludes the possibility that 125I-EGF 
released by disruption of cytosolic EGF-accumulating structures (e.g endocytic 
vesicles) was taken up during the nuclear isolation procedure. In addition, the data 
shown in column 4 represents an important control. Serum starvation does not effect 
the normal internalisation and lysosomal targeting of the EGF/EGFR complex 
(Carpentier et al, 1980, also figure 8.3). The data shown in column 4 can therefore be 
interpreted as an indication of the amount of contamination obtained from cytosolic 
and cytoskeletal structures, as well as from cell membrane. The significant difference 
observed between serum-starved and serum-containing samples indicates that the 
observed nuclear 125I-EGF uptake in the serum-containing sample does not result 
from contamination of the isolated nuclear pellet by other cellular components.
The 125I-EGF used had a specific activity of 4 MBq/pg.
8.3.5 Effect o f EGF concentration and incubation time on nuclear 
EGF uptake.
Figure 8.9 shows the effect of incubation time on the nuclear accumulation of 
exogenously added 125I-EGF. A431 cells were incubated in 50 ng/ml 125I-EGF, 
with or without a 100-fold excess (5 pg/ml) of unlabelled EGF, at 37oC for a range 
of incubation times. Statistical analysis was carried out using the paired Student’s T- 
test. A statistically significant increase (p < 0.05) in nuclear accumulation of 1251- 
EGF was observed after 8 hours. Nuclear uptake of 125I-EGF had not reached 
saturation by 24 hours incubation: the longest incubation period examined. A non-
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Fig 8.8. Effect of  serum deprivation and low temperature on 
I 9 51~J I-EGF uptake in A43l cell nuclei Intact nuclei isolated from
A43l cells incubated with 50 ng/ml * -^ I -EG F  for 24 hours at
3 7 °C  (column 1) and 4°C  (column 2). Column 3 indicates nuclei 
isolated from untreated A431 cells, which were subsequently
incubated for 4 hours with 50 ng/ml ^ -^ I -E G F  to establish the 
uptake of  EGF by isolated nuclei. The effect of  serum starvation 
on nuclear EGF uptake is also demonstrated (column 4). A431 
cells were grown in serum-free medium for 24 hours prior to
incubation with 50 ng/ml ^ -^ I -EG F,  also in serum-free 
conditions. Results are means of  two triplicate determinations +/-
S.E.M. l - ^ I - E G F  specific activity was 4 MBq/pg.
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F ig  8 .9  Effect of incubation time on the nuclear uptake of
l - ^ I - E G F  in A431 cells Cells were incubated as described in
section 8.3.6 with 50 ng/ml ^“ ^I-EGF in the presence (open 
circles) or absence (full circles) of  5 pg/ml unlabelled EGF for 
the times indicated. Each point represents the mean of  at least 
two triplicate determinations +/- S.E.M. * denotes p < 0.05.
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Fig  8 .10  Effect of l - ^ I - E G F  concentration on the nuclear
uptake of  ^ -^ I -EG F in A431 cells. Cells were incubated as
described in section 3.3.4. with the ' “ ^I -EGF concentration 
indicated in the presence (open circles) or absence (full circles) 
of  a 100-fold excess of  unlabelled EGF for 24 hours. Each point 
represents the mean of  at least two triplicate determinations +/- 
S.E.M. * denotes p < 0.05.
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statistically significant increase in nuclear accumulation of 125I-EGF was observed 
between 0-4 hours incubation.
The effect on nuclear accumulation of increasing extracellular 125I-EGF 
concentration is shown in figure 8.10. A431 cells were incubated at the indicated 
125I-EGF concentrations, with or without a 100-fold excess of unlabelled EGF, for 
24 hours at 37oC. Statistical analysis was carried out using the paired Student’s T- 
test. A statistically significant increase (p < 0.05) in nuclear 125I-EGF was observed 
at 5 ng/ml. Nuclear 125I-EGF uptake was maximal at 50 ng/ml over the 24 hour 
incubation period.
Having established the 125I-EGF concentration and incubation time which results 
in maximal nuclear 125I-EGF uptake, experiments were performed to establish the 
degree of nuclear 125I-EGF uptake in different EGFR-expressing cell lines under 
these conditions. The results obtained are presented in figure 8.11. This demonstrates 
the nuclear uptake of 125I-EGF by four EGFR-expressing cell lines. The cell lines 
(A431, HN5, B2A4 and CaSki) were incubated with 50 ng/ml 125I-EGF for 24 hours 
at either 4oC or 37oC. Intact nuclei were extracted and assayed for 1251 and 3H 
uptake as described in sections 8.3.4 and 8.3.5.
All four cell lines showed a statistically significant increase in nuclear 125I-EGF 
uptake when incubated at 37oC, compared to 4oC. The increases in each cell line 
were : A431 - 5.7 fold, B2A4 - 5.6 fold, HN5 - 6.8 fold and CaSki - 4.5 fold.
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F i g .  8 .1 1  Nuclear  accumula t ion  of  ^ - ^ I - E G F  in a panel of 
squamous carc inoma cell l ines. Four squamous carc inom a cell
l ines were incubated with 50 ng/ml ^ - ^ I - E G F  for 24 hours at
e i ther  4 ° C  or 3 7 ° C  as described in section 8.3.6 Each column 
r e p re s e n t s  the m eans  o f  at leas t  two separa te  t r ip l i c a te  
d e te rm in a t io n s  +/- S .E .M . In each ins tance ,  a s ta t i s t ica l ly  
significant  increase was observed when cells were incubated at
37°C ,  compared to 4°C  (p < 0.05).
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8.4 Discussion
8 .4.1 Microscopic examination o f intact cells
The microscopic examinations described in this chapter were designed to investigate 
whether exogenously applied EGF, conjugated to biotin, accumulated in the nucleus 
of EGFR-expressing cell lines. Using several different techniques, we were able to 
detect the presence of label in the nucleus of cell lines with a high EGFR expression. 
Also presented is preliminary characterisation of the conditions required for this 
nuclear accumulation, as well as a comparison of nuclear uptake in a panel of 
squamous carcinoma cell lines. It is important to note that no experiment was 
performed to establish the exact nature of the species which eventually accumulates 
in the nucleus, and the data presented cannot rule out the possibility that some form 
of intracellular metabolism of labelled EGF has occured before nuclear uptake. This 
possibility is discussed later in this chapter. However, for the purposes of this report, 
the term “nuclear EGF” describes the species derived from biotin-labelled or I- 
labelled EGF which was detected in the cell nucleus.
Accumulation of nuclear EGF was assessed using two separate microscopic 
techniques; laser scanning confocal microscopy (LSCM) and electron spectroscopic 
imaging (ESI). These had not previously been used to examine EGF nuclear 
localisation. There are reports of nuclear localisation of EGF and EGFR using 
conventional fluorescence and electron microscope techniques (Jiang and Schindler, 
1990, Holt et al, 1994 and 1995), but the reliability of these observations has been 
questioned (Hopkins, 1994).
Using optical sectioning on LSCM, it was possible to discriminate between genuine 
EGF nuclear localisation and cytoplasmic EGF which overlay the nucleus. This was 
not possible using conventional fluorescence microscopy. LSCM also allows 
visualisation of smaller quantities of fluorochrome than conventional fluorescence 
techniques.
ESI allows identification of labelled EGF, and some discrimination of cellular 
structures without the need for the heavy metal stains used in conventional electron 
microscopy, again reducing the possibility of artifacts. ESI also allowed rapid and 
accurate screening of designated intracellular regions for the presence of gold label.
The results obtained from LSCM indicated the presence of nuclear EGF in A431 
cells after incubation with 50 ng/ml EGF-biotin for 24 hours at 37oC in the presence
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of serum. Removal of serum or reduction of incubation temperature from 37oC to 
4oC markedly reduced nuclear localisation (figures 8.1, 8.2 and 8.3).
This technique, whilst producing clear images, can only be used to produce data of 
a qualitative nature. Quantification of nuclear EGF using LSCM could be open to 
misinterpretation, and has not been attempted.
Results obtained using ESI can be semi-quantitiative. While absolute quantitation 
is not possible, it is possible to compare the relative numbers of particles detected in 
different cellular compartments. Comparison of 1.5 pm2 regions of nucleus and non­
vesicle containing cytoplasm was carried out. A431 cells treated in the presence of 
serum showed a 4.3-fold increase in nuclear gold particles when compared to the 
nuclei of cells treated in serum-free medium (figure 8.4). The amount of non- 
vesicular EGF detected in the cytoplasm was small. Similar results were obtained 
using 125I-EGF isolated nuclei, where a 5.7 fold increase in nuclear EGF was 
observed following treatment under identical conditions (figure 8.11.)
One drawback using this technique is the poor quality of photographic images 
obtained. The low intensity of heavy metal staining results in images of low 
resolution. Therefore, in terms of resolution of intracellular structure, ESI images are 
inferior to classical EM immunogold representations. However, the accurate and 
unequivocal detection of gold particles, combined with the semi-quantitative nature 
of the data obtained results in a useful novel technique for the detection of nuclear 
EGF and other polypeptide growth factors.
An important consideration when using microscopic techniques such as those 
employed in this study is the low absolute quantity of label detected in the nucleus, 
compared to the total cellular uptake of labelled EGF. Whilst quantitation of the total 
cellular uptake of EGF-biotin has not been attempted in this study, previous reports 
have indicated that nuclear EGF constitutes approximately 1% of the total cell- 
associated EGF, after incubation with EGF for 24 hours in the the absence of 
chloroquine (Johnson et al, 1980). Such low quantities of nuclear EGF allow the 
possibility that the observed nuclear accumulation is simply due to a leakage of a 
degradation product from the lysosome, or an artifact of the cell fixation procedure, 
rather than a specific uptake of nuclear EGF. These qualifications have previously 
been applied to microscopic examinations of nuclear EGF accumulation (Hopkin, 
1994).
We have attempted to address this question by the use of control populations of 
serum-starved cells. Serum-starvation does not prevent EGF/EGFR complex 
internalisation, or subsequent lysosomal targeting (Carpentier et al, 1980). The total
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cellular EGF uptake in both serum-treated and serum-starved populations should 
therefore be equivalent. However, the effects of serum-starvation on the intracellular 
metabolism of EGF has not yet been fully established, and the possibility remains 
that metabolism of EGF is altered under different serum conditions, giving rise to 
particular degradation products observed only in the serum-containing cell 
population. For these reasons, it is not possible to conclude that the observed nuclear 
accumulation is that of intact EGF. Possible resolutions of this problem are discussed 
later in this chapter.
8.4.2 Evaluation o f intact isolated nuclei as a model system 
for the study o f nuclear EGF uptake
The use of isolated intact nuclei to study the nuclear uptake of peptides is prone to 
artifacts. A standard method of obtaining isolated nuclei involves washing whole 
cells in a detergent-containing buffer. This removes the plasma membrane, and 
releases the cytosolic contents, including detergent-insoluble intact nuclei.
Of fundamental importance is the level of contamination of the nuclei with plasma 
membrane and other cytoskeletal structures, which may bind the peptide of interest. 
This can be determined using a variety of methods, including microscopic 
morphological assessment and the assay of membrane-bound marker enzymes.
In this study, two methods of membrane contamination assessment were used. 5’- 
nucleotidase activity is a commonly used marker of plasma membrane contamination 
in isolated nuclear samples (Burwen and Jones, 1987). 5 ’-nucleotidase activity 
(assayed by the formation of 3H-adenosine from the substrate 3H-AMP) is only 
present on the cell membrane, and can be used as a marker of membrane 
contamination (Newby ey al, 1975). After 6 washes in detergent-containing buffer, 
5’-nucleotidase activity was reduced by 97.9% of that observed in intact cells (figure
8.7), indicating minimal plasma membrane contamination of the isolated nuclear cell 
pellet.
The second method utilised to determine membrane contamination was designed to 
follow closely the method used to determine specific EGF nuclear localisation. 
Incubation of intact A431 cells at 4oC with 125I-EGF results in binding of 125I-EGF 
only to the cell surface, as internalisation of EGF is inhibited at this temperature 
(Carpenter and Cohen, 1976). 1251 counts are therefore an indication of membrane 
contamination in the subsequently isolated nuclear pellet. After 6 washes in 
detergent-containing buffer, membrane-bound 125I-EGF counts were reduced by
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98.9% of that observed in intact cells (figure 8.6), indicating minimal plasma 
membrane contamination of the isolated nuclear cell pellet.
It is more difficult to assess the degree of contamination from cytoplasmic 
components in the isolated nuclear pellet. Many studies have employed 
morphological assessment, using both light and electron microscopy, to demonstrate 
that cytoplasmic contamination is minimal (Jiang and Schindler, 1990, Raper et al, 
1987). In addition, assay of lysosome-specific enzymes, such as acid phosphatase, 
have been used to determine the degree of lysosomal contamination of the nuclear 
pellet (Johnson et al, 1980, Holt et al, 1995). However, the observation that EGFR is 
able to bind to actin filaments at the cell membrane after ligand-binding demonstrates 
that the lysosome may not be the only potential source of cytoplasmic contamination 
(Rijken et al, 1995, den Hartigh et al, 1997).
The observation that serum-starvation inhibits the nuclear translocation of EGF 
and EGFR allows a more reliable control for cytoplasmic contamination (Holt et al, 
1996). Serum-starvation does not prevent EGF/EGFR complex internalisation, or 
subsequent lysosomal targeting (Carpentier et al, 1980). Taken together, these 
observations indicate that nuclei isolated from serum-starved, 1251-EGF-treated cells 
controls for the amount of contamination obtained from cytosolic 1251-EGF-binding 
components. The data presented in figure 8.8 indicate that nuclei isolated from 1251- 
EGF-treated, serum-starved cells contain significantly lower amounts of 1251 than 
nuclei isolated from serum-containing cells. This demonstrates that the observed 
nuclear uptake of 125I-EGF is not due to contamination from cytosolic components
The determination of the number of nuclei in a given sample can also present 
problems. Because nuclei have a tendency to aggregate, quantitation using a Coulter 
counter or haemocytometer is unreliable. Determination of DNA content using a 
fluorescent stain such as Hoesht 33258 (bis benzimide trihydrochloride) is commonly 
used as a method of quantifying the nuclear pellet. In this study, it was observed that 
a simple 3H-thymidine pulse- labelling procedure provided consistent results, and 
allowed quantitiation of nuclei to be performed in preparations of both intact cells 
and isolated nuclei.
8.4.3 Accumulation o f nuclear 125I-EGF inA431 cells
Intact A431 cells were treated with 125I-EGF under various conditions, and the 
nuclear uptake determined by isolation of the nuclei followed by assaying for 1251 
and 3H uptake. For each experimental treatment, a separate 3H-thymidine-only
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control experiment was performed, as alterations in temperature, serum concentration 
and EGF concentration can influence 3H-thymidine incorporation.
Nuclear accumulation of 1251 was observed after incubation of A431 cells with 50 
ng/ml 125I-EGF for 24 h. This was abolished when cells were treated at 4oC, or in 
serum-free conditions (figure 8.8). Nuclei isolated from untreated cells and incubated 
in 125I-EGF failed to take up significant amounts of the labelled ligand, indicating 
that the observed nuclear accumulation occured prior to cell disruption, and was not 
an artifact of the isolation procedure.
8.4.4 Effect o f ligand concentration and incubation time on 
nuclear uptake o f 125I-EGF
Ligand concentration- and time-dependent increases in nuclear EGF accumulation 
were observed (figures 8.9 and 8.10). Statistically significant (p< 0.05) quantities of 
nuclear 1251 were observed after exposure of cells to 5 ng/ml 125I-EGF for 24 hours, 
with maximal uptake observed at 50 ng/ml 125I-EGF over the same incubation 
period. Incubation of cells with a higher concentration of 125I-EGF did not increase 
specific nuclear uptake, suggesting that the uptake mechanism is saturable.
Using a single 125I-EGF concentration (50 ng/ml) for varying incubation periods, 
statistically significant nuclear uptake was observed after 8 h incubation at 37oC (p < 
0.05). Nuclear uptake did not appear to be maximal after 24 h, suggesting that a 
longer incubation period may result in higher nuclear 1251 uptake.
8.4.5 Comparison o f nuclear 125I-EGF uptake in a cell line panel
Nuclear 125I-EGF accumulation was assesed in a panel of EGFR-expressing cell 
lines (Table 6.1). Cells were incubated in 50 ng/ml 125I-EGF for 24 h at 37oC. 
Significant nuclear 125I-EGF accumulation was observed in four cell lines (A431, 
HN5, B2A4 and CaSki). Nuclear uptake in these cells was 4.5 - 6.8 fold higher than 
control cells incubated at 4oC (figure 8.11). No significant nuclear 125I-EGF uptake 
was observed in the remaining cell lines.
8.4.6 General discussion
Several attempts have been made to establish the nuclear localisation of EGF and 
EGFR after receptor-mediated internalisation. The earliest studies (Johnson et al,
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1980, Savion et al, 1981) used cells which were treated in the presence of 
chloroquine, which prevents endosomal acidification by inhibition of the membrane- 
bound Na+/H+ exchange pump (Carpenter and Cohen, 1976). This results in 
inhibition of endosomal proteases, and also prevents the pH-dependent uncoupling of 
the ligand-receptor complex. The overall effect observed is a large increase in 
intracellular EGF concentration, and consequently a large increase in nuclear 
localised EGF. The reason for the use of chloroquine to study nuclear EGF 
localisation was that significant amounts of EGF could not be detected in the cell 
nuclei without treatment (Johnson et al, 1980).
Our data was obtained using cell lines with a very high EGFR expression (table
6.3) which allowed assessment of nuclear localisation without the use of chloroquine 
or other protease inhibitors.
Several observations made in the present studies are supported by the results of 
previously published work. Firstly, nuclear localisation of EGF appears to dependent 
on internalisation, presumably along with the EGFR. This is indicated by the lack of 
nuclear EGF uptake when the incubation was carried out at 4oC. Receptor-mediated 
internalisation of EGF is inhibited at this temperature, compared to 37oC. Other 
investigators have reported an inhibition of nuclear EGF accumulation (Johnson et 
al, 1980, Rakowicz-Szulczynska et al, 1989), and of nuclear accumulation of EGFR 
(Murthy et al, 1986, Holt et al, 1994) at 4oC.
We have also demonstrated that serum is required to facilitate nuclear EGF 
accumulation (figures 8.3, 8.4 and 8.8). While there is no published evidence which 
directly supports this, indirect confirmation is provided by the observation of serum- 
dependent nuclear localisation of EGFR in an EGFR-transfected fibroblast cell line 
(Holt et al, 1995). Two separate reports examining intracellular EGFR distribution 
failed to observe nuclear EGFR translocation (Carpentier et al, 1987, Miller et al, 
1986). However, both of these investigations were performed in serum-free 
conditions.
The incubation of untreated, detergent-extracted, intact nuclei with 125I-EGF does 
not result in binding or nuclear uptake (figure 8.8). Similar findings in nuclei isolated 
from other cell line cultures have also been reported (Johnson et al, 1980, Savion et 
al, 1981).
The effects of incubation time and external EGF concentration on the maximal 
uptake and rate of uptake of EGF vary widely amongst published reports. This may 
be in part due to the different cell lines used in the different studies, and also partly
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due to the use in some studies of chloroquine and other lysosomal protease inhibitors. 
This makes direct comparison of the data presented here difficult.
Two reports of EGF nuclear localisation describe a lag-phase in the nuclear uptake 
of EGF (Johnson et al, 1980, Savion et al, 1981). No significant nuclear uptake of 
EGF was observed bt these workers for the first 6-12 hours of incubation. Nuclear 
EGF concentration then rose, and a plateau is observed at 24-30 hours. Our results 
confirm this finding. Figure 8.9 indicates a rise in nuclear EGF concentration 
between 4-8 hours, and sub-maximal accumulation after 24 hours. Nuclei assayed 0- 
4 hours after exposure of cells to 125I-EGF showed a small, non-statistical increase 
in EGF concentration. In contrast to these findings, a study using a fibroblast cell line 
observed half-maximal nuclear accumulation of EGF between 2-5 hours incubation 
(Jiang and Schindler, 1990). However, the authors state that nuclear EGF (in the 
form 125I-EGF) binding was low, making this observation difficult to assess.
There is only one report of the effect of external EGF concentration on the nuclear 
accumulation of EGF (Savion et al, 1981). Using corneal endothelial cells, the 
authors observed maximal nuclear uptake of EGF using 20 ng/ml EGF for an 
incubation period of 30 hours. In our study, maximal nuclear uptake of EGF in A431 
cells was observed at 50 ng/ml EGF for a 24 hour incubation period (figure 8.10). It 
is difficult to draw a direct comparison between these two observations, as the 
presence of chloroquine in the former study would have affected the nuclear uptake 
kinetics. However, the observation that the nuclear uptake of EGF was saturable is 
common to both reports.
It is probable that intracellular EGF concentration is an important determinant of 
nuclear EGF concentration. In previous reports, chloroquine has been used to 
increase intracellular EGF concentration (Jiang and Schindler,1990, Savion et al, 
1981, Johnson et al, 1980). All of these reports indicate that chloroquine-induced 
increases in intracellular EGF concentration were paralleled by similar increases in 
nuclear EGF concentration. Since EGF internalisation is dependent upon EGFR, it is 
likely that, in the absence of protease inhibitors, cell surface EGFR expression is an 
important determinant of the intracellular EGF concentration. Figure 8.11 shows the 
maximal nuclear accumulation of EGF in a panel of cell lines which were all derived 
from squamous cell carcinomas. The cell surface EGFR expression of each of these 
cell lines was established experimentally (table 6.3). The results presented (figure 
8.11) indicate that three of the cell lines (A431, B2A4 and HN5) accumulated 
approximately equal amounts of nuclear EGF when incubated under identical 
conditions. While the EGFR expression differs widely amongst these cell lines, they
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all have uncommonly high EGFR expressions (1.8-4.4 x 106/cell) when compared to 
the numbers of receptors observed in primary cultures from tumours. CaSki express a 
lower number of receptors per cell than the other three cell lines (5.8 x 105/cell). The 
accumulation of EGF in CaSki nuclei was found to be lower than the other cell lines 
examined. Cell lines with even lower EGFR expressions were examined in this 
study, but no significant nuclear EGF uptake could be detected. This suggests that the 
nuclear uptake of EGF may be related to the cell surface expression of EGFR.
A question which was not addressed in this study is the nature of the EGF-derived 
compound which accumulates in the cell nucleus. EGF is rapidly degraded after 
internalisation, with an intracellular half-life of 20 mins (Carpenter and Cohen, 
1976). It is possible that the species which localises in the cell nucleus is not intact 
EGF, but a degradation product. However, there is some published evidence which 
suggests that nuclear ‘EGF’ may not be significantly degraded. Early studies of the 
nuclear uptake of EGF were performed in cells treated with endodomal and 
lysosomal protease inhibitors such as chloroquine and leupeptin (Johnson et al, 1980, 
Savion et al, 1981). This treatment of cells resulted in a large increase in both 
cytoplasmic and nuclear 125I-EGF concentration. The observation that inhibition of 
degradation of internalised EGF results in increased nuclear accumulation suggests 
that the species taken up by the nucleus is not a degradation product of EGF. 
However, these observations are not conclusive evidence that nuclear EGF is 
undegraded
Some studies which have addressed this question have concluded that precipitation 
with anti-EGFR antibodies indicates that nuclear EGF is undegraded (Savion et al, 
1981, Raper et al, 1987). This interpretation should be treated with caution, as 
antibody binding merely indicates the presence of intact epitope, and not intact EGF.
Data presented in this chapter also suggests that nuclear EGF may not be 
significantly degraded. Similar patterns of nuclear uptake were observed using both 
EGF-biotin and 125I-EGF (figures 8.1-3 and figure 8.8). Conjugation of biotin to 
EGF occurs at lysine residues, whilst iodination typically occurs at tyrosine residues. 
Again, this suggests that the eventual nuclear EGF species is not a product of the 
complete degradation of EGF. However, this cannot be interpreted as conclusive 
evidence that nuclear EGF is not a metabolite of the native EGF species.
Given the uncertainty over the physical nature of nuclear EGF, there is another 
possible interpretation of the data presented in this chapter. As outlined earlier in this 
chapter, the significant difference in the nuclear EGF uptake observed between 
serum-starved and serum-competent cells may result from differences in the
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intracellular metabolism of EGF in the two cell populations. If the species which is 
detected in the nucleus is a product of the cytoplasmic degradation of EGF, then the 
uptake of nuclear EGF would then be a function of the total cellular EGF uptake, 
and/or of the rate of metabolism of cytoplasmic EGF. It would also cast doubt upon 
the specificity of uptake of nuclear EGF, as data similar to that presented in this 
report could be explained by the the non-specific nuclear accumulation of such a 
degradation product. In keeping with this possible interpretation, the results presented 
in this chapter indicate that the highest absolute nuclear EGF concentrations were 
observed in cell lines with highest EGFR expression, and thus the highest total 
cellular EGF uptake.
To resolve this uncertainty, an investigation into the physical nature of nuclear EGF 
should be carried out. It may be possible to determine the molecular weight of 
nuclear EGF by carrying out SDS-PAGE analysis of nuclear fractions from 125I-EGF- 
labelled cells. However, it may prove difficult to resolve small alterations in 
molecular weight between 125I-EGF and nuclear 125I-EGF. Chromatographic 
techniques could also be used to determine some of the physical properties of nuclear 
EGF. Gel filtration chromatography, using a matrix with an appropriate molecular 
weight sieving range, should provide a more accurate molecular weight 
determination than SDS-PAGE. Reverse phase fractionation of nuclear extracts from 
1251-EGF-treated cells could also resolve the question of the degradation of nuclear 
EGF. Comprison of the elution profiles of nuclear and 125I-EGF would indicate 
differences in the structures of these molecules. In addition, peptide sequence 
analysis following reverse phase purification of nuclear EGF should provide exact 
details of the amino acid sequence of the nuclear species.
8.4.4 Conclusions
The data presented in this chapter demonstrated that, after application of exogenous 
labelled EGF, the presence of the label could be detected in the nucleus of EGFR- 
expressing cell lines. The highest amounts of nuclear label could be detected in cell 
lines with high EGFR expression. This accumulation also appeared to be dependent 
upon incubation temperature and serum concentration. The amount of nuclear uptake 
varied with incubation time and exogenous ligand concentration. Whilst an 
investigation into the nature of the nuclear EGF-derived species requires to be carried 
out to establish the specific nature of this uptake, these observations imply that EGF
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may be suitable for the delivery of short range Auger-emitting radionuclides to the 
nuclei cells which overexpress EGFR.
Chapter 9 describes experiments designed to assess the radiobiological effect of 
EGF labelled with an Auger-emitting radionuclide (1231) on the same panel of 
EGFR-expressing cells.
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CHAPTER 9
THE EFFECT OF 123I-EGF ON THE CLONOGENICITY OF 
EGFR-EXPRESSING CELL LINES
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9.1 Introduction
As outlined earlier (section 2.3.1), the use of radionuclide conjugates in targeted 
therapy have several advantages over both cytotoxic drug and biological toxin 
conjugates as targeted therapeutic agents. The development of novel tumour- 
targeting radiopharmaceuticals may be of clinical benefit. This chapter describes 
preliminary studies into the radiobiological effect of an Auger-emitting radionuclide 
(1231) conjugated to EGF, on a panel of EGFR-expressing cell lines.
9.1.1 Particle range and tumour curability
The range of particles emitted by radionuclides has important dosimetric 
implications for tumour curability. Mathematical models have indicated, assuming 
homogeneous distribution of radionuclide, that tumour deposits which are smaller 
than the mean particle range will not recieve the maximum achievable radiation dose. 
This is because a proportion of the decay energy is deposited outside of the tumour 
mass (Humm, 1986). Subsequent mathematical modelling studies have indicated 
that for each radionuclide, there is an optimal tumour size for cure (Wheldon et al, 
1991, O’Donoghue et al, 1995). The clinical implication of these calculations is that 
very small tumour deposits may be more resistant to some types of radionuclide 
therapy, and could be sites of disease recurrence.
Studies employing EGFR-seeking radio-conjugates have mainly focused on the use 
of the p-emitting radionuclide 1311 (Epenetos et al, 1985, Kalofonos et al, 1989, 
Capala and Carlsson, 1991). This radionuclide is most effective in sterilising tumour 
deposits of 2.6 - 5 mm diameter, due to the mean emitted p-particle range of 800 pm 
(Wheldon et al, 1991, O’Donoghue et al, 1995). Tumour deposits with smaller 
dimensions may be more resistant to therapy. EGFR-targeting using radionuclide 
conjugates with ultra-short particle ranges may facilitate the sterilisation of very 
small tumour deposits or single cells.
9.1.2 Short-range particle-emitting radionuclide conjugates
Two strategies for short-range radionuclide targeting of EGFR-expressing tumour 
cells have been described. The first involves the tumour targeting of the non­
radioactive isotope 10B (Carlsson et al, 1994). The interaction of 10B with a thermal 
neutron field causes nuclear fission of the isotope, yielding high LET radiation in the
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form of short-range a-particles and Li3+ ions (Barth et al, 1990). The ability to 
deliver 10B to EGFR-expressing cells by the use of EGF-10B conjugates has been 
demonstrated (Capala et al, 1996). However, the clinical use of this conjugate may be 
limited by the availability of the means of generating an activating thermal neutron 
beam.
The second involves the use of a monoclonal antibody (mAb 425) conjugated to 
1251 (Brady et al, 1990 a and b). Whilst this agent demonstrated therapeutic 
potential, limitations to its efficiency may result from incomplete tumour penetration 
(Mairs et al, 1990). In addition, 1251 may not be the most appropriate radionuclide 
conjugate. As outlined in section 2.2, the radionuclide half-life should closely match 
the biological half-life of the delivery vehicle. The biological half-life of most 
monoclonal antibodies is much shorter than the half-life of 1251 (half-life = 60 days). 
Therefore, the use of alternative Auger electron-emitting radionuclides such as 1231 
(half-life = 13.1 hours) may result in increased energy deposition to tumour and 
enhanced tumour cell sterilisation.
9.1.3 Aims of this study
The aim of this study was to determine the effect of 1231, conjugated to EGF, on 
the clonogenic capacity of a panel of cell lines with widely varying EGFR 
expression.
9.2 Materials and methods
9.2.1 Iodination o f EGF
Carrier-free Nal23I was obtained from Cygne, Eindhoven, The Netherlands and 
murine EGF was obtained from Boehringer Mannheim. Iodination was carried out 
using the Iodogen method as described in section 8.2.3. For 1231 labelling, lpg 
mEGF was incubated in buffered conditions with 74 MBq Nal23I. The resulting 
specific activity of 123I-EGF was 51-59 MBq/pg. Unlabelled EGF was then added to 
achieve a specific activity of 50 MBq/pg. As a control, 1231 was also conjugated to 
fatty-acid-free BSA (Sigma, U.K.) in an identical manner.
137
9 .2.2 Colony forming assay
5x104 cells were seeded in the wells of a 24-well plate and allowed to attach. 
Medium was removed, and replaced with fresh medium containing either 123I-EGF 
or unlabelled EGF to a final concentration of 50 ng/ml. Cells were then incubated for 
a further 24 hours using the conditions described in section 6.2.2. After incubation, 
cells were washed three times in PBS and removed from the wells by trypsinisation. 
Cell numbers were established by counting control, unlabelled, EGF-treated cells 
using a haemocytometer
A feeder layer of sterilised cells was prepared for each cell line, as described in 
section 7.2.2. Treated cells were then seeded in 10 cm Petri dishes (1000 - 3000 cells, 
depending upon the individual growth characteristics of each cell line), and feeder 
cells added to a total cell number of 5 xl04 per Petri dish. Cells were then incubated 
for 10-14 days to allow colony formation. Colonies were stained with Carbol- 
fuschin. Those colonies which contained 50 or more cells were scored as viable.
9.3 Results
9.3.1 Effect o f 123I-EGF on clonogenicity ofA431 cell line
The results shown in figure 9.1 are expressed as surviving fraction relative to 
untreated control cells. All incubations were carried out at 37oC, in a 2% C02 
atmosphere. Results are means and standard deviations from at least two separate 
triplicate determinations. Statistical analysis was performed using the paired 
Student’s T-test. * denotes p < 0.05 compared to untreated control (column 1). Figure
9.1 demonstrates the effect of EGF, 123I-EGF and Nal23l on the clonogenic 
capacity of A431 squamous cell line. Cells were incubated under the conditions 
indicated for 24 hours. Clonogenic capacity was assessed by colony forming assay.
50 ng/ml unlabelled EGF reduced the clonogenic capacity of A431 cells by 52%, 
indicating that EGF is cytotoxic to a sub-population of A431 cells. 123I-EGF (50 
ng/ml, 2.5 MBq/ml) reduced the clonogenic capacity of A431 cells by 81.3% when 
compared to unlabelled EGF-treated A431 cells, indicating that 123I-EGF is more 
toxic to A431 cells than unlabelled EGF. Incubation of cells with unconjugated 
Nal23l (2.5 MBq/ml) had only a minimal effect on clonogenicity (clonogenic 
capacity reduced by 11% +/-14%), indicating that 1231 is not toxic to A431 cells 
unless it is conjugated to EGF. Similarly, 123I-BSA (2.5 MBq/ml) had a minimal
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Fig 9.1 Effect of ^ ^ I - E G F  on the clonogenic capacity of  A431 
cell line.
Column 1 - Untreated control A431 cells
Column 2 - Control A431 cells incubated for 24 hours with 50 ng/ml unlabelled 
EGF
Column 3 - A431 cells incubated for 24 hours with 50 ng/ml 1 - V E G F  
(2.5 MBq/ml)
Column 4 - A431 cells incubated with 2.5 MBq/ml Na ^ 3 j  
Column 5 - A431 cells incubated with ^ ^ I -B S A  (2.5 MBq/ml)
Column 6 - A431 cells incubated with 50 ng/ml ^ I - E G F  (2.5 MBq/ml) in the 
presence of 5pg/ml unlabelled EGF
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effect on clonogenicity, indicating the dependence of conjugation to EGF for 1231- 
mediated cytotoxicity. The presence of 5pg/ml unconjugated EGF greatly reduced 
1231-EGF-mediated cytotoxicity, suggesting that 1231-EGF-mediated cytotoxicity is 
dependent upon binding to EGFR.
9.3.2 Effect o f low temperature and seum starvation on 1231- 
EGF-mediated cytotoxicity
The results shown in figure 9.2 are means and standard deviations from at least two 
separate triplicate determinations. Serum-starved cells were incubated in serum-free 
medium for 24 hours before addition of EGF. Statistical analysis was performed 
using the paired Student’s T-test. * denotes p < 0.05.
Incubation of A431 cells with 123I-EGF for 24 hours at 4oC dramatically reduced 
1231-EGF-mediated reduction in clonogenicity. However, incubation of serum- 
starved A431 cells for 24 hours with 123I-EGF in serum-free conditions did not fully 
abolish 1231-EGF-mediated cytotoxicity (clonogenic capacity reduced by 62% +/- 
8%).
9.3.3 Assesement o f the 1231-EGF-mediated cytotoxicity in a 
panel o f EGFR-expressing cell lines
Figure 9.3 demonstrates the effect on clonogenicity of 123I-EGF on a panel of cell 
lines with differing EGFR expressions, and differing responses to EGF (figure 7.2 
and table 6.3). Figure 9.3(a) indicates clearly that the three cell lines examined 
(A431, B2A4, HN5) all display a reduced clonogenic capacity after treatment with 
123I-EGF, when compared to cells treated with unlabelled EGF. The reductions in 
clonogenic capacity observed were : A431 - 90.7% +/- 5%, HN5 - 91.3% +/- 4%, 
B2A4 - 78.5% +/- 9%.
Figure 9.3 (b) shows the clonogenicity of three cell lines (CaSki, HER14, K721A) 
whose response to 123I-EGF treatment was less dramatic. The reductions in 
clonogenic capacity observed were: CaSki - 21% +/- 11%, HER14 - 16% +/- 15%, 
K721A - 45.5% +/- 10%. Of these three cell lines, only K721A showed a response to 
123I-EGF treatment which was significantly different from the unlabelled EGF 
control. CaSki and HER14 showed a small, statistically non-significant reduction in 
clonogenicity. Figure 9.3 (c) indicates that the three cell lines MCF-7, SiHa and EJ 
showed no reduction in clonogenic capacity after treatment with 123I-EGF.
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Fig 9.2 Effect of  incubation temperature and serum conditions 
on I i -EGF-media ted alteration in A431 clonogenic capacity
Column 1 - Control A431 cells incubated with 50 ng/ml unlabelled EGF for 
24 hours at 4°C
Column 2- A431 cells incubated with 50 ng/ml 123i_EGF (2.5 MBq/ml) for 
24 hours at 4°C
Column 3 - Serum-starved control A 4 3 1 cells incubated with 50 ng/ml 
unlabelled EGF for 24 hours at 37°C in serum-free medium
Column 4 - Serum-starved A431 cells incubated with 50 ng/ml 123[_
EGF (2.5 MBq/ml) for 24 hours at 37°C in serum-free medium
Column 5 - Positive control. A431 cells incubated with 50 ng/ml 123i_
EGF (2.5 MBq/ml) for 24 hours at 37oC in serum-containing medium
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F ig  9 .3  Effect of *2 3 I-EGF on the clonogenic capacity of  a panel 
o f  EG FR-express ing  cell lines.  Cells incubated with 50 ng/ml
unlabelled EGF or 50 ng/ml 1 2 3 I-EGF (2.5 MBq/ml) for 24 hours
at 37 °C .  Results are means and standard deviations from at least 
two s ep a ra te  t r ip l i c a te  d e te rm in a t io n s .  S ta t i s t i c a l  a n a ly s is  
performed using the paired Student’s T-test. * denotes p < 0.05.
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9.4 Discussion
The experiments described in this section were designed to establish whether EGF 
conjugated to an Auger-emitting radionuclide had therapeutic potential against cells 
which express EGFR. Auger emitting radionuclides require to be localised in the cell 
nucleus, preferably in close proximity to DNA, to cause DNA strand breaks and cell 
sterility (Bloomer et al, 1981). The results described in chapter 8 indicated that 
exogenously added EGF, or one of its metabolites, can accumulate in the cell nucleus 
under certain conditions, indicating that EGF has potential as a delivery vehicle for 
therapeutic Auger emitting radionuclides.
The radionuclide used in this series of experiments was 1231-iodine. This was 
selected for several reasons. Firstly, iodination of EGF is a simple procedure, and the 
optimal conditions for EGF iodination had previously been established (section 
8.2.3). Another important consideration was the half-life of the radionuclide. 1231 
has a much shorter half-life (13.1 hours) than other Auger emitting iodine isotopes, 
such as 1251 (60 days). The practical significance of the difference in half-life is that 
1231 will release a much larger proportion of its decay energy in a given time period 
than 1251. The assessment of the effect of 1251 on clonogenic capacity usually 
requires that treated cells be stored at -170oC to allow 1251-decay-mediated, high 
LET damage to accumulate before seeding (Hofer et al, 1992). The use of 1231 
allows this procedure to be omitted, as approximately 75% of the total decay energy 
will be released in the 24 hour (two half-life) incubation period.
We have established that incubation of some of the cell lines with EGF caused a 
reduction in plating efficiency (table 7.1). To control for this effect, the 
clonogenicity of 123I-EGF treated cells was compared to cells treated with an 
identical concentration of unlabelled EGF.
Figure 9.1 indicates that treatment of A431 cells with 123I-EGF caused a reduction 
in clonogenic capacity when compared to cells treated with unlabelled EGF. This 
effect was not apparent when the cells were incubated with the equivalent 
radioactivity (2.5 MBq/ml) in the form Nal23I. This indicates that nuclear uptake of 
1231- is negligible, and that the effect on clonogenicity of the long-range gamma 
component of the 1231 decay over 24 h is minimal. As a further control, A431 cells 
were incubated with 123I-BSA. This conjugate had only a minimal effect on 
clonogenicity, demonstrating that 1231-mediated cytotoxicity is EGF-dependent. 
Futher evidence for the role of EGFR in 1231-EGF-mediated cytotoxicity comes from 
the observation that incubation of cells with an excess of unconjugated EGF resulted
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in abolition of the effect (column 6). This suggests that EGFR binding was essential 
for 1231-EGF-mediated cytotoxicity.
The effects of low incubation temperature and serum-starvation on 1231-EGF- 
mediated reduction in clonogenicity were also examined. Incubation of A431 cells 
with 123I-EGF at 4oC abolished 123I-EGF mediated cytotoxicity. Serum-starvation 
did not result in a complete loss of 123I-EGF dependent cytotoxicity, but a 
substantial reduction was observed (figure 9.2.).
The effect of 123I-EGF treatment on the clonogenicity of a panel of cell lines was 
examined to determine the effect of EGFR expression. 123I-EGF caused a significant 
reduction in clonogenicity in four cell lines (A431, HN5, B2A4, K721A), a non­
significant trend towards reduction in two cell lines (CaSki, HER 14), and had no 
effect on three cell lines (MCF-7, SiHa, EJ) (figure 9.3).
The results presented in this chapter support the hypothesis that EGF has the 
potential to deliver radionuclides to the nucleus of cells expressing EGFR. The 
finding that neither unconjugated 1231 nor membrane-localised 123I-EGF (as a result 
of incubation at low temperature) had no significant effect on clonogenicity indicate 
that the gamma photons emitted by 1231 decay are not responsible for the toxicity of 
123I-EGF. It follows that the Auger component of 1231 decay is probably 
responsible. The average range of Auger electrons is very short (less than 1pm), 
implying that 123I-EGF must be localised close to DNA.
This is the first report of an EGFR ligand conjugated to an Auger emitting 
radionuclide causing cell sterility. However, similar observations have been made 
with an anti-EGFR monoclonal antibody labelled with another Auger emitter, 1251 
(Bender et al, 1992). 1251-mAb 425 has been shown to be more effective than 1311- 
mAb 425 at sterilising glioma cells both in vivo and in vitro. 1311 has a much higher 
energy emission than 1251, and the emitted P-particle has a range of several cell 
diameters (Humm, 1986). The observation that 1251-labelled antibody is more 
effective in sterilising cells than 1311-labelled antibody could be explained by the 
greater radiobiological effectiveness of Auger electrons. Such a radiobiological effect 
could only occur if the 1251-labelled antibody comes into close proximity with DNA. 
The nuclear localisation of this antibody has been demonstrated in cell line models 
(Emrich et al, 1994). Interestingly, mAb 425 internalises after binding EGFR. There 
is no report of a similar finding with antibodies which do not internalise after EGFR 
binding.
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The data presented in this chapter, and the observations made by others outlined 
above, do not constitute definitive proof of nuclear uptake of EGF or antibody. 
Whilst the mean range of Auger electrons is <lpm, mathematical models indicate 
that 1231 and 1251 may emit electrons with a significantly longer range (Sastry, 
1992). Under normal conditions, internalised EGFR accumulates in vesicles in the 
perinuclear region (Murthy et al, 1987). It is possible that the release of Auger 
electrons from this site could cause DNA damage. However, this would constitute 
only a small fraction of the total energy released per decay, as over 70% of DNA 
strand breaks occur within 1.5 nm of a DNA-incorporated 1251- decay site (Martin 
and Haseltine, 1981). DNA damage resulting from the decay of 1231 in the cytoplasm 
is unlikely to explain the radiobiological effects observed in this report. Other 
investigators have reported that cytoplasmic localisation of 1251, in the form 1251- 
iododihydrorhodamine, does not result in significant radiotoxicity (Kassis et al,
1989). Also, this data does not confirm that the species responsible for the 
sterilisation effect is native 123I-EGF. As discussed in chapter 8, it is possible that 
the 123I-EGF may have been metabolised before nuclear uptake.
The finding that serum-starvation, whilst apparently abolishing EGF nuclear 
localisation in A431 cells (figures 8.3 and 8.4) yet not completely inhibiting 1231- 
EGF-mediated cell sterilisation (figure 9.2) may be a reflection of the relative 
sensitivity of the methods used to detect nuclear EGF. In the cell line HN5, after EGF 
treatment, found that serum starvation resulted only in partial inhibition of nuclear 
uptake of EGFR (Holt et al, 1995). The authors suggested that autocrine stimulation 
of EGFR was able to maintain the functional permeability of the nuclear pore under 
serum-free conditions.
The effect of 123I-EGF on a panel of cell lines provided insight into the effect of 
EGFR expression. Of the four cell lines which showed a reduction in clonogenicity 
after 123I-EGF treatment, three (A431, HN5 and B2A4) had the highest EGFR 
expression in the panel examined (table 6.3). Several studies have indicated that the 
intracellular concentration of a range of EGF-conjugates correlates with EGFR 
expression (Arteaga et al, 1994, Jinno et al, 1996, Cristiano and Roth, 1996). 
Therefore it is possible that nuclear uptake of 123I-EGF is dependent upon the cell 
surface EGFR expression, and consequent intracellular concentration. Evidence to 
support this hypothesis comes from the use of lysosomal protease inhibitors in early 
studies of EGF nuclear localisation (Johnson et al, 1980). Prevention of proteolytic 
degradation of intracellular EGF resulted in an increase in intracellular EGF 
concentration, and a parallel increase in nuclear EGF uptake. The finding that K721A
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cells are sensitive to 123I-EGF treatment may also support this hypothesis. K721A 
cells are non-EGFR expressing NIH-3T3 fibroblasts transfected with an EGFR 
deficient in the kinase domain. These receptors internalise normally when bound to 
EGFR ligand, but do not undergo ligand-induced downregulation (Honneger et al,
1987). HER 14 cells are identical in every respect to K721A except that they are 
transfected with wild-type EGFR. Therefore ligand binding in this cell line induces 
downregulation of EGFR expression (Honneger et al, 1987). Treatment of both cell 
lines with EGF results in K721A cells expressing a much larger number of cell 
surface receptors than HER 14 (Chen et al, 1989). This should lead to a higher 
intracellular EGF concentration, and may also explain the difference in sensitivity to 
123I-EGF between these two cell lines. However, as outlined in chapter 8, it is 
possible to interpret this data in another way. If the eventual nuclear species is a 
product of the cytoplasmic degradation of 123I-EGF, then the amount of nuclear 
uptake becomes a function of the total cellular EGF concentration and/or the rate of 
EGF metabolism. Without a detailed examination of the nuclear 1231-carrying 
species, it is not possible to conclude that the amount of nuclear 123I-EGF is soley 
dependent upon the cellular EGFR expression.
It is more difficult to explain why CaSki cells, which express a high number of 
EGFR (table 6.3), and take up detectable amounts of nuclear 125I-EGF (figure 8.11) 
do not show significant sensitivity to 123I-EGF (figure 9.3(b)). CaSki nuclei took up 
significantly less 125I-EGF than A431, B2A4 or HN5 cells, and it is probable that 
123I-EGF nuclear uptake mirrors this. It may be that the amount of nuclear 123I-EGF 
taken up by CaSki cells represents a threshold concentration for sensitivity in this cell 
line. This hypothesis could be tested by treating CaSki cells with 123I-EGF of higher 
specific activity.
9.4.1 Conclusions
The results presented in this chapter indicate that incubation of some EGFR-
1 9 ^expressing cell lines with exogenous I-EGF results in a reduction in clonogenicity. 
The ultra-short range of Auger electrons emitted following the decay of this 
radionuclide implies that the radioactive decay occurs in the region of cellular DNA. 
It is therefore possible to conclude that 123I, conjugated to EGF, localises in or close 
to, the nucleus of some EGFR-expressing cell lines. However, as outlined above and 
in chapter 8, it is possible that 123I-EGF is metabolised in the cell cytoplasm before 
nuclear uptake, and thus it is not possible to conclude that the eventual nuclear
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species is intact 123I-EGF. However, these results suggest that some EGFR- 
expressing cell lines are sensitive to 123I-EGF, possibly in a EGFR-dependent 
manner, and that 123I-EGF has potential as a therapeutic agent against EGFR-positive 
cells.
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CHAPTER 10 
CONCLUSIONS AND FUTURE STUDIES
10.1 Findings of this study
This report contains in several interesting findings which may have implications in 
the treatment of EGFR-expressing tumours. Firstly, we observed that EGF treatment 
does not affect the sensitivity of EGFR-expressing cell lines to gamma irradiation, 
contrary to previous reports. This finding implies that administration of EGF is 
unlikely to improve upon the efficacy of radiotherapy regiemes. Secondly, we have 
demonstrated that treatment of EGFR-expressing cell lines with exogenous EGF 
results in nuclear uptake of EGF. This observation suggests that EGF may have a 
specific role in the regulation of nuclear function, and may have implications in the 
design of novel pharaceuticals aimed at inhibition of EGFR-mediated signalling 
cascades. Thirdly, we have demonstrated that EGF conjugated to an Auger-emitting 
radionuclide is cytotoxic to cells in an EGFR-dependent manner. Our data also shows 
that nuclear localisation of the conjugate is essential for cytotoxicity to be observed. 
This suggests that high LET radiation in the form of short-range Auger electrons may 
be responsible for the cytotoxic effect. The design of novel Auger electron-emitting 
radiopharmaceuticals could improve the efficiency of sterilisation of micrometasasis, 
resulting in improved patient response to therapy.
The principle aims of this study were to investigate methods by which tumour-cell 
overexpression of EGFR could be exploited in a radiotherapeutic context. The 
results obtained in this study raise several questions of both academic and practical 
relevance which need to be addressed by further studies.
10.2 Growth factor-mediated alteration in radiation 
sensitivity
10.2.1 Administration o f EGF before and after irradiation
We attempted to establish the effect of EGF administration after irradiation on the 
radiosensitivity of EGFR-positive cell lines. The results presented show that EGF did 
not modify the radiosensitivity of eleven EGFR-expressing cell lines, including 
A431, HN5 and CaSki. These findings were opposite to previously published results, 
where EGF administration after irradiation resulted in the radiosensitisation of the 
cell lines listed above (Kwok and Sutherland 1991 a). Possible explanations for the 
differences observed are discussed in section 7.4.
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There is confusion in the published literature regarding the effect on 
radiosensitivity of EGF administration before and after irradiation. One study found 
that EGF-mediated radiosensitisation could only be observed if cells were pre­
incubated with EGF before irradiation (Bonner et al, 1994), whilst another found that 
only post-irradiation EGF administration resulted in radiosensitisation (Kwok and 
Sutherland, 1991 a). It is difficult to draw conclusions from these observations, since 
both studies involved the use of cell lines cultured in serum, which contains EGFR 
ligands. In addition the degree of endogenous EGFR ligand production by the cells 
was not taken into account in either study. In both studies, therefore, activation of 
EGFR occurs both pre- and post-irradiation, regardless of the timing of exogenous 
EGF administration. The control of the signalling capacity of the EGFR, by the use 
of antibodies which bind to ligand, and prevent ligand-receptor association 
(neutralising antibodies), or non-activating anti-EGFR antibodies which compete for 
ligand binding, could ensure that cells are not inappropriately stimulated by EGFR- 
ligand derived from serum, or the cells themselves.
10.2.2. Mechanisms involved in altered radiation sensitivity
Future studies are required to understand why our observations of the effect of EGF 
on radiation sensitivity differ from those previously reported. As discussed in section 
7.4, the responses of A431, HN5 and CaSki cell lines to EGF, and the degree of 
EGFR expression in each cell line were similar to those reported by Kwok and 
Sutherland (1991 a). This implies that the divergence in the post-irradiation EGF 
response is not due to alterations in EGFR expression or the EGFR signal 
transduction pathway.
It is possible that clonal evolution of the cell lines has resulted in an altered 
radiation response. It may be possible, using subtractive hybridisation, to identify 
specific genes, differentially expressed in the two cell populations, (radiosensitising 
and non-radiosensitising), which are involved in the cellular response to radiation 
damage. The use of subtractive hybridisation usually results in the identification a 
large number of genes which are differentially expressed between two cell 
populations. However, a comparison of two cell populations derived from a single 
clone should result in a smaller number of differentially expressed genes, facilitating 
the identification of important genes.
The scope of these investigations could be widened to include radiation-resistant 
sub-clones of cell lines derived from other tissue types. Radiation-resistant clones of
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cell lines derived from neuroblastoma and Burkitt’s lymphoma have previously been 
described (Russell et al, 1995, Michael et al, 1997). The identification of common 
genetic indicators of radiation resistance could have important implications in the 
understanding of the mechanisms involved in cellular radiation sensitivity.
Laderoute et al, (1994) observed alterations in the cell cycle distribution of 
irradiated, EGF-treated, A431 cells when compared to untreated irradiated cells. The 
authors hypothesised that these cell cycle alterations resulted in an increase in the 
proportion of cells undergoing apoptosis. Similarly, Russell et al (1995) observed 
that a radiation-resistant sub-clone, derived from a neuroblastoma cell line, was less 
prone to radiation-induced apoptosis. A radiation-resistant sub-clone derived from 
Burkitt’s lymphoma was found to be defective in the ceramide signalling pathway 
(Michael et al, 1997). The role of ceramide in the apoptotic pathway (discussed in 
section 1.4) suggests that differences in the degree of radiation-induced apoptosis 
may also account for the radiation-resistant phenotype observed in these cells.
Analysis of genes, differentially expressed between parent and radiation-resistant 
cell populations, or sensitising and non-sensitising populations, which are involved in 
apoptotic signalling, or regulation of cell cycle, could provide genetic indicators 
predictive of radiation response and, eventually, cellular targets for pharmacological 
intervention.
It is important to note that subtractive hybridisation will only identify differentially 
expressed genes. Genetic mutations resulting in altered protein function could also be 
responsible for the observed differences in EGF-mediated radiosensitisation. Such 
mutations could not be identified by subtractive techniques.
10.3 The nuclear accumulation of EGF
10.3.1 Regulation o f nuclear EGF uptake
As described in sections 8 and 9, cell lines with high EGFR expression accumulate 
more 125I-EGF in the cell nucleus, and are more sensitive to 123I-EGF treatment 
than cell lines with low EGFR expression. The possibility that nuclear uptake of EGF 
is dependent upon the level of EGFR expression has already been discussed (section 
9.4). However, there are other possibilities. The three cell lines with the greatest 
sensitivity to 123I-EGF treatment (A431, HN5 and B2A4) are all growth-inhibited by 
high concentrations of EGF (figure 7.2.). Growth inhibition by EGF results in cell 
cycle arrest in the G1 phase of the cell cycle (McLeod et al, 1986), possibly by
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induction of the p llw a fl cyclin dependent kinase inhibitor (Fan et al, 1995). There 
are several proteins whose intracellular localisation is known to be cell-cycle 
dependent (Jans et al, 1995 and references therein). The nuclear localisation or 
nuclear exclusion of these proteins may be regulated by phosphorylation by cyclin- 
dependent kinases. Significantly, the nuclear uptake of bFGF is observed mainly in 
the G1 phase of the cell cycle (Bouche et al, 1987, Baldin et al, 1990), although there 
is no data to suggest a role for cyclin dependent kinases in this process.
It is possible that the levels of nuclear EGF detected in the cell lines indicated 
above are due not only to the high EGFR expression, but also due to the EGF- 
mediated increase in the length of the G1 phase. This may also partially explain the 
difference in sensitivity to 123I-EGF observed between transfected fibroblast cell 
lines K721A and HER 14. EGF stimulates growth of HER 14, but has no effect on 
the growth of K721A, as this cell line expresses a non-signalling EGFR (figure 6.3 
b). Mitogenic stimulation by EGF results in a shortening of the G1 phase of the cell 
cycle (e.g Xiong et al, 1996). HER 14 cells may be less sensitive to 123I-EGF 
because EGF stimulation causes a decrease in the length of time spent in G1 phase, 
compared to K721A.
Future studies into the nuclear uptake of EGF should include an investigation into 
the cell cycle-dependence of nuclear translocation. An understanding of the factors 
which govern the nuclear uptake of EGF may also help to elucidate the specific role 
of EGF in the cell nucleus. Previous studies into the cell-cycle dependence of nuclear 
uptake of aFGF have been performed on cells which were serum-starved, resulting in 
their entering Go phase (Imamura et al, 1994). This ensured a cell cycle- synchronous 
population prior to FGF stimulation. This study demonstrated that serum-starvation 
inhibited nuclear EGF accumulation (figures 8.3, 8.4 and 8.8). Whilst examination of 
the cell cycle-dependence of EGF uptake would require a synchronised cell 
population, the use of cells which were synchronised by other methods, e.g. mitotic 
shake-off, would be preferable.
In addition, our data suggests that an investigation into the effect of tyrosine kinase 
inhibitors on nuclear EGF uptake should be performed. We have shown that K721A 
cells were more sensitive to 1231-EGF-mediated sterilisation than HER 14 cells 
(figure 9.3 b). Possible explanations for this observation (dependence of 123I-EGF 
toxicity upon ligand-induced EGFR downregulation and cell cycle status) are 
discussed in section 9.4. Pharmacological inhibition of EGFR kinase activity could 
result in an increase in nuclear EGF uptake due to inhibition of ligand-induced 
receptor downregulation, and also by abolishing the EGF-mediated shortening of the
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G1 cell cycle phase. Experiments designed to investigate the effects of EGFR- 
specific- and broad spectrum tyrosine kinase inhibitors on nuclear EGF uptake could 
provide information about the role of intracellular signalling pathways in the 
regulation of his system.
10.3.2 The nature of nuclear EGF
As discussed in chapters 8 and 9, the data presented in this report cannot exclude 
the possibility that the eventual nuclear EGF species is a metabolite of native EGF, 
despite some evidence to suggest that nuclear EGF may not be significantly 
degraded. This question may have more than simply academic significance. If the 
species taken up by the nucleus is a large metabolite of EGF, it may be possible to 
design vehicles, based upon specific EGF truncations, which are taken up with 
greater efficiency by the nucleus. In addition, resolution of this question may also 
provide important information regarding the nuclear translocation mechanism.
Experiments could be performed to establish the nature of nuclear EGF. 
Immunoprecipitation followed by SDS-PAGE would indicate the molecular weight 
of the nuclear species. In addition, chromatographic analysis of nuclear EGF could 
establish whether there are differences between nuclear and native EGF. Purification 
followed by peptide sequence analysis would establish the precise nature of nuclear 
EGF, although obtaining the required quantities of nuclear EGF for this procedure 
represents a significant undertaking.
10.3.3 The intranuclear localisation o f EGF
Data obtained using ESI (section 8.2.2) indicated that nuclear EGF was not 
exclusively associated with either nuclear membrane or nucleolus. This finding was 
confirmed by the observations using LSCM, which indicated that EGF was evenly 
distributed throughout the cell nucleus. However, the sensitivity of cells to 123I-EGF 
suggests, given the ultra-short range of Auger electrons emitted by this radionuclide, 
that nuclear EGF may be associated with DNA. Other investigators have indicated 
that EGF and ‘EGFR-like’ epitopes associate specifically with chromatin (Pierard- 
Franchimont et al, 1991, Rakowicz-Szulczynska et al, 1986, 1989, Holt et al, 1994). 
In particular, one study demonstrated that EGF binds tightly to chromatin at specific 
sites (Rakowicz-Szulcynska, 1989). However, EGF lacks a DNA-binding consensus
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sequence, implying that it may interact with DNA as part of a complex with other 
nuclear proteins.
There is no published evidence to indicate a specific function for nuclear EGF. 
However, the interaction of EGF with DNA suggests that it may have a role in the 
regulation of gene transcription. An investigation into the DNA-binding site of EGF 
may provide more information of the biological systems involved. In addition, it is 
important to establish the nuclear proteins with which EGF interacts. Co- 
immunoprecipitation of nuclear EGF, using isolated intact nuclei, could provide 
information about these proteins, and also the systems affected by nuclear EGF.
10.3.4 Nuclear translocation mechanism
Reports of the nuclear accumulation of some growth factors remain controversial. 
Part of this controversy concerns the lack of identification of a translocation 
mechanism. However, the unequivocal and specific nuclear uptake of AR, SDGF and 
the FGFs indicates a physiological mechanism of translocation of growth factors 
from the cell membrane to the nucleus. Evidence from this study and others (Jiang 
and Schindler, 1990) appears to indicate that nucleocytoplasmic transport occurs at 
the nuclear pore. Serum starvation and low temperature reduce nuclear uptake of 
both EGF and EGFR (figures 8.2, 8.3 and Holt, 1995). Similar conditions have also 
been shown to reduce the nuclear uptake of other proteins (Jiang and Schindler,
1990).
It is unclear how EGF (or any other peptide growth factor), which is contained 
entirely within endocytic vesicles after internalisation, is able to interact with the 
nuclear pore. The perinuclear localisation of the endocytic vesicle may provide the 
opportunity for interaction with the translocation apparatus, but there is no evidence 
to indicate that this occurs.
It is also unclear how EGF, which lacks a nuclear localisation sequence, is targeted 
to the nuclear pore. The EGF molecule is small enough to pass through the nuclear 
pore by diffusion, but this is an unlikely mechanism of translocation as cytoplasmic 
EGF is exclusively found in endocytic vesicles. The lack of free cytoplasmic EGF 
implies that the endocytic vesicle must be the source of eventual nuclear EGF.
One possibility is that EGF is translocated together with EGFR. EGFR has a 
putative nuclear localisation sequence in the cytoplasmic domain (residues 645-658, 
sequence RRRH3VRKRTLRR, where R= arginine and K=lysine). This sequence 
remains cytoplasmic after internalisation, and is available to interact with the
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importin ap  complex, which is essential for docking with the nuclear pore (Imamato 
et al, 1995). Experiments to determine whether EGFR co-immunoprecipitates, or co- 
localises with the importin ap  complex would provide evidence to support this 
hypothesis.
Acidification of the early endosome acts to dissociate ligand from receptor, and only 
a proportion of the endosomal EGFR will be in a ligand-bound state (Maxfield, 1982, 
Dunn et al, 1986). This may explain the differences observed between the kinetics of 
nuclear EGF uptake (figure 8.9), and EGFR uptake (Holt et al, 1994 and 1995).
Two other EGFR ligands, AR and SDGF, localise in the cell nucleus (Johnson et 
al, 1991, Kimura, 1993). In common with the FGF family, they both contain an NLS. 
The nuclear uptake of these peptides is dependent upon the cell surface expression of 
EGFR, providing more evidence of the importance of the receptor in the nuclear 
translocation process.
Mutation of the SDGF NLS results in a peptide which binds and activates EGFR, 
but does not localise in the nucleus (Kimura et al, 1993). This appears to contradict 
the hypothesis that the nuclear translocation of EGFR-ligand may occur by the NLS- 
dependent co-transport of the EGFR. However, the observations made may be 
interpreted differently. The acidified endosome contains free ligand and receptor, 
along with actively signalling ligand-receptor complexes (Vieira et al, 1996). Free 
SDGF, bearing an NLS will be able to bind directly to the importin ap  complex, 
resulting in transport through the nuclear pore. SDGF without a functional NLS will 
only be able to associate with importin when bound to EGFR, with nuclear uptake 
dependent upon the EGFR NLS. Since the endosome contains both free ligand and 
receptor, as well as ligand-receptor complexes, only a proportion of the total 
endosomal NLS-mutated-SDGF will be translocated across the nuclear membrane.
In this study, we were only able to detect nuclear 125I-EGF in cell lines with a 
very high EGFR expression which were incubated for several hours in a high 
concentration of 125I-EGF. Since NLS-mutant-SDGF and wild-type EGF have 
similar affinities for the EGFR (Kimura, 1993), it would be expected that, if the same 
translocation mechanism was involved in each case, that the nuclear uptake kinetics 
of EGF and NLS-mutant-SDGF would also be similar. It is unlikely, therefore, that 
nuclear 1251-NLS-mutant SDGF could be detected, given the ligand concentration 
and EGFR expression of the cell lines used in the study, explaining the observed loss 
of nuclear uptake. Future studies should test this hypothesis. Such experiments could 
involve the use of 1231-labelled SDGF mutants in a similar manner to the 
experiments detailed in this report using 123I-EGF. The generation of a cell line
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which expresses an EGFR with a mutated NLS would also provide a useful tool in 
the elucidation of the nuclear translocation mechanism.
10.4 Targeted sterilisation of tumour cells using Auger- 
emitting radionuclides
10.4.1125I-EGF nuclear uptake and 1231-EGF-mediated cell 
killing
We have demonstrated that exogenously applied EGF (in the form 125I-EGF) can 
be detected in the nuclei of several cell lines. The same cell lines were sensitive to 
treatment with 123I-EGF. Three cell lines (A431, HN5 and B2A4), which 
accumulate most nuclear 125I-EGF also show the greatest sensitivity to 1231-EGF- 
mediated sterilisation. Sensitivity to 123I-EGF is reduced by low temperature and 
serum starvation. These conditions also reduce the nuclear uptake of 125I-EGF 
(figures 8.8 and 9.2). These findings suggest that cellular sensitivity to 123I-EGF is 
dependent upon the amount of 123I-EGF in the cell nucleus. The experiments 
performed in this report were designed to determine whether EGF is a suitable 
vehicle for the delivery of therapeutic short-range radionuclides to EGFR expressing 
cells. They were not intended to determine whether sensitivity to 123I-EGF is a 
marker of EGF nuclear localisation. This could be determined by performing a 
dose/survival experiment. Survival curves produced by exposure to high LET 
radiation have distinctive profiles. A dose/survival curve specific for high LET 
radiation would indicate that 1231-EGF-mediated cell sterility was caused by Auger 
electron emission, and consequently that EGF must be localised in the cell nucleus. 
Another distinctive feature of Auger electron-mediated DNA damage is the lack of 
an oxygen-enhancement effect (Hall, 1994). Experiments to determine 123I-EGF 
mediated cell sterilisation under hypoxic conditions could also provide evidence of 
an Auger electron effect.
Whilst the data presented in this report does not prove that Auger electrons are 
responsible for 123I-EGF mediated cell sterility, there is evidence to indicate that this 
is a reasonable assumption. Localisation of 123I-EGF at the cell membrane, as a 
result of incubation at 4oC has no effect on clonogenic capacity (figure 9.2). The 
same applies to cells incubated in medium containing unconjugated 1231 (figure 9.1). 
Both of these findings indicate that the photon component of the decay emission of 
1231 is not responsible for the observed reduction in clonogenic capacity.
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Taken together with traditional approaches, this assay provides yet more evidence 
of the nuclear uptake of EGF.
10.4.2 EGFR-ligands as delivery vehicles
Both EGF and TGF-a have been used to deliver therapeutic toxins or radionuclides 
to EGFR-overexpressing cells (Chaudhary et al, 1987, Shaw et al, 1991, Capala and 
Carlsson, 1991). The toxins conjugated to EGF and TGF-a act in the cytosol to effect 
cell kill. The sub-cellular localisation of 131I-EGF or 10B-EGF conjugates will not 
greatly alter their radiotoxic effects, due to the relatively long range of the decay 
emissions from these radionuclides. The cytotoxicity of these conjugates correlates 
with the intracellular concentration of toxin or radionuclide (Andersson et al, 1992, 
Carlsson et al, 1994), whilst sub-cellular localisation of the internalised conjugate is 
of minor importance.
None of the more recently discovered EGFR binding ligands (AR and HB-EGF) 
have been used in this manner. These ligands bind EGFR with similar affinity to 
EGF, suggesting that they would not offer any advantage, as delivery vehicles of 
toxins or radionuclides, over EGF or TGF-a.
However, the observation of high LET effects from Auger-emitting radionuclides is 
entirely dependent upon the nuclear localisation of the radionuclide. We have 
demonstrated that EGF, which localises in the cell nucleus, has potential as a delivery 
vehicle for Auger-emitting radionuclides.
Amphiregulin has also been observed to localise in the cell nucleus (Shoyab et al,
1988). Unfortunately, there is no published study of an investigation of the 
comparative rates or maximal nuclear uptake of AR and EGF. Given the unequivocal 
nature of the reports of AR nuclear uptake, and the relative difficulty in observing 
EGF nuclear uptake, AR may be superior to EGF as a nuclear delivery vehicle for 
1231.
Future studies should assess the sensitivity of EGFR-expressing cells to 123I-AR, 
compared with 123I-EGF.
HB-EGF has a structure which is similar to AR. In common with AR, it binds 
heparin and contains a putative NLS (Higashiyama et al, 1991). There has been no 
study carried out to determine the sub-cellular localisation of HB-EGF. However, the 
similarity in structure to AR, coupled with a putative NLS suggests that HB-EGF 
may localise in the cell nucleus. It is possible that HB-EGF may have potential as a
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delivery vehicle for Auger-emitting radionuclides. Experimental evidence is required 
to confirm this hypothesis.
10.4.3 Sphingomyelin hydrolysis and apoptosis
The mechanisms involved in radiation-induced cell death, and the role of 
sphingomyelin hydrolysis in radiation-induced apoptosis are discussed in chapter 1.
Our observations of 123I-EGF mediated cell killing have been interpreted as a 
result of nuclear accumulation of EGF, and Auger-electron mediated DNA damage. 
From our data it is not possible to discount the possibility that the cell kill resulted 
from irradiation of the cell membrane by 123I-EGF, inducing the intracellular 
accumulation of ceramide, leading to apoptosis. Irradiation of cell membrane 
preparations has previously been demonstrated to result in ceramide production 
(Haimovitz-Friedman et al, 1994) However, some of our observations suggest that 
this mechanism of cell kill is unlikely. Incubation of A431 cells with 123I-EGF at 
4oC does not result in a significant reduction in clonogenic capacity (figure 9.2). At 
this temperature, ligand-induced internalisation and downregulation of the EGFR is 
inhibited (Carpenter and Cohen, 1976). The amount of receptor-bound, and thus 
membrane-associated, 123I-EGF is significantly higher after incubation at 4oC than 
at 37oC, a temperature at which ligand-induced receptor internalisation and 
downregulation is not inhibited. If membrane irradiation and sphingomyelin 
hydrolysis was responsible for the cell killing observed, the effect would be expected 
to increase after incubation with 123I-EGF at 4oC. Such an increase was not 
observed.
It is possible, though, that low temperature may affect the ceramide-activated signal 
transduction pathway, resulting in abrogation of the apoptotic signal, which could 
also explain our results.
Future studies must determine the mechanism of 1231-EGF-mediated cell killing by 
assay of apoptotic markers, or by morphological assessment of cells. In addition, a 
123I-EGF dose/survival curve typical of high LET radiation would also indicate 
direct DNA damage by 123I-EGF.
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10.4.4 123I-EGF as a therapeutic agent
We have shown that 123I-EGF is able to sterilise some EGFR-expressing cell lines. 
Agents which sterilise cells in an EGFR-dependent manner may be useful in the 
treatment of tumours which overexpress EGFR. There are several reasons why the 
development of Auger-emitting radionuclide therapies may improve on current 
therapeutic strategies.
Current ligand-based targeted radionuclide strategies (discussed in section 5.3) 
centre mainly on the use of p-emitting radionuclides, p-particles have a range of 
several cell diameters, and are thus capable of sterilising the targeted cell as well as 
those in close proximity which are not directly targeted. This effect is useful because 
it reduces the effect of heterogeneous uptake of targeted radionuclide within the 
tumour mass. However, as discussed in section 9.1.1, small tumour masses may be 
disproportionately resistant to p-particle therapy.
Auger-emitting radionuclides cause cell sterilisation only when the radionuclide 
decays in close proximity to DNA, due to the ultra-short range of Auger electrons. 
Only cells which are directly targeted are sterilised, and no cross-fire effect is 
observed. Heterogeneous uptake of Auger-emitting radionuclides results in the 
sparing of non-targeted tumour cells. Therefore, 123I-EGF may not be suitable as a 
single agent therapeutic modality. However, combinations of EGFR-targeted P- and 
Auger-emitting radionuclides could result in improved clinical outcome, as Auger- 
emitting radionuclides are particularly suitable for the sterilisation of small tumour 
masses, which are spared by P-particle therapy.
Another potential clinical application of 123I-EGF is in the purging of bone 
marrow, or peripheral blood stem cell collections used for autologous bone marrow 
rescue. It is essential that haematopoetic stem cells to be reinfused are free from 
tumour cells, as these may be responsible for disease recurrence. As discussed above, 
Auger-emitting radionuclides are particularly suitable for the sterilisation of 
micrometastes. In addition, because EGFR is not expressed by hematopoetic cells, it 
would represent a tumour cell-specific target in this system. Sterilisation of non­
tumour cells would be greatly reduced using 123I-EGF, compared to a P-emitting 
radionuclide-EGF conjugate, as only EGFR-expressing cells would be sterilised.
EGFR-targeted radionuclide strategies take advantage of the overexpression of 
EGFR, and preferential accumulation of radionuclide by tumour cells, as opposed to 
non-tumour cells. However, systemic administration of EGF-radionuclide conjugates
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results in uptake by a wide variety of cell types which express EGFR. One of the 
major sites of non-tumour EGF uptake is the liver, which concentrates EGFR ligands 
from the circulation. Liver damage is a potential limitation to EGFR ligand-based 
therapies.
There is evidence to suggest that systemic administration of EGF-Auger-emitting, 
radionuclide conjugates may result in less damage to the liver than p-emitting 
radionuclide conjugates. Several studies of EGF nuclear localisation have been 
performed on cells isolated from liver regenerating after partial hepatectomy (Marti 
et al, 1991, Ichii et al, 1988). The authors observed that hepatocytes isolated from 
these animals showed increased nuclear EGF, when compared to cells isolated from 
non-regenerating liver. Nuclear accumulation of EGF by hepatocytes isolated from 
normal liver, or fully regenerated liver, was much less, even though the cells retained 
the capacity to bind EGF.
As discussed above, the cytotoxicity of Auger-emitting radionuclides is dependent 
upon nuclear localisation, whilst the sub-cellular localisation of p-emitting 
radionuclides is of lesser importance. The non-nuclear localisation of EGF in normal 
hepatocytes should render them insensitive to 1231-EGF-mediated cytotoxicity. 
However, similar uptake of p-emitting radionuclides would result in cell killing, due 
to the longer range of these particles. Thus systemic administration of Auger-emitting 
radionuclide-EGF conjugates may result in less liver damage than would be expected 
from similar administration of p-emitting radionuclide conjugates. This hypothesis, 
however, requires experimental investigation.
10.5 Conclusions
We have observed the accumulation of nuclear EGF by cell lines which 
overexpress EGFR, and demonstrated that this phenomenon can be exploited to 
deliver therapeutic short range radionuclides to the nuclei of these cells. Many of the 
factors which control the nuclear uptake of EGF remain to be elucidated, as does the 
function of nuclear EGF, and the nuclear translocation mechanism. Investigation of 
these mechanisms may lead to a greater understanding of the ways in which peptide 
growth factors exert their influence on normal and malignant cells.
The development of novel therapeutic strategies based on these observations 
depends on our understanding of the factors which govern nuclear EGF uptake. A 
significant amount of work is required before appropriate targeting strategies can be 
designed and optimised. However, preliminary results presented here indicate that the
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nuclear localisation of peptide growth factors may be exploited therapeutically, and 
in a manner which may complement and improve on therapies both in clinical use, 
and those being considered for clinical use.
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